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3 Heart surgery with cardio-pulmonary bypass (CPB) is associated with lung ischemia 
4 leading to injury and inflammation. It has been suggested this is a result of the lungs 
5 being kept deflated throughout the duration of CPB.  Low frequency ventilation 
6 (LFV) during CPB has been proposed to reduce lung dysfunction. 
7
8 Methods
9 We used a semi-biased multi-omic approach to analyse lung biopsies taken before and 
10 after CPB from 37 patients undergoing coronary artery bypass surgery randomised to 
11 both lungs left collapsed or using LFV for the duration of CPB. We also examined 




16 30 genes were induced when the lungs were left collapsed and 80 by LFV. Post-
17 surgery 26 genes were significantly higher in the LFV vs. lungs left collapsed, 
18 including genes associated with inflammation (e.g. IL6 and IL8) and 
19 hypoxia/ischemia (e.g. HIF1A, IER3 and FOS). Relatively few changes in protein 
20 levels were detected, perhaps reflecting the early time point or the importance of post-
21 translational modifications. However, pathway analysis of proteomic data indicated 
22 that LFV was associated with increased “cellular component morphogenesis” and a 
23 decrease in “blood circulation”. Lipidomic analysis did not identify any lipids 




2 Taken together these data indicate the keeping both lungs collapsed during CPB 
3 significantly induces lung damage, oxidative stress and inflammation. LFV during 
4 CPB increases these deleterious effects, potentially through prolonged surgery time, 












2 Cardiopulmonary bypass (CPB), which allows operation on a motionless and 
3 bloodless heart, is used in most heart surgery procedures. Recovery from cardiac 
4 surgery utilising CPB is generally good with a 30 day survival rate of 98.4% [1]. 
5 However, CPB is still associated with severe systemic inflammation and tissue 
6 damage with an accompanying mortality of 1.5% along with post-operative lung 
7 dysfunction of various degrees in  up to 30% of patients [2]. The underlying 
8 mechanisms driving inflammation following CPB are yet to be fully elucidated and 
9 there are currently no strategies to effectively prevent it. 
10
11 Institution of CPB is associated with significant physiological changes and insults to 
12 the lung. Ventilation is generally stopped, and lungs deflated to reduce mediastinal 
13 motions. Venous return is directed away from the right heart thereby pulmonary 
14 artery flow is dramatically reduced. Furthermore, bronchial blood flow is reduced due 
15 to haemodynamic and pulsatility changes during bypass and changes in vascular 
16 resistances. These atelectatic and ischemic changes may promote tissue hypoxia, 
17 oxidative stress and lung cellular damage [3–6]. Towards the end of CPB, full 
18 ventilation is recommenced and pulmonary blood flow is restored with potential 
19 injury by reperfusion including oxidative stress [7,8], and inflammatory cell 
20 infiltration [9]. Further oxidative stress could be triggered by free iron catalysed 
21 reactions [10,11] from iron released by haemolysis as the blood passes through the 
22 bypass circuit. 
23
24 There have been various attempts made to protect the lung during CPB. Among these, 
25 it has been suggested that low frequency ventilation (LFV) during CPB may alleviate 
6
1 hypoxia and ischemia of the lungs and thereby help to reduce inflammation.  In 
2 contrast to previous animal trials [12], we have recently provided evidence that in 
3 patients undergoing elective coronary artery bypass grafting (CABG), the use of LFV 
4 during CPB when compared to both lungs left collapsed does not seem to reduce 
5 inflammation in lung biopsies and blood [13,14]. 
6  
7 The low frequency ventilation technique reported in our study has been investigated 
8 previously by different groups with contrasting results.  This study, for the first time, 
9 uses the simultaneous of human lung biopsy and blood samples to assess the effect of 
10 the technique. In order to establish a mechanistic link between the effects of both 
11 interventions on the lung we used a semi-biased multi-omics approach 
12 (transcriptomics, proteomics and lipidomics) to analyse lung biopsies taken at the start 
13 of surgery before CPB and at the end of surgery after lung reperfusion but before 
14 weaning from CPB from the above mentioned randomised study recently published 




2 2.1 Study design
3 37 patients undergoing elective or urgent CABG with CPB and cold blood 
4 cardioplegic arrest at the Hammersmith Hospital, were recruited as part of a  single-
5 centre, parallel group, randomised, controlled trial investigating low frequency 
6 ventilation study recently published [14]. 
7  
8 Venous blood samples were taken from the patients at induction, 10mins, 2, 6 and 24 
9 hours post CPB. 
10 Lung biopsies were taken both prior to and immediately after surgery. The pre-
11 surgery biopsies were taken from the left upper lobe immediately after sternotomy 
12 with lungs ventilated for both groups. The post-surgery biopsy was taken from the left 
13 lower lobe at the end of the operation just before weaning from CPB.  
14 This study was approved by the NRES committee London- Camden and Islington 
15 (Research Ethics Committee reference number 12/LO/0458) on 25/04/2012. Further 
16 approval was obtained from the research and development department of the Imperial 
17 College Healthcare NHS Trust. This research complied with the Helsinki Declaration. 
18 The trial is registered as ISRCTN No: 34428459. All patients involved in the study 
19 gave written and informed consent
20
21 2.2 Luminex:
22 Cytokines in human plasma samples, taken 24 hours post-surgery, were quantified 




1 RNA was extracted and analysed by Affymetrix GeneChip Human Gene 1.0 ST 
2 Array (ThermoFisher) following the manufacturer’s instructions.  




7 Protein was extracted as described previously [14]. More details are available in the 
8 supplemental materials.
9
10 2.5 Heme assay:
11 Heme levels in the whole cell protein extracts were measured using the Heme 
12 colorimetric assay kit (BioVision, Milpitas, CA, USA) following manufacturer’s 
13 instruction.  
14
15 2.6 Lipidomics:
16 Lung tissue was processed as described previously [15,16].  
17 More details are available in the supplemental materials.
18
19 2.7 Oxidative stress/ Anti-oxidant capacity:
20 We used the RedoxSys® to electrochemically measure the oxidant redox potential 
21 (ORP) and antioxidant capacity (AOC), following manufacturer’s instructions (Aytu 
22 Biosciences, Englewood, CO, USA). 
23
24 2.8 Statistics and Data analysis:
9
1 Gene arrays were analysed by Partek genomics Suite (Partek Inc). Gene and protein 
2 classification were tested using PANTHER Overrepresentation Test analysed against 
3 the Homo Sapiens reference list, using the PANTHER Go-SLIM Biological process 
4 annotation dataset [17]. Analysis included Bonferroni correction for multiple data.
5
6 The remaining data were analysed using Graphpad Prism 6 (Graphpad Software Inc, 
7 La Jolla, CA, USA) utilising Friedman and using Dunn’s multiple comparison test 




2 Patient demographics and clinical characterisation are provided in detail in Fiorentino 
3 et al, 2019 [14].
4
5 3.1 Patient serum samples:
6 3.1.1 Luminex of serum cytokines:
7 Plasma IL-6, IL-8 and IL-10 levels increased significantly 24 hours post-surgery in 
8 both groups compared to the pre-surgery control samples. IL-6 levels increased 17-
9 fold in lungs collapsed group and 25-fold in the LFV group (Figure 1A). IL-8 levels 
10 (Figure 1B) increased approximately 1.5-fold in both study groups, whilst IL-10 
11 (Figure 1C) increased approximately 1.3x. In contrast, there was no significant 
12 change in inflammatory cytokines IL-1β and MCP-1 in the plasma of patients before 
13 CPB and 24hrs after CPB in both groups (Figure 1D & E). 
14
15 3.1.2 Cell-Free heme:
16 The levels of cell free heme were measured in the blood plasma following surgery. 
17 Cell free heme was significantly higher in both groups at 10 minutes and 2 hours after 
18 surgery before returning to baseline. Cell-free heme levels in plasma were increased 
19 but not significantly in the LFV group (51.5μM vs 38.1μM, 2-way ANOVA p=0.17) 
20 (Figure 2).
21
22 3.1.3 Oxidative stress in blood:
23 Plasma ORP and AOC from all patients were measured following bypass. By 2-way 
24 ANOVA time after surgery was linked to significantly increased ORP (p<0.0001) and 
25 this was matched by a significant decline in AOC (p<0.0001).  However, the ANOVA 
11
1 did not identify any statistical significance related to intervention, indicating that CPB 
2 induced changes in ORP and AOC were not altered by LFV (p=0.44, p=0.16 
3 respectively) (Figure 2). 
4
5 Since LFV intervention did not effect plasma ORP or AOC we examined the 
6 combined data to increase statistical power and determine the effects of surgery. The 
7 combined data showed a significant increase in ORP within 10 minutes following 
8 surgery, which increased at all timepoints measured but appeared to plateau at 6 
9 hours. Similarly, the decrease in AOC following surgery reached a nadir at 6 hours 
10 which was maintained (Figure 2).
11
12 3.2 Biopsy RNA gene expression data:
13 Full data set is available at https://figshare.com/articles/_/4772167. Principle 
14 component analysis (PCA) did not identify any significant outliers; therefore, no 
15 patient samples were excluded from the analysis (Supplemental Figure 1).  There 
16 were no significant differences in gene expression between the two groups at baseline. 
17
18 3.2.1 Transcriptional response to CPB with lungs collapsed:
19 Lungs left collapsed significantly increased the expression of 30 genes in the biopsy 
20 immediately after surgery (Supplemental data: Table 1). These genes include the 
21 inflammatory genes CCL2 (encoding MCP-1) and IL6, which had the highest increase 
22 following surgery (6.7x and 6.6x higher than baseline respectively). Panther pathway 
23 analysis identified the “cholecystokinin receptor (CCKR) signalling map” (p=2.26E-
24 08), the “Interleukin signalling pathway” (5.41E-05) and the “p53 pathway” (4.81E-
12
1 02) as significantly over-represented within the genes induced in the lung collapsed 
2 group (Supplemental data: Table 2). 
3
4 3.2.2 Transcription response to CPB with LFV:
5 LFV significantly induced 80 genes in lung tissue after surgery (Supplemental data: 
6 Table 3). No genes were significantly suppressed.  All CPB-induced genes were 
7 enhanced in the LFV group and up-regulated genes shared the same pathways as 
8 those induced by lungs collapsed CPB namely the “CCKR signalling map” (p= 
9 2.14E-10), the “interleukin signaling pathway” (p=4.34E-03) and the “p53 pathway” 
10 (p=4.46E-02)(Supplemental data: Table 4).  In addition, the “Inflammation 
11 mediated by chemokine and cytokine signaling pathway” and the “Gonadotropin-
12 releasing hormone receptor pathway” were also enriched.  Biological process analysis 
13 identified “endoderm development”, “MAPK cascade”, “cell death” and “response to 
14 stress” as significantly over-represented.
15
16 The 50 genes that were upregulated in the LFV group alone (i.e. not in CPB lungs 
17 collapsed group) included inflammatory genes such as IL1B and CYR61.  Pathway 
18 and biological process analysis did not identify any specific pathways or processes as 
19 overrepresented in these 50 genes although raw, uncorrected p values indicated over-
20 representation of the ‘CCKR signalling map’ and “Inflammation mediated by 
21 chemokine and cytokine signaling” pathways (p=2.01E-03).  
22
23 3.2.3 Effect of low frequency ventilation: 
24 Comparing gene expression biopsies from the LFV and lungs left collapsed groups 
25 taken after surgery identified statistically significant changes in 26 genes in patients 
13
1 who underwent LFV compared to patients undergoing lungs collapsed CPB 
2 (Supplemental data: Table 5).  HLA-DRB5, encoding the HLA class II 
3 histocompatibility antigen DRB5 was reduced in the LFV group whilst the remaining 
4 25 genes were increased with LFV.  The expression of HLA-DRB5 was not 
5 significantly altered following surgery in either groups compared to their respective 
6 pre-surgical controls.
7
8 The genes significantly increased by LFV intervention compared to lungs left 
9 collapsed included the inflammatory IL6, CCL2 and CCL8 (encoding IL-6, MCP1 and 
10 MCP2 respectively). Pathway analysis showed that LFV significantly activated the 
11 “Plasminogen activating cascade” (p=3.17E-02), “CCKR signaling map” (p=6.81E-
12 03), and “Inflammation mediated by chemokine and cytokine signaling pathway” 
13 (p=3.30E-02)(Supplemental data: Table 2).
14
15 Combining both intervention groups to increase the analytical power of the effects of 
16 surgery identified 51 genes with significantly altered expression following surgery 
17 (Supplemental data: Table 6). Pathway analysis of this data identified the 
18 “Oxidative stress response” (p= 4.76E-02), “Interleukin signaling” (p= 5.10E-04), 
19 “CCKR signaling map” (p=9.53E-07) and “p53” (p= 8.22E-03) pathways as over-
20 represented.
21
22 3.2.4 Validation of transcriptomic response:
23 We have previously examined the induction of IL6, IL8 and IL1B gene expression in 
24 the lung biopsies by Taqman qPCR. The gene expression data following CPB showed 
25 the same increase in inflammatory gene expression in the LFV group compared to the 
14
1 lungs collapsed group [14].   In addition, we demonstrated significant up-regulation of 
2 hypoxia inducible factor 1A (HIF1A) gene expression in the biopsies after lungs 
3 collapsed CBP, which was further enhanced in the biopsies from patients who 
4 underwent LFV (Figure 3A), compared to the pre-surgery control biopsies.
5
6 3.3 Biopsy Proteomic analysis:
7 Full data set is available at https://figshare.com/articles/_/4772167. Whole cell protein 
8 extracts from each biopsy were pooled into 4 groups: lungs left collapsed or LFV both 
9 pre and post-surgery. Tandem mass tagging (TMT) identified over 3000 distinct 
10 proteins in the pooled biopsy samples. There was minimal variation in the pre-surgery 
11 baseline levels of proteins detected.  Two proteins were significantly elevated >2-fold 
12 in the lungs left collapsed group and 34 were elevated >2x in the LFV group 
13 (Supplemental data: Table 7) before surgery.  Panther pathways analysis of these 
14 proteins did not identify any biological pathways or processes as overrepresented.  
15 Using a 1.5-fold cut-off, there were 4 significantly different proteins in the lungs 
16 collapsed group and 155 proteins more highly expressed in the LFV group.  
17 PANTHER analysis of these proteins identified “immune system process” as over-
18 represented in the LFV group at baseline before surgery.
19
20 3.3.1 Proteomic response to CPB with lungs collapsed:
21 Lungs collapsed CBP resulted in 25 proteins having a >2-fold increase in expression 
22 post-surgery and 1 protein decreased >2-fold (Supplemental data: Table 8) relative 
23 to the same donors before surgery. The up-regulated proteins included the detoxifying 
24 enzyme glutathione S-transferase P (GSTP1), and eosinophil peroxidase.  The 
25 decreased protein was identified as “cDNA FLJ50754, highly similar to voltage-
15
1 dependent L-type calcium channel subunit alpha-1D”.  Reducing the cut-off ratio to 
2 1.5-fold change increased the number of differentially expressed proteins to 109 with 
3 enhanced expression and 8 proteins that were decreased.  These did not reflect any 
4 pathways or processes although at the unadjusted p value level the “CCKR signalling 
5 map” and “intergrin signalling pathways” were identified as over-represented 
6 (p=4.91E-2 and p=1.33E-02 respectively). 
7
8 3.3.2 Proteomic response to CPB with LFV:
9 CBP in the presence of LFV resulted in >2-fold upregulation of 7 proteins with 
10 keratin, both type I and II, making up 6 out of 7 of these proteins (Supplemental 
11 data: Table 8).  Keratin is a common contaminant of proteomic experiments, so these 
12 changes may simply be an artefact, however keratin expression in the lungs has 
13 previously been reported, including its upregulation during lung repair [18] and by 
14 shear forces.[19,20] The remaining protein was “cDNA FLJ50754, highly similar to 
15 Voltage-dependent L-type calcium channel subunit alpha-1D”.  Whilst no pathways 
16 were identified as changed the keratin proteins were all linked to the process of 
17 “cellular component organisation or biogenesis” (p=2.8x10-6).  15 proteins were 
18 decreased >2-fold following surgery with LFV, including 5 haemoglobin subunits 
19 (HBA2, HBB, HBD). Analysis of biological processes identified “blood circulation” 
20 as overrepresented (p>0.001).  
21
22 19 proteins were increased following LFV using a 1.5-fold cut off, 7 of which were 
23 linked to the “cellular component morphogenesis” process (p>0.001).  47 proteins 
24 were decreased following surgery. The analysis did not identify any pathways 
16
1 significantly altered by LFV at the protein level, however, cellular process analysis 
2 again identified “blood circulation” as overrepresented (p=0.001).   
3
4 3.3.3 Comparison of LFV with lungs left collapsed:
5 Direct comparison of the post-bypass samples identified 4 proteins that were 
6 increased in the lungs collapsed group with >2-fold change and 9 proteins that were 
7 increased in the LFV group (Supplemental data: Table 5). Biological pathway and 
8 process analysis did not identify any significantly over-represented 
9 pathways/processes between these groups.  16 proteins were identified as >1.5-fold 
10 higher in lungs collapsed compared to LFV, of which 3 were also higher at baseline 
11 and therefore excluded from the analysis.  Proteins increased in the lungs collapsed 
12 group included haemoglobin alpha, beta and delta. These proteins were not associated 
13 with any significant changes in biological pathways but were identified with the 
14 processes of blood circulation (p=2.27E-04) and transport (p=3.14E-05).   
15 11 proteins were higher in the LFV group compared to lungs collapsed post-surgery 
16 but not pre-surgery. No processes or pathways were identified as significant. 
17
18 3.4 Confirmation of reduced haemoglobin in biopsies following LFV:
19 Due to the proteomics identification of haemoglobin as downregulated in the LFV 
20 group the level of heme was measured in the protein isolated from each lung biopsy 
21 (Figure 3B). The amount of heme in the biopsies did not significantly change 
22 following CPB with lungs collapsed, however, it was significantly reduced following 




1 Full data set is available at https://figshare.com/articles/_/4772167. There were no 
2 significant differences in lipid class or species between groups either before or after 




2 Surgery with CPB is associated with acute systemic and pulmonary inflammation and 
3 can lead to pulmonary dysfunction in a significant number of patients.  We confirmed 
4 previous data showing enhanced levels of inflammatory cytokines, oxidative stress, 
5 cell free heme and decreased plasma anti-oxidant capacity with CPB. We also 
6 provided evidence for the first time in transcriptomic analysis of lung biopsy in 
7 patients undergoing CABG, that CPB triggers a significant increase in hypoxic and 
8 inflammatory responses and a decrease in genes associated with blood flow. These 
9 effects were amplified in patients undergoing CPB with LFV when compared with 
10 CPB with lungs collapsed.  These data provide a mechanistic link to the adverse 
11 clinical effects seen with the addition of LFV to CPB in patients undergoing CABG 
12 (14).  
13
14 Analysis of the patients’ plasma showed that following CPB with lungs collapsed 
15 there was a significant increase in the levels of inflammatory cytokines, oxidative 
16 stress, cell free heme and a decrease in plasma anti-oxidant capacity corresponding to 
17 the effects of CPB surgery previously reported [21]. These systemic effects were not 
18 significantly altered by CPB with LFV intervention. 
19
20 LFV may increase the deleterious effects of CPB by three main mechanisms: 
21 increased surgical time, direct oxygenation of the lungs or ventilator-associated 
22 injury.  The movement of the lungs during CPB with LFV may increase surgery time.  
23 The LFV group had a  higher levels of cell free heme in the blood following CPB, a  
24 reflection  of the longer CPB time compared to the lungs left collapsed CPB group 
19
1 (87.5 minutes median (range 68-97) vs 69 minutes median (range 54-79)) (p=0.03) 
2 [14]. 
3
4 The increased oxygenation of the lungs during LFV may also enhance lung injury. 
5 Without the hypoxic response to reduce metabolic rates, LFV may cause a more rapid 
6 use of metabolic substrates and the build-up of by-products causing increased lung 
7 damage. Hyperoxia during surgery showed similar inflammation and stress following 
8 CPB as normoxia, although hyperoxia led to oxygen-mediated myocardial, hepatic 
9 and cerebral injury [22]. This hypothesis is unlikely as the LFV group showed 
10 increased HIF1A gene expression in blood indicating that the lungs were less, not 
11 more, oxygenated during LFV. However, intermittent hypoxia has been shown to be 
12 more potent at activating HIF-1α and FOS/AP-1  than continuous hypoxia [23].
13
14 Finally, LFV may cause biotrauma to the lung by repetitive alveolar collapse and 
15 hyperinflation [24]. 
16
17 Our data are unique because of the use of lung biopsies taken during the surgery in the 
18 on-going debate regarding relative contributions of ischaemia and reperfusion to 
19 tissue injury. The data indicate that the practice of lungs left collapsed during CPB 
20 prior to reperfusion, can trigger gene expression, inflammation and stress in the lungs. 
21 These could be the consequence of atelectasis, direct effect of lung hypoperfusion and 
22 ischemia superimposed by perfusion with activated inflammatory cells due to their 
23 activation by the CPB machine and circuit.  There has been considerable debate as to 
24 the relative importance of these mechanisms in driving lung inflammation [3,4,25] but 
25 the strong correlation between increased stress, hypoxia and inflammation in the lungs 
20
1 support the hypothesis that ischemia alone is enough to drive inflammation.   
2 Ischemia during surgery is associated with significant changes in inflammation 
3 (interleukin signalling pathway) and stress (CCKR and p53 pathways) in the lung. 
4
5 In addition, the principle driver of increased inflammation in the LFV group appears 
6 to be increased surgery time, and hence ischemic, time, whilst reperfusion remained 
7 unchanged. As our lung biopsies were collected immediately after reperfusion it is 
8 unlikely that systemic inflammation or reperfusion injury would have been able to 
9 influence gene expression, but rather that ischemia alone is capable of significantly 
10 damaging the lungs.
11
12 Whilst the proteomic analysis of CPB identified several proteins that changed 
13 expression in the pooled samples, this did not identify any specific pathways as 
14 activated by routine CPB with lungs left collapsed. Proteomic analysis is hampered by 
15 the short timeframes in which the surgery occurs and (to overcome resource 
16 constraints) the pooling of samples from all patients in each treatment group. Whilst 
17 pooling the samples loses the ability to discern individual patient variation, this 
18 approach reduces biological variation and thereby increases the power to detect 
19 treatment differences [26]. Nevertheless, CCKR signalling and integrin signalling 
20 pathways were significantly over-represented by proteins up-regulated by CPB when 
21 assessed using a raw p value <0.05.  As stated above, the CCKR signalling may be 
22 induced by hypoxic conditions and up-regulated protein levels correlated well with 
23 gene expression. The integrin signalling proteins consisted of collagen alpha-1 (I) 
24 chain, the collagen alpha-1 (XIV) chain, the adapter molecule Crk and Crk-like 
25 (CrkL) proteins. Crk and CrkL have been shown to play a key role in the activation 
21
1 and transformation of fibroblasts, which are the principle produces of extracellular 
2 matrix, including collagen in response to injury. These data indicate that fibroblast 
3 activation, in response to lung injury, occurs at an early stage in CPB. This study 
4 provides valuable insight into the underlying mechanisms that drive lung 
5 inflammation during CPB. This increased understanding may lead to more effective 
6 interventions in the future.
7
8
9 Proteomic analysis of the LFV group showed a significant decrease in proteins 
10 representing blood circulation, such as haemoglobin, which was confirmed in the 
11 biopsy samples. These data indicate that LFV may have increased vascular resistance 
12 and further reduced pulmonary blood flow during surgery, which may increase the 
13 level of ischemia and the level of pulmonary inflammation [27]. Patients undergoing 
14 LFV did show an increase in requiring haemodynamic support following surgery 
15 compared to those undergoing CPB with lungs left collapsed, so alternatively this 
16 may reflect a reduction in blood pressure [14].
17
18 Whilst changes in lipids have been reported in response to oxidative stress, such as 
19 the accumulation of pro-inflammatory isoprostanes and oxylipins in smokers and in 
20 patients with cardiovascular disease, no significant changes in lipidomics were 
21 detected following CPB, indicating that either the timeframe of the study was too 
22 short for these changes to occur or CPB has little effect on the lipid composition of 
23 the lung. The lack of change in the proteomics and lipidomic profiles detected may 
24 also reflect the important role that post-translational modifications play in regulating 
22
1 protein and lipid function. Unfortunately, examination of post-translational 
2 modifications was beyond the scope of this study. 
3
4 A major limitation of the study is the timing of the sample collection. The initial pilot 
5 study was not designed to identify differences between ischemia and reperfusion and 
6 ideally lung biopsies should have been taken immediately before and after reperfusion 
7 occurred. Additionally the timing may be suboptimal for detecting changes which  
8 drive lung injury following CPB. A study by Hepponstall examining the plasma 
9 proteome following CPB found changes in C-reactive protein and hepatoglobin 
10 peaked at 12-24 hours following surgery [28]. This is reflected in the differences in 
11 results between the Luminex measure of cytokines in the plasma and the lung biopsy 
12 proteomics. In the biopsies collected immediately post-surgery there was no 
13 significant increases in the levels of inflammatory cytokines detected, which 
14 contrasted with the significant increases in the plasma samples collected 24 hours 
15 later, reflecting the several hours of transcription, translation and post-translational 
16 modification required for fully mature cytokines to be produced. However, as shown 
17 by our previous publication on LFV and CPB inflammatory signals, such as NF-κB 
18 were significantly higher immediately after surgery in the lung biopsies [14]. 




23 LFV increased pulmonary, but not systemic inflammation, following CPB. Semi-
24 biased transcriptomic and proteomic analysis of lung biopsies suggest that ischemia is 
25 the principle driver of pulmonary inflammation following CPB and that LFV, 
23
1 possibly through reduced blood flow through the bronchial artery and increased 
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Figure 1. Cytokine levels following surgery. 
Plasma was extracted from the blood of patients collected after anaesthetic induction 
but before the cardio-pulmonary bypass (CPB) procedure (pre-CPB), and at 24hrs 
post-operation (post-CPB). Patients who underwent CPB with lungs left collapsed 
shown in black (n=18). Patients shown in grey (n=18) received CPB with low 
frequency ventilation (LFV). Concentrations of (A) IL-6, (B) IL-8, (C) IL-10, (D) IL-
1β and (E) MCP-1 in the plasma were quantified with a multiplex assay. Data was 
analysed Freidman Test statistical analysis with Dunn’s multiple comparison post-
test; **p<0.01, ***p<0.001, ****p<0.0001. 
Figure 2. Measurements in blood plasma following surgery. 
Plasma samples were measured at various timepoints following surgery, (A) cell free 
heme in the patients undergoing CPB with lungs left collapsed (n=18), (B) heme in 
patients undergoing CPB with LFV (n=18) (C) oxidation reduction potential (ORP) 
(D) anti-oxidant capacity (AOC). The control group is shown in black and the LFV 
group in grey. Data from both patient groups were combined to examine the effects of 
the CPB circuit on (E) ORP and (F) AOC. Data were analysed using Freidman Test 
statistical analysis with Dunn’s multiple comparison post-test *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
Figure 3.  Measurements in lung biopsies following surgery.
32
(A) Hypoxia inducible factor 1 alpha (HIF1A) gene expression in lung biopsies pre- 
and post-surgery using either CPB with lungs left collapsed or with LFV. HIF1A gene 
expression (normalised to 18S) was significantly increased (the median gene 
expression doubled) in lung tissue following CPB, with (n=18) or without LFV 
(n=18). LFV biopsies had significantly higher levels of HIF1A gene expression 
compared to biopsies from patients who underwent CPB with lungs left collapsed. 
Lung biopsies were taken prior to bypass (Pre) and after surgery, immediately before 
reperfusion (Post). n=18 in each group of patients *p<0.05, **p<0.01 comparing 
groups post-surgery, Wilcoxon matched-pairs signed rank test.
(B) Total Heme in lung biopsy samples from both groups, both pre- and post-surgery. 
Whilst heme levels were not significantly altered in the biopsies from patients 
undergoing CPB with lungs left collapsed they were significantly reduced in the 
biopsies from patients undergoing CPB with LFV following surgery. n=18 in each 
group of patients *p<0.05, **p<0.01 comparing groups post-surgery, Wilcoxon 
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3 Multi-omic analysis of the effects of low frequency ventilation during 
4 cardiopulmonary bypass surgery.
5
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13 For RNA extraction biopsies were placed in in RLT buffer (Qiagen) and 
14 homogenized using Precellys® ceramic beads (Cayman Chemicals, Cambridge, 
15 UK). Subsequently RNA was extracted using RNeasy extraction kit following 
16 manufacturer’s instructions (Qiagen, Manchester, UK).
17
18 RNA was quantified by NanoDrop spectrophotometer (ThermoFisher, Waltham, 
19 MA, USA) and quality was checked by LabChip® spectrophotometer (Perkin 
20 Elmer). Subsequently RNA was amplified, converted to cDNA using the cDNA 
21 Ovation Pico WTA System (NuGen, San Carlos, CA, USA) and biotin labelled, using 
22 the Encore BiotinIL Module (Nugen), following the manufacturer’s instructions.  
23 The cDNA was quantified and qualified, as above, and gene expression was 
24 measured using the Affymetrix GeneChip Human Gene 1.0 ST Array 
25 (ThermoFisher) following the manufacturer’s instructions. Microarray data was 
2
1 analysed using Partek Genomics Suite 6.6 (Partek GS, St. Louis, MI, USA ) 
2 software and PANTHER gene ontology.[1]
3
4 RNA samples were also quantified using RT-qPCR. In brief the RNA 
5 concentration was determined using a NanoDrop 2000c spectrophotometer and 
6 standardised to 50ng/L.  Reverse transcription to create single stranded cDNA 
7 was performed using a high-capacity cDNA kit (Applied Biosystems, Foster City, 
8 CA, USA), following the manufacturer's instructions. qPCR was performed using a 
9 Rotor-Gene 3000 PCR machine (Corbett Research, Cambridge, UK) using a 
10 QuantiTect SYBR Green PCR kit and normalised to 18S rRNA. 
11
12 Proteomics:
13 Protein was extracted as described previously. In brief samples were 
14 homogenized in RIPA buffer (Sigma Aldrich, Poole, UK) containing HALT 
15 protease and phosphatase inhibitors (ThermoFisher, Paisley, UK) using 
16 Precellys® ceramic beads (Cayman Chemicals). After 30 minutes incubation at 
17 4°C the samples were centrifuged (13,000g, 5 minutes, 4°C). 
18
19 Supernatants from each group were quantified against a standard curve using 
20 the bininchoninic acid (BCA) assay (Sigma Aldrich) and equal amounts from each 
21 sample were pooled and changes in protein expression analysed using tandem 
22 mass tagging (TMT), as described previously.[2] 
23
24 TMT Labelling and cation exchange chromatography
3
1 Aliquots of 100µg of each sample were digested with trypsin (2.5µg trypsin per 
2 100µg protein; 37°C, overnight) and labelled with Tandem Mass Tag (TMT) 
3 sixplex reagents according to the manufacturer’s protocol (Thermo Fisher 
4 Scientific, Loughborough, LE11 5RG, UK).  After labelling, samples were pooled 
5 and a 50µg aliquot evaporated to dryness and resuspended in Buffer A (10mM 
6 KH2PO4, 25%MeCN pH3) prior to fractionation by strong cation exchange using 
7 an Ettan LC system (GE Healthcare).  In brief, the sample was loaded onto a 
8 PolysulphoethylA column (100 x 2.1mm, 5µm, 200A; PolyLC Inc.) in buffer A and 
9 peptides eluted with an increasing gradient of buffer B (10mM KH2PO4, 
10 25%MeCN 1M KCl pH3) from 0-100% over 30 minutes.  The resulting fractions 
11 were evaporated to dryness, resuspended in 5% formic acid and then desalted 
12 using SepPak cartridges according to the manufacturer’s instructions (Waters, 
13 Milford, Massachusetts, USA)).  Eluate from the SepPak cartridge was again 
14 evaporated to dryness and resuspended in 1% formic acid prior to analysis by 
15 nano-LC MSMS using an LTQ-Orbitrap Velos Mass Spectrometer.  
16
17 Nano-LC Mass Spectromerty
18 Cation exchange fractions were further fractionated using an Ultimate 3000 
19 nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrometer 
20 (Thermo Scientific).  In brief, peptides in 1% (vol/vol) formic acid were injected 
21 onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 
22 washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides 
23 were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse phase 
24 analytical column (Thermo Scientific) over a 150 min. organic gradient, using 7 
25 gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 15-32%B 
4
1 over 58min., 32-40%B over 5min., 40-90%B over 1min., held at 90%B for 6min 
2 and then reduced to 1%B over 1min.) with a flow rate of 300 nl min−1.  Solvent A 
3 was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% 
4 formic acid.  Peptides were ionized by nano-electrospray ionization at 2.0kV 
5 using a stainless-steel emitter with an internal diameter of 30 μm (Thermo 
6 Scientific) and a capillary temperature of 250°C. Tandem mass spectra were 
7 acquired using an LTQ- Orbitrap Velos mass spectrometer controlled by Xcalibur 
8 2.1 software (Thermo Scientific) and operated in data-dependent acquisition 
9 mode.  The Orbitrap was set to analyze the survey scans at 60,000 resolution (at 
10 m/z 400) in the mass range m/z 300 to 1800 and the top ten multiply charged 
11 ions in each duty cycle selected for MS/MS fragmentation using higher-energy 
12 collisional dissociation (HCD) with normalized collision energy of 45%, 
13 activation time of 0.1 ms and at a resolution of 7500 within the Orbitrap.  Charge 
14 state filtering, where unassigned precursor ions were not selected for 
15 fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30s; 
16 exclusion list size, 500) were used. 
17
18 Data Analysis
19 The raw data files were processed and quantified using Proteome Discoverer 
20 software v1.2 (Thermo Scientific) and searched against the UniProt Human 
21 database using the SEQUEST algorithm.  Peptide precursor mass tolerance was 
22 set at 10ppm, and MS/MS tolerance was set at 20mmu.  Search criteria included 
23 oxidation of methionine (+15.9949) as a variable modification and 
24 carbamidomethylation of cysteine (+57.0214) and the addition of the TMT 6Plex 
25 mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. 
5
1 Searches were performed with full tryptic digestion and a maximum of 1 missed 
2 cleavage was allowed.  The reverse database search option was enabled and all 
3 peptide data was filtered to satisfy false discovery rate (FDR) of 5%.  
4
5 Lipidomics:
6 Lung tissue was weighed and homogenised on ice in 1.6ml of 0.9% saline 
7 together with 20μl of the anti-oxidant butylated hydroxyl toluene (BHT) (20 
8 mg/ml in methanol), using a Heidolph Silent Crusher S. The homogenised lung 
9 samples were stored at -80oC for subsequent lipid extraction. An aliquot of lung 
10 homogenate (800 μl) was lipid extracted with dichloromethane and methanol[3] 
11 after addition of internal quantification standards (PC14:0/14:0 10nmol, 
12 PE14:0/14:0 4nmol, TAG14:0/14:0/14:0 10nmol, PG14:0/14:0 2nmol, 
13 PS14:0/14:0 2nmol, PS14:0/14:0 2nmole, CE17:0 1nmol, 
14 CL14:0/14:0/14:0/14:0/14:0 1nmol) in 100μl methanol.  The dichloromethane 
15 fraction was dried under nitrogen gas and the resultant extract was analysed 
16 using a Waters Xevo TQ mass spectrometer (Waters, Wythenshaw, UK). Samples 
17 were introduced to the mass spectrometer by syringe-driven direct infusion and 
18 the various lipid classes analysed by a comprehensive platform of diagnostic 
19 precursor and neutral loss scans as described previously.[4]  Mass spectrometry 
20 results were initially processed by MassLynx software and subsequently 
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2 Table 1. Differentially expressed genes in lung following CBP with lungs left 
3 collapsed.
4 Gene expression was measured in lung biopsies taken immediately following 
5 induction of bypass and immediately prior to the commencement of reperfusion. 
6 Data are organised by ratio of gene expression of the post: pre-surgery samples 
7 from patients undergoing CPB with lungs left collapsed.
8




































1 Table 2. Altered transcriptomic pathways and processes altered by lungs left collapsed and LFV. 
2 Table showing the pathways and biological processes activated during cardio-pulmonary bypass with lungs left collapsed (collapsed) or 
3 with low-frequency ventilation (LFV) during surgery. Data shows the fold enrichment compared to the expected gene number in the 
4 sample size. P values include Bonferroni correction for multiple comparisons.
5
Collapsed LFV LFV vs. Collapsed
Combined Collapsed and 
LFV groups post vs. pre 
surgery
Pathway Fold-change Adj P value Fold-change Adj P value Fold-change Adj P value Fold-change Adj P value
CCKR signalling map + 31.28 2.26E-08 + 19.66 2.14E-10 + 20.20 6.81E-03 + 20.20 9.53E-07
Interleukin signaling pathway + 34.52 5.41E-05 + 14.46 4.34E-03 + 22.29 5.10E-04
p53 pathway + 23.06 4.81E-02 + 12.88 4.46E-02 + 19.86 8.22E-03
Inflammation mediated by 
chemokine and cytokine 
signaling pathway





Plasminogen activating cascade + 97.09 3.17E-02
Oxidative Stress Response + 23.41 4.76E-02
Process
Endoderm development + >100 3.66E-02 + >100 1.53E-02
MAPK cascade + 7.75 3.16E-02 + 11.95 4.62E-04
Cell death + 65.40 3.30E-02 + >100 2.53E-02
Response to stress + 4.28 2.23E-03 5.08 5.05E-03





1 Table 3. Differentially expressed genes in lung samples in the LFV group. The 
2 expression of the same genes in the lungs left collapsed (Collapsed) group is 
3 shown for comparison (where also significantly changed).
4 The data shows the genes that were significantly changed post-surgery 
5 comparing the pre- and post-surgery samples from the LFV group. Data are 
6 organised by ratio of gene expression of the post: pre-surgery samples. Also 
7 shown are the p-values and ratios for the same genes in the CPB group pre- and 





post vs. pre 
LFV)
Ratio (Post LFV 
post vs. pre 
LFV)
p-value (Collapsed 
post vs. Collapsed 
pre)
Ratio (Collapsed 
post vs. Collapsed 
pre)
EGR1 1.52E-10 4.31211 1.19E-11 4.85421
CCL2 3.14E-11 3.7367 1.56E-17 6.7442
ZFP36 2.33E-10 3.39726 8.06E-13 4.24673
IER3 5.24E-10 3.36618 3.45E-14 4.95907
FOSB 1.97E-06 3.23688 1.59E-05 2.85606
IL6 4.20E-07 3.20897 2.66E-13 6.59224
AXUD1 7.36E-09 2.97975 6.87E-12 3.93191
GADD45B 8.53E-09 2.84233 7.16E-11 3.41388
RGS2 9.57E-09 2.82692 1.27E-09 3.05557
PTGS2 2.02E-07 2.71364 1.89E-10 3.63922
NAMPT 2.76E-08 2.69011 7.02E-14 4.38552
12
ADAMTS1 3.20E-07 2.65546 9.20E-13 4.52339
THBS1 4.31E-05 2.58619 2.69E-10 4.99284
CDKN1A 2.66E-09 2.58471 7.22E-13 3.39603
NR4A2 4.81E-08 2.54051 4.01E-10 3.03127
MT2A 1.58E-05 2.3859 9.45E-11 4.18274
MYC 3.80E-08 2.34622 6.46E-13 3.37585
SIK1 2.79E-08 2.33506 4.11E-11 2.88863
DUSP5 1.37E-08 2.3046 2.27E-10 2.61988
CYR61 0.000139197 2.28028
BHLHB2 1.21E-07 2.26944 7.16E-10 2.69932
MT1A 0.00023541 2.21719
FOS 9.31E-06 2.21653 1.52E-05 2.16802
SLC2A3 1.90E-07 2.20188 8.13E-09 2.44753
NFIL3 5.29E-08 2.19547 4.68E-14 3.38138
IL8 1.23E-05 2.17884 2.29E-09 3.11566
PIM1 4.81E-07 2.172 1.77E-11 3.07144
CXCL2 7.34E-07 2.13394 1.13E-10 2.87649
DUSP1 0.000566532 2.12812
CRISPLD2 0.000119155 2.12754
MIDN 1.03E-05 2.087 7.50E-07 2.31974
NR4A3 1.67E-07 2.02404 4.53E-11 2.57595
EGR3 2.96E-07 2.00958 6.07E-11 2.59004
SGK 0.000488729 2.00601



















































1 Table 4.  Differentially expressed proteins identified by TMT, comparing CPB 
2 with lungs left collapsed and LFV. 











Q15423 64 7.1 8.18 3.700 Serum amyloid A protein (Fragment) 
B4DIF5 345 39.2 8.92 2.478 cDNA FLJ55687, highly similar to Cell 
cycle control protein 50A 
P20851 252 28.3 5.14 2.283 C4b-binding protein beta chain
Q8IUL9 105 11.5 6.05 2.251 Hemoglobin beta chain variant 
Hb.Sinai-Bel Air (Fragment) 
Q6VFQ6 42 4.5 8.24 1.766 Hemoglobin beta chain (Fragment) 
Q92531 187 19.7 6.32 1.712 P35-related protein (Fragment) 
Q3MIB5 262 28.7 5.27 1.617 INMT protein (Fragment) 
P02774 474 52.9 5.54 1.608 Vitamin D-binding protein 
B4DWJ7 155 17.5 8.37 1.597 cDNA FLJ54968 
P11686 197 21.0 6.65 1.583 Pulmonary surfactant-associated 
protein C 
Q5T619 568 62.3 8.62 1.573 Zinc finger protein 648 
E5RGQ7 148 16.8 8.88 1.563 Dematin (Fragment) 
S6BGD6 235 24.8 7.24 1.557 IgG L chain 
Q6J1Z9 90 9.6 9.50 1.540 Hemoglobin alpha 1 (Fragment)
16
P02042 147 16.0 8.05 1.522 Hemoglobin subunit delta 
Q6J1Z8 42 4.5 9.38 1.507 Hemoglobin beta (Fragment) 
D3DTX7 885 84.7 6.24 0.664 Collagen, type I, alpha 1, isoform 
CRA_a 
M0QZ50 93 9.8 4.48 0.663 Microtubule-associated protein 1S 
P01861 327 35.9 7.36 0.662 Ig gamma-4 chain C region 
A0A087WTA8 1364 129.1 9.01 0.658 Collagen alpha-2(I) chain 
O76041 1014 116.4 7.99 0.654 Nebulette 
P08519 4548 501.0 5.88 0.652 Apolipoprotein(a) 
C9JNE5 191 21.7 9.61 0.648 Myeloid leukemia factor 1 (Fragment) 
H3BRW3 109 11.7 9.96 0.636 FAD-linked sulfhydryl oxidase ALR 
P27701 267 29.6 5.24 0.636 CD82 antigen 
Q9NZ09 502 55.0 5.11 0.635 Ubiquitin-associated protein 1 
A4FU00 317 35.6 5.81 0.634 SYT2 protein (Fragment) 
B4DMJ5 242 27.3 4.50 0.634 cDNA FLJ53012, highly similar to 
Tubulin beta-7 chain 
P07451 260 29.5 7.34 0.633 Carbonic anhydrase 3 
Q6PII6 533 58.3 4.77 0.610 TMF1 protein (Fragment) 
P35908 639 65.4 8.00 0.603 Keratin, type II cytoskeletal 2 
epidermal 
P01880 384 42.2 7.93 0.591 Ig delta chain C region 
A2J1N5 94 10.4 9.13 0.590 Rheumatoid factor RF-ET6 (Fragment) 
P81605 110 11.3 6.54 0.586 Dermcidin 
Q7Z6I6 1101 118.5 4.81 0.567 Rho GTPase-activating protein 30 
SV=3 
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P13761 266 29.8 7.44 0.562 HLA class II histocompatibility antigen, 
DRB1-7 beta chain 
A8K9A9 638 71.3 8.22 0.521 cDNA FLJ77744, highly similar to 
Homo sapiens kallikrein B, plasma 
(Fletcher factor) 1 (KLKB1), mRNA 
Q96Q06 1357 134.3 8.73 0.519 Perilipin-4 
B3KMX3 270 28.5 4.73 0.497 cDNA FLJ12857 fis, clone 
NT2RP2003513, highly similar to 
Homo sapiens paralemmin (PALM), 
Q15323 416 47.2 4.88 0.436 Keratin, type I cuticular Ha1 
Q30167 266 30.0 7.75 0.373 HLA class II histocompatibility antigen, 
DRB1-10 beta chain 
B7Z269 351 40.3 7.24 0.299 cDNA FLJ50754, highly similar to 
Voltage-dependent L-type calcium 
channel subunit alpha-1D 
A0JNT2 447 49.6 5.39 0.240 KRT83 protein 
A0A087X2I6 404 46.1 4.84 0.206 Keratin, type I cuticular Ha3-II 
O76013 467 52.2 4.94 0.144 Keratin, type I cuticular Ha6 
Q701L7 513 56.6 6.74 0.073 Type II hair keratin 2 







1 Table 5. Differentially expressed genes in lung biopsies post CBP with collapsed 
2 lungs (Collapsed) versus post CBP+LFV (LFV).
3 The data shows the genes that were significantly changed post-surgery 
4 comparing the LFV and CPB with lungs collapsed groups. Data are organised by 
5 ratio of gene expression in the CPB:LFV groups. Also shown are the p-values and 























post vs. LFV 
pre)
HLA-DRB5 0.0311729 1.69779
MIR21 0.00716334 0.664162 0.00026313 1.76523 3.13E-08 2.5143
PLAU 0.00027089 0.663153 9.09E-05 1.56036 3.92E-10 2.18467
NAMPT 0.00887185 0.653954 2.76E-08 2.69011 7.02E-14 4.38552
CRISPLD2 0.0245826 0.65374 0.00011915 2.12754 2.77E-08 3.19182
SPSB1 0.00543046 0.652837 0.0011272 1.65691 3.46E-08 2.51871
PIM1 0.00237397 0.643988 4.81E-07 2.172 1.77E-11 3.07144
MT2A 0.0212365 0.64331 1.58E-05 2.3859 9.45E-11 4.18274
CYR61 0.0334855 0.642119 0.00013919 2.28028 1.35E-05 2.60616
PTX3 3.35E-05 0.633302 0.0140338 1.29593 3.50E-09 2.00809
NFIL3 0.00061884 0.630321 5.29E-08 2.19547 4.68E-14 3.38138
C13ORF33 4.01E-06 0.629229 0.00088378 1.3788 9.54E-13 2.24342
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PTGS2 0.00877579 0.627638 2.02E-07 2.71364 1.89E-10 3.63922
OBFC2A 0.00039958 0.619068 0.00020414 1.65775 1.34E-09 2.46718
SERPINB2 6.89E-05 0.604865 0.00229441 1.45598 4.19E-10 2.37424
FST 3.24E-07 0.604399 0.0263664 1.22358 1.07E-09 1.87432
TRK1 9.80E-05 0.598732 0.0259384 1.32595 3.25E-08 2.16599
NNMT 0.00050317 0.598371 0.00555558 1.49559 2.12E-10 2.85178
IER3 0.00213579 0.585514 5.24E-10 3.36618 3.45E-14 4.95907
TRQ1 1.05E-06 0.575413 0.00924457 1.3179 3.91E-10 2.12356
ADAMTS1 0.00128987 0.560691 3.20E-07 2.65546 9.20E-13 4.52339
CCL2 0.00088664 0.560328 3.14E-11 3.7367 1.56E-17 6.7442
CCL8 8.14E-06 0.537271 0.00033771 1.62543 2.39E-12 2.99664
ALDH1A3 0.00014072 0.498751 0.00342271 1.68698 3.40E-09 3.22296
IL6 0.00081229 0.481974 4.20E-07 3.20897 2.66E-13 6.59224






Genes significantly altered in the combined CPB with collapsed lungs and LFV 
dataset (all patients) comparing biopsies taken before and immediately post-
surgery (prior to reperfusion).
Probeset ID p-value Fold-Change (Post vs. Pre) Fold-Change (Post vs. Pre)
ADAMTS1 2.29E-14 3.46579 Post up vs Pre
ALDH1A3 2.06E-08 2.33175 Post up vs Pre
AXUD1 7.62E-16 3.42288 Post up vs Pre
BHLHB2 1.27E-13 2.47507 Post up vs Pre
CCL2 5.10E-20 5.02006 Post up vs Pre
CCL8 9.21E-11 2.20699 Post up vs Pre
CDKN1A 2.13E-16 2.96273 Post up vs Pre
CEBPD 1.48E-12 2.29829 Post up vs Pre
CHSY1 2.26E-09 2.15588 Post up vs Pre
CRISPLD2 6.38E-10 2.6059 Post up vs Pre
CXCL2 3.47E-13 2.47755 Post up vs Pre
CYR61 9.06E-08 2.43778 Post up vs Pre
DUSP1 7.63E-07 2.21634 Post up vs Pre
DUSP5 1.01E-14 2.45719 Post up vs Pre
EGR1 6.78E-17 4.57514 Post up vs Pre
EGR3 1.29E-13 2.28143 Post up vs Pre
ELL2 9.39E-10 2.13515 Post up vs Pre
ERRFI1 7.92E-10 2.21222 Post up vs Pre
FOS 3.79E-09 2.19214 Post up vs Pre
FOSB 9.80E-10 3.04051 Post up vs Pre
FOSL2 1.28E-13 2.11261 Post up vs Pre
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GADD45A 1.46E-14 2.10184 Post up vs Pre
GADD45B 4.21E-15 3.11502 Post up vs Pre
IER3 3.18E-17 4.08572 Post up vs Pre
IL6 1.54E-14 4.59938 Post up vs Pre
IL8 1.49E-11 2.60548 Post up vs Pre
LOC441019 4.99E-12 2.27893 Post up vs Pre
MIDN 5.01E-10 2.20029 Post up vs Pre
MIR21 2.24E-09 2.10673 Post up vs Pre
MT1A 4.47E-10 2.90963 Post up vs Pre
MT2A 2.60E-12 3.15905 Post up vs Pre
MTE 1.97E-09 2.35834 Post up vs Pre
MYC 1.82E-15 2.81434 Post up vs Pre
NAMPT 2.56E-16 3.43475 Post up vs Pre
NFIL3 1.39E-15 2.72465 Post up vs Pre
NNMT 3.81E-09 2.06521 Post up vs Pre
NR4A2 3.74E-14 2.77506 Post up vs Pre
NR4A3 5.09E-14 2.28338 Post up vs Pre
OBFC2A 7.07E-10 2.02236 Post up vs Pre
PIM1 1.76E-13 2.58286 Post up vs Pre
PTGS2 2.79E-13 3.14254 Post up vs Pre
RASD1 5.52E-07 2.12328 Post up vs Pre
RGS2 2.93E-14 2.93902 Post up vs Pre
RNF122 3.02E-12 2.34752 Post up vs Pre
SGK 9.65E-07 2.07768 Post up vs Pre
SIK1 4.42E-15 2.59714 Post up vs Pre
SLC2A3 8.98E-13 2.32146 Post up vs Pre
SPSB1 9.27E-09 2.04286 Post up vs Pre
22
THBS1 4.71E-11 3.59339 Post up vs Pre
TRIB1 3.44E-08 2.15623 Post up vs Pre
ZFP36 1.56E-17 3.79832 Post up vs Pre
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Table 7:
Data showing the proteins changed between the pooled control CPB with 
collapsed lung and LFV groups immediately prior to surgery, with a 1.5x change 
cutoff. Only 2 proteins had a greater than 2x increase in the CPB group and 34 









Q15423 64 7.1 8.18 4.664
Serum amyloid A protein (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q15423_HUMAN]
B7Z269 351 40.3 7.24 3.939
cDNA FLJ50754, highly similar to Voltage-dependent L-type calcium channel 
subunit alpha-1D OS=Homo sapiens PE=2 SV=1 - [B7Z269_HUMAN]
Q6P4A8 553 63.2 9.06 1.677
Phospholipase B-like 1 OS=Homo sapiens GN=PLBD1 PE=1 SV=2 - 
[PLBL1_HUMAN]
O96009 420 45.4 6.61 1.507 Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 - [NAPSA_HUMAN]
F2X0V0 23 2.8 7.78 0.666
Truncated CD61 (Fragment) OS=Homo sapiens GN=ITGB3 PE=4 SV=1 - 
[F2X0V0_HUMAN]
Q96T46 76 8.4 7.14 0.666
Hemoglobin alpha 2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 SV=1 - 
[Q96T46_HUMAN]
Q96P70 1041 115.9 4.81 0.665 Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 - [IPO9_HUMAN]
Q86Z07 374 41.7 9.14 0.664
Guanine nucleotide binding protein-like 1 OS=Homo sapiens GN=HSR1 PE=4 
SV=1 - [Q86Z07_HUMAN]
Q9NWH4 148 16.9 11.09 0.664
cDNA FLJ10024 fis, clone HEMBA1000636 OS=Homo sapiens PE=2 SV=1 - 
[Q9NWH4_HUMAN]
Q7Z379 478 51.6 6.52 0.664
Putative uncharacterized protein DKFZp686K04218 (Fragment) OS=Homo 
sapiens GN=DKFZp686K04218 PE=1 SV=1 - [Q7Z379_HUMAN]
B4E0V3 947 107.2 6.11 0.663
cDNA FLJ61519, highly similar to Leukocyte common antigen (EC 3.1.3.48) 
OS=Homo sapiens PE=2 SV=1 - [B4E0V3_HUMAN]
P32456 591 67.2 5.71 0.661
Interferon-induced guanylate-binding protein 2 OS=Homo sapiens GN=GBP2 
PE=1 SV=3 - [GBP2_HUMAN]
Q0PNF2 2570 275.3 6.49 0.661 FEX1 OS=Homo sapiens PE=2 SV=1 - [Q0PNF2_HUMAN]
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Q5VW33 215 24.2 7.09 0.660
BRO1 domain-containing protein BROX (Fragment) OS=Homo sapiens 
GN=BROX PE=1 SV=1 - [Q5VW33_HUMAN]
A2MYC8 104 11.0 7.28 0.659
V5-2 protein (Fragment) OS=Homo sapiens GN=V5-2 PE=1 SV=1 - 
[A2MYC8_HUMAN]
F8WD82 762 88.1 6.95 0.659
Sodium channel protein type 7 subunit alpha OS=Homo sapiens GN=SCN7A 
PE=4 SV=1 - [F8WD82_HUMAN]
B2R4C9 102 11.2 9.52 0.659
cDNA, FLJ92044, highly similar to Homo sapiens death-associated protein 
(DAP), mRNA OS=Homo sapiens PE=2 SV=1 - [B2R4C9_HUMAN]
A8K6V3 1217 135.5 5.21 0.659
cDNA FLJ78677, highly similar to Homo sapiens splicing factor 3b, subunit 3, 
130kDa (SF3B3), mRNA OS=Homo sapiens PE=2 SV=1 - [A8K6V3_HUMAN]
S6B2A1 184 20.4 5.52 0.658 IgG L chain OS=Homo sapiens PE=2 SV=1 - [S6B2A1_HUMAN]
Q9H3P7 528 60.6 5.06 0.658
Golgi resident protein GCP60 OS=Homo sapiens GN=ACBD3 PE=1 SV=4 - 
[GCP60_HUMAN]
C9JIN6 264 29.8 7.84 0.657
Transporter (Fragment) OS=Homo sapiens GN=SLC6A20 PE=3 SV=1 - 
[C9JIN6_HUMAN]
E5RHW5 125 13.1 5.39 0.657
Pulmonary surfactant-associated protein C (Fragment) OS=Homo sapiens 
GN=SFTPC PE=4 SV=3 - [E5RHW5_HUMAN]
F8WAW4 140 15.6 9.13 0.656
Enoyl-CoA delta isomerase 2, mitochondrial OS=Homo sapiens GN=ECI2 PE=1 
SV=1 - [F8WAW4_HUMAN]
B8ZZ75 194 21.5 6.93 0.655
Aldose 1-epimerase OS=Homo sapiens GN=GALM PE=1 SV=1 - 
[B8ZZ75_HUMAN]
H3BML9 118 13.1 5.68 0.655
Myosin regulatory light chain 2, skeletal muscle isoform (Fragment) OS=Homo 
sapiens GN=MYLPF PE=4 SV=1 - [H3BML9_HUMAN]
P16157 1881 206.1 6.01 0.655 Ankyrin-1 OS=Homo sapiens GN=ANK1 PE=1 SV=3 - [ANK1_HUMAN]
A0A087WXZ6 250 28.9 9.00 0.655
High affinity immunoglobulin gamma Fc receptor IB (Fragment) OS=Homo 
sapiens GN=FCGR1B PE=4 SV=1 - [A0A087WXZ6_HUMAN]
P31942 346 36.9 6.87 0.654
Heterogeneous nuclear ribonucleoprotein H3 OS=Homo sapiens GN=HNRNPH3 
PE=1 SV=2 - [HNRH3_HUMAN]
P40261 264 29.6 5.74 0.654
Nicotinamide N-methyltransferase OS=Homo sapiens GN=NNMT PE=1 SV=1 - 
[NNMT_HUMAN]
P15529 392 43.7 6.74 0.654
Membrane cofactor protein OS=Homo sapiens GN=CD46 PE=1 SV=3 - 
[MCP_HUMAN]
G3XAJ6 542 58.7 5.34 0.653
Raft-linking protein, isoform CRA_c OS=Homo sapiens GN=RFTN1 PE=1 SV=1 
- [G3XAJ6_HUMAN]
H7BZW6 143 16.0 9.13 0.652 Histone deacetylase complex subunit SAP18 (Fragment) OS=Homo sapiens 
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GN=SAP18 PE=1 SV=2 - [H7BZW6_HUMAN]
P19397 219 24.3 7.52 0.652
Leukocyte surface antigen CD53 OS=Homo sapiens GN=CD53 PE=1 SV=1 - 
[CD53_HUMAN]
Q9C055 306 35.6 7.50 0.652
Inositol polyphosphate-5-phosphatase (Fragment) OS=Homo sapiens 
GN=INPP5A PE=4 SV=1 - [Q9C055_HUMAN]
P16402 221 22.3 11.02 0.651 Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=2 - [H13_HUMAN]
P01023 1474 163.2 6.46 0.650
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 - 
[A2MG_HUMAN]
Q19UK3 33 3.7 8.09 0.648
Truncated coagulation factor IX (Fragment) OS=Homo sapiens GN=F9 PE=4 
SV=1 - [Q19UK3_HUMAN]
Q59FC4 687 75.9 6.51 0.648
Presynaptic protein SAP97 variant (Fragment) OS=Homo sapiens PE=4 SV=1 - 
[Q59FC4_HUMAN]
Q15661 275 30.5 7.11 0.647
Tryptase alpha/beta-1 OS=Homo sapiens GN=TPSAB1 PE=1 SV=1 - 
[TRYB1_HUMAN]
D3JV43 68 7.4 8.78 0.646
C-X-C motif chemokine (Fragment) OS=Homo sapiens PE=3 SV=1 - 
[D3JV43_HUMAN]
H0YH87 916 98.1 9.41 0.639
Ataxin-2 (Fragment) OS=Homo sapiens GN=ATXN2 PE=1 SV=1 - 
[H0YH87_HUMAN]
B7Z7P4 547 59.9 5.59 0.639
cDNA FLJ53627, highly similar to Antigen peptide transporter 1 OS=Homo 
sapiens PE=2 SV=1 - [B7Z7P4_HUMAN]
P13761 266 29.8 7.44 0.638
HLA class II histocompatibility antigen, DRB1-7 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=1 - [2B17_HUMAN]
B7Z539 645 72.1 7.68 0.637
cDNA FLJ56954, highly similar to Inter-alpha-trypsin inhibitor heavy chain H1 
OS=Homo sapiens PE=2 SV=1 - [B7Z539_HUMAN]
H7C034 173 19.3 4.88 0.636
AP-1 complex subunit beta-1 (Fragment) OS=Homo sapiens GN=AP1B1 PE=1 
SV=1 - [H7C034_HUMAN]
A8K2T4 843 93.3 6.51 0.636
cDNA FLJ78207, highly similar to Human complement protein component C7 
mRNA OS=Homo sapiens PE=2 SV=1 - [A8K2T4_HUMAN]
Q9UL88 131 14.1 9.63 0.636
Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 - [Q9UL88_HUMAN]
P23381 471 53.1 6.23 0.636
Tryptophan--tRNA ligase, cytoplasmic OS=Homo sapiens GN=WARS PE=1 
SV=2 - [SYWC_HUMAN]
E9PC44 393 43.9 6.15 0.635
Protein transport protein Sec24D OS=Homo sapiens GN=SEC24D PE=1 SV=2 - 
[E9PC44_HUMAN]
O76013 467 52.2 4.94 0.634 Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 SV=1 - 
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[KRT36_HUMAN]
B4DM28 634 72.1 9.67 0.633
cDNA FLJ50575, highly similar to U4/U6 small nuclear ribonucleoprotein Prp3 
OS=Homo sapiens PE=2 SV=1 - [B4DM28_HUMAN]
M0R088 681 78.1 12.06 0.633
Serine/arginine repetitive matrix protein 1 (Fragment) OS=Homo sapiens 
GN=SRRM1 PE=1 SV=1 - [M0R088_HUMAN]
E3Q1J2 273 31.6 5.97 0.633
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-B PE=3 SV=1 - 
[E3Q1J2_HUMAN]
Q5JTB5 87 9.3 7.09 0.631
Placenta-specific protein 9 OS=Homo sapiens GN=PLAC9 PE=4 SV=1 - 
[Q5JTB5_HUMAN]
Q5CZ93 159 19.2 9.88 0.630
Putative uncharacterized protein DKFZp686A0568 OS=Homo sapiens 
GN=DKFZp686A0568 PE=2 SV=1 - [Q5CZ93_HUMAN]
P33764 101 11.7 4.78 0.628
Protein S100-A3 OS=Homo sapiens GN=S100A3 PE=1 SV=1 - 
[S10A3_HUMAN]
Q6GMX6 465 51.1 8.69 0.628 IGH@ protein OS=Homo sapiens GN=IGH@ PE=1 SV=1 - [Q6GMX6_HUMAN]
Q9P2B2 879 98.5 6.61 0.628
Prostaglandin F2 receptor negative regulator OS=Homo sapiens GN=PTGFRN 
PE=1 SV=2 - [FPRP_HUMAN]
Q15323 416 47.2 4.88 0.627
Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 - 
[K1H1_HUMAN]
H0YA93 1400 158.1 5.82 0.625
NEDD4-binding protein 2 (Fragment) OS=Homo sapiens GN=N4BP2 PE=1 
SV=1 - [H0YA93_HUMAN]
A5Z217 470 53.6 5.27 0.623 Mutant desmin OS=Homo sapiens PE=2 SV=1 - [A5Z217_HUMAN]
K7EMQ9 140 16.3 6.89 0.622
Eukaryotic translation initiation factor 3 subunit K (Fragment) OS=Homo 
sapiens GN=EIF3K PE=1 SV=1 - [K7EMQ9_HUMAN]
A0A024RAL1 2409 264.9 4.54 0.620
Chondroitin sulfate proteoglycan 2 (Versican), isoform CRA_c OS=Homo 
sapiens GN=CSPG2 PE=4 SV=1 - [A0A024RAL1_HUMAN]
H3BPF7 236 25.5 8.46 0.618
Lon protease homolog 2, peroxisomal (Fragment) OS=Homo sapiens 
GN=LONP2 PE=4 SV=3 - [H3BPF7_HUMAN]
A0A087WUP0 265 30.0 5.34 0.617
Annexin A8-like protein 1 OS=Homo sapiens GN=ANXA8L1 PE=4 SV=1 - 
[A0A087WUP0_HUMAN]
A0A068LKQ0 120 13.3 5.99 0.617
Ig heavy chain variable region (Fragment) OS=Homo sapiens PE=4 SV=1 - 
[A0A068LKQ0_HUMAN]
Q86YQ1 91 9.7 9.25 0.614
Hemoglobin alpha-2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 SV=1 - 
[Q86YQ1_HUMAN]
B5MBZ8 274 31.3 4.63 0.610
Protein phosphatase 1 regulatory subunit 7 OS=Homo sapiens GN=PPP1R7 
PE=1 SV=1 - [B5MBZ8_HUMAN]
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Q8N1G4 583 63.4 8.28 0.609
Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 
PE=1 SV=1 - [LRC47_HUMAN]
O15078 2479 290.2 5.95 0.609
Centrosomal protein of 290 kDa OS=Homo sapiens GN=CEP290 PE=1 SV=2 - 
[CE290_HUMAN]
Q9BXN1 380 43.4 7.08 0.608 Asporin OS=Homo sapiens GN=ASPN PE=1 SV=2 - [ASPN_HUMAN]
C0IMJ3 781 87.2 7.94 0.604 Periostin isoform thy6 OS=Homo sapiens PE=2 SV=1 - [C0IMJ3_HUMAN]
B7ZMG8 83 9.1 4.59 0.602 Uncharacterized protein OS=Homo sapiens PE=2 SV=1 - [B7ZMG8_HUMAN]
E9PQ22 191 22.9 9.45 0.602
Uncharacterized protein C11orf65 (Fragment) OS=Homo sapiens GN=C11orf65 
PE=4 SV=3 - [E9PQ22_HUMAN]
Q5CZB5 1157 125.0 4.49 0.601
Putative uncharacterized protein DKFZp686M0430 OS=Homo sapiens 
GN=DKFZp686M0430 PE=2 SV=1 - [Q5CZB5_HUMAN]
E9PQI8 164 17.5 11.17 0.600
U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 PE=1 
SV=1 - [E9PQI8_HUMAN]
P19075 237 26.0 5.60 0.600 Tetraspanin-8 OS=Homo sapiens GN=TSPAN8 PE=1 SV=1 - [TSN8_HUMAN]
B4DSW4 157 16.4 12.25 0.598
cDNA FLJ51541, moderately similar to Transcription factor Sp8 OS=Homo 
sapiens PE=2 SV=1 - [B4DSW4_HUMAN]
P31146 461 51.0 6.68 0.597 Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 - [COR1A_HUMAN]
Q0KKI6 219 24.0 8.06 0.593
Immunoblobulin light chain (Fragment) OS=Homo sapiens PE=1 SV=1 - 
[Q0KKI6_HUMAN]
P01623 109 11.7 8.91 0.593
Ig kappa chain V-III region WOL OS=Homo sapiens PE=1 SV=1 - 
[KV305_HUMAN]
P08311 255 28.8 11.19 0.593 Cathepsin G OS=Homo sapiens GN=CTSG PE=1 SV=2 - [CATG_HUMAN]
P01598 108 11.8 8.44 0.592
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 - 
[KV106_HUMAN]
Q6P3R8 708 81.4 8.87 0.592
Serine/threonine-protein kinase Nek5 OS=Homo sapiens GN=NEK5 PE=1 SV=1 
- [NEK5_HUMAN]
Q4QZC0 273 31.8 6.09 0.592
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 - 
[Q4QZC0_HUMAN]
C9JW69 372 39.6 8.37 0.591
Regulator of chromosome condensation (Fragment) OS=Homo sapiens 
GN=RCC1 PE=1 SV=1 - [C9JW69_HUMAN]
P10109 184 19.4 5.83 0.591
Adrenodoxin, mitochondrial OS=Homo sapiens GN=FDX1 PE=1 SV=1 - 
[ADX_HUMAN]
A0A075B785 1018 112.7 5.49 0.591
LisH domain and HEAT repeat-containing protein KIAA1468 OS=Homo sapiens 
GN=KIAA1468 PE=1 SV=2 - [A0A075B785_HUMAN]
K7ERI9 77 8.6 6.71 0.590 Truncated apolipoprotein C-I (Fragment) OS=Homo sapiens GN=APOC1 PE=4 
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SV=1 - [K7ERI9_HUMAN]
P01833 764 83.2 5.74 0.589
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 - 
[PIGR_HUMAN]
P62854 115 13.0 11.00 0.587
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 - 
[RS26_HUMAN]
B4E1L5 555 63.8 6.37 0.585
cDNA FLJ51601, highly similar to Interferon-induced guanylate-binding protein 
1 OS=Homo sapiens PE=2 SV=1 - [B4E1L5_HUMAN]
Q9HCM7 1045 110.8 9.67 0.585
Fibrosin-1-like protein OS=Homo sapiens GN=FBRSL1 PE=1 SV=4 - 
[FBSL_HUMAN]
P01611 108 11.6 7.28 0.581
Ig kappa chain V-I region Wes OS=Homo sapiens PE=1 SV=1 - 
[KV119_HUMAN]
B4DRW1 474 51.7 6.81 0.576
cDNA FLJ55805, highly similar to Keratin, type II cytoskeletal 4 OS=Homo 
sapiens PE=2 SV=1 - [B4DRW1_HUMAN]
J3KPM9 714 83.3 6.42 0.574
Signal transducer and activator of transcription OS=Homo sapiens GN=STAT1 
PE=1 SV=1 - [J3KPM9_HUMAN]
Q8N1W1 1705 191.8 6.04 0.573
Rho guanine nucleotide exchange factor 28 OS=Homo sapiens GN=ARHGEF28 
PE=1 SV=3 - [ARG28_HUMAN]
P23946 247 27.3 9.29 0.573 Chymase OS=Homo sapiens GN=CMA1 PE=1 SV=1 - [CMA1_HUMAN]
Q7L0Q8 258 28.2 8.06 0.572
Rho-related GTP-binding protein RhoU OS=Homo sapiens GN=RHOU PE=1 
SV=1 - [RHOU_HUMAN]
O75443 2155 239.4 5.40 0.569 Alpha-tectorin OS=Homo sapiens GN=TECTA PE=1 SV=3 - [TECTA_HUMAN]
A0A087WZW8 233 25.6 6.01 0.569
Protein IGKV3-11 OS=Homo sapiens GN=IGKV3-11 PE=4 SV=1 - 
[A0A087WZW8_HUMAN]
A0A087WX11 918 103.3 5.12 0.565
Folliculin-interacting protein 1 OS=Homo sapiens GN=FNIP1 PE=4 SV=1 - 
[A0A087WX11_HUMAN]
Q9H029 130 14.8 5.30 0.564
GTP-binding protein SAR1b OS=Homo sapiens GN=DKFZp434B2017 PE=1 
SV=1 - [Q9H029_HUMAN]
H0YD72 237 26.1 9.39 0.563
Liprin-alpha-1 (Fragment) OS=Homo sapiens GN=PPFIA1 PE=1 SV=1 - 
[H0YD72_HUMAN]
Q5NV82 104 11.1 7.97 0.562
V4-2 protein (Fragment) OS=Homo sapiens GN=V4-2 PE=1 SV=1 - 
[Q5NV82_HUMAN]
H3BRW3 109 11.7 9.96 0.562
FAD-linked sulfhydryl oxidase ALR OS=Homo sapiens GN=GFER PE=1 SV=1 - 
[H3BRW3_HUMAN]
P02452 1464 138.9 5.80 0.555
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 - 
[CO1A1_HUMAN]
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B2R9B9 120 13.0 6.37 0.551
cDNA, FLJ94321, highly similar to Homo sapiens eukaryotic translation 
initiation factor 4E binding protein 2 (EIF4EBP2), mRNA OS=Homo sapiens 
PE=2 SV=1 - [B2R9B9_HUMAN]
Q9UK54 128 14.0 6.95 0.547
Hemoglobin beta subunit variant (Fragment) OS=Homo sapiens GN=HBB PE=2 
SV=1 - [Q9UK54_HUMAN]
P81605 110 11.3 6.54 0.547 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN]
Q05707 1796 193.4 5.30 0.547
Collagen alpha-1(XIV) chain OS=Homo sapiens GN=COL14A1 PE=1 SV=3 - 
[COEA1_HUMAN]
C9JA05 70 8.2 8.56 0.547
Immunoglobulin J chain (Fragment) OS=Homo sapiens GN=IGJ PE=1 SV=1 - 
[C9JA05_HUMAN]
S6C4R7 212 22.5 8.24 0.546 IgG L chain OS=Homo sapiens PE=2 SV=1 - [S6C4R7_HUMAN]
P01861 327 35.9 7.36 0.541
Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 - 
[IGHG4_HUMAN]
B2R7Z6 484 52.5 7.55 0.539 cDNA, FLJ93674 OS=Homo sapiens PE=2 SV=1 - [B2R7Z6_HUMAN]
Q9NZ09 502 55.0 5.11 0.532
Ubiquitin-associated protein 1 OS=Homo sapiens GN=UBAP1 PE=1 SV=1 - 
[UBAP1_HUMAN]
Q64FY1 1364 146.2 6.60 0.530
AKNA transcript B1 (Fragment) OS=Homo sapiens GN=AKNA PE=2 SV=1 - 
[Q64FY1_HUMAN]
M0QZ50 93 9.8 4.48 0.526
Microtubule-associated protein 1S OS=Homo sapiens GN=MAP1S PE=1 SV=1 - 
[M0QZ50_HUMAN]
B4DQY2 711 78.9 7.06 0.525
cDNA FLJ59388, highly similar to Mitochondrial inner membrane protein 
OS=Homo sapiens PE=2 SV=1 - [B4DQY2_HUMAN]
B4DEH8 168 19.0 9.23 0.516
Polyadenylate-binding protein 2 OS=Homo sapiens GN=PABPN1 PE=1 SV=1 - 
[B4DEH8_HUMAN]
D6RC64 136 15.6 10.14 0.513
SH3 domain-binding protein 2 (Fragment) OS=Homo sapiens GN=SH3BP2 
PE=4 SV=1 - [D6RC64_HUMAN]
Q6N095 475 52.3 8.57 0.511
Putative uncharacterized protein DKFZp686K03196 OS=Homo sapiens 
GN=DKFZp686K03196 PE=1 SV=1 - [Q6N095_HUMAN]
B4DLF9 342 39.4 8.68 0.510
cDNA FLJ56988, highly similar to cGMP-dependent protein kinase 2 (EC 
2.7.11.12) OS=Homo sapiens PE=2 SV=1 - [B4DLF9_HUMAN]
H0Y892 688 79.3 9.14 0.508
Zinc finger protein 782 (Fragment) OS=Homo sapiens GN=ZNF782 PE=4 SV=1 
- [H0Y892_HUMAN]
Q4ZGM8 100 10.8 9.04 0.502
Hemoglobin alpha-2 globin mutant (Fragment) OS=Homo sapiens PE=3 SV=1 
- [Q4ZGM8_HUMAN]
Q6N093 417 46.0 7.59 0.497 Putative uncharacterized protein DKFZp686I04196 (Fragment) OS=Homo 
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sapiens GN=DKFZp686I04196 PE=1 SV=1 - [Q6N093_HUMAN]
A0A075B6L1 106 11.3 8.29 0.496
Ig lambda-7 chain C region (Fragment) OS=Homo sapiens GN=IGLC7 PE=4 
SV=2 - [A0A075B6L1_HUMAN]
B2R941 417 48.7 9.00 0.495
cDNA, FLJ94198, highly similar to Homo sapiens carboxypeptidase A3 (mast 
cell) (CPA3), mRNA OS=Homo sapiens PE=2 SV=1 - [B2R941_HUMAN]
P14555 144 16.1 9.23 0.492
Phospholipase A2, membrane associated OS=Homo sapiens GN=PLA2G2A 
PE=1 SV=2 - [PA2GA_HUMAN]
C9JNE5 191 21.7 9.61 0.481
Myeloid leukemia factor 1 (Fragment) OS=Homo sapiens GN=MLF1 PE=4 
SV=1 - [C9JNE5_HUMAN]
Q7Z3E2 898 103.6 6.27 0.478
Coiled-coil domain-containing protein 186 OS=Homo sapiens GN=CCDC186 
PE=1 SV=2 - [CC186_HUMAN]
P08519 4548 501.0 5.88 0.474 Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 - [APOA_HUMAN]
Q7L7X3 1001 116.0 7.65 0.468
Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 
SV=1 - [TAOK1_HUMAN]
B2R8C8 140 15.1 5.26 0.461
Ubiquitin-like protein ATG12 OS=Homo sapiens PE=2 SV=1 - 
[B2R8C8_HUMAN]
B7Z962 190 19.9 10.84 0.461 cDNA FLJ52231 OS=Homo sapiens PE=2 SV=1 - [B7Z962_HUMAN]
F8W9J4 7461 847.4 5.25 0.457 Dystonin OS=Homo sapiens GN=DST PE=1 SV=1 - [F8W9J4_HUMAN]
Q5T4S7 5183 573.5 6.04 0.450
E3 ubiquitin-protein ligase UBR4 OS=Homo sapiens GN=UBR4 PE=1 SV=1 - 
[UBR4_HUMAN]
B0QYR0 100 11.1 5.36 0.447
BTB/POZ domain-containing protein 3 (Fragment) OS=Homo sapiens 
GN=BTBD3 PE=4 SV=3 - [B0QYR0_HUMAN]
Q3MI39 167 16.7 9.70 0.447
HNRPA1 protein (Fragment) OS=Homo sapiens GN=HNRPA1 PE=2 SV=1 - 
[Q3MI39_HUMAN]
Q701L7 513 56.6 6.74 0.430
Type II hair keratin 2 OS=Homo sapiens GN=KRTHB2 PE=2 SV=1 - 
[Q701L7_HUMAN]
P01880 384 42.2 7.93 0.404
Ig delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 - 
[IGHD_HUMAN]
B3KMX3 270 28.5 4.73 0.398
cDNA FLJ12857 fis, clone NT2RP2003513, highly similar to Homo sapiens 
paralemmin (PALM), transcript variant 2, mRNA OS=Homo sapiens PE=2 SV=1 
- [B3KMX3_HUMAN]
Q9BYT5 123 12.9 7.81 0.397
Keratin-associated protein 2-2 OS=Homo sapiens GN=KRTAP2-2 PE=2 SV=3 - 
[KRA22_HUMAN]
P46109 303 33.8 6.74 0.388 Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 - [CRKL_HUMAN]
H7BZ55 2252 248.2 5.83 0.386 Putative ciliary rootlet coiled-coil protein-like 3 protein OS=Homo sapiens PE=5 
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SV=2 - [CROL3_HUMAN]
Q5RHS7 95 11.0 9.28 0.379
Protein S100-A2 OS=Homo sapiens GN=S100A2 PE=1 SV=2 - 
[Q5RHS7_HUMAN]
Q05D28 370 41.8 5.44 0.377
CCDC91 protein (Fragment) OS=Homo sapiens GN=CCDC91 PE=2 SV=1 - 
[Q05D28_HUMAN]
B3KS56 594 68.5 5.45 0.376
cDNA FLJ35559 fis, clone SPLEN2005009, highly similar to GRIP and coiled-coil 
domain-containing protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B3KS56_HUMAN]
H0UI60 536 60.7 5.17 0.369
Taxilin beta, isoform CRA_a OS=Homo sapiens GN=TXLNB PE=4 SV=1 - 
[H0UI60_HUMAN]
Q30167 266 30.0 7.75 0.357
HLA class II histocompatibility antigen, DRB1-10 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=2 - [2B1A_HUMAN]
A4FU00 317 35.6 5.81 0.351
SYT2 protein (Fragment) OS=Homo sapiens GN=SYT2 PE=2 SV=1 - 
[A4FU00_HUMAN]
B4E1L4 668 71.6 5.63 0.347
cDNA FLJ59081, highly similar to Mucin-5B OS=Homo sapiens PE=2 SV=1 - 
[B4E1L4_HUMAN]
Q69YL0 99 10.9 12.00 0.337
Uncharacterized protein NCBP2-AS2 OS=Homo sapiens GN=NCBP2-AS2 PE=4 
SV=1 - [NCAS2_HUMAN]
A8K9A9 638 71.3 8.22 0.334
cDNA FLJ77744, highly similar to Homo sapiens kallikrein B, plasma (Fletcher 
factor) 1 (KLKB1), mRNA OS=Homo sapiens PE=2 SV=1 - [A8K9A9_HUMAN]
A2J1N5 94 10.4 9.13 0.306
Rheumatoid factor RF-ET6 (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[A2J1N5_HUMAN]
Q6PII6 533 58.3 4.77 0.288
TMF1 protein (Fragment) OS=Homo sapiens GN=TMF1 PE=2 SV=1 - 
[Q6PII6_HUMAN]
A0A087X243 69 7.4 7.08 0.286
Glutathione S-transferase P (Fragment) OS=Homo sapiens GN=GSTP1 PE=4 
SV=1 - [A0A087X243_HUMAN]
O76041 1014 116.4 7.99 0.275 Nebulette OS=Homo sapiens GN=NEBL PE=1 SV=1 - [NEBL_HUMAN]
B4DMJ5 242 27.3 4.50 0.118
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B4DMJ5 242 27.3 4.50 8.276
cDNA FLJ53012, highly similar to Tubulin beta-7 chain OS=Homo sapiens 
PE=2 SV=1 - [B4DMJ5_HUMAN]
A0A087X243 69 7.4 7.08 3.627
Glutathione S-transferase P (Fragment) OS=Homo sapiens GN=GSTP1 
PE=4 SV=1 - [A0A087X243_HUMAN]
Q69YL0 99 10.9 12.00 3.266
Uncharacterized protein NCBP2-AS2 OS=Homo sapiens GN=NCBP2-AS2 
PE=4 SV=1 - [NCAS2_HUMAN]
A4FU00 317 35.6 5.81 2.985
SYT2 protein (Fragment) OS=Homo sapiens GN=SYT2 PE=2 SV=1 - 
[A4FU00_HUMAN]
B4DIF5 345 39.2 8.92 2.960
cDNA FLJ55687, highly similar to Cell cycle control protein 50A OS=Homo 
sapiens PE=2 SV=1 - [B4DIF5_HUMAN]
H0UI60 536 60.7 5.17 2.740
Taxilin beta, isoform CRA_a OS=Homo sapiens GN=TXLNB PE=4 SV=1 - 
[H0UI60_HUMAN]
Q9BYT5 123 12.9 7.81 2.683
Keratin-associated protein 2-2 OS=Homo sapiens GN=KRTAP2-2 PE=2 
SV=3 - [KRA22_HUMAN]
O76041 1014 116.4 7.99 2.555 Nebulette OS=Homo sapiens GN=NEBL PE=1 SV=1 - [NEBL_HUMAN]
F8W9J4 7461 847.4 5.25 2.521 Dystonin OS=Homo sapiens GN=DST PE=1 SV=1 - [F8W9J4_HUMAN]
Q701L7 513 56.6 6.74 2.519
Type II hair keratin 2 OS=Homo sapiens GN=KRTHB2 PE=2 SV=1 - 
[Q701L7_HUMAN]
Q6PII6 533 58.3 4.77 2.512
TMF1 protein (Fragment) OS=Homo sapiens GN=TMF1 PE=2 SV=1 - 
[Q6PII6_HUMAN]
A2J1N5 94 10.4 9.13 2.497
Rheumatoid factor RF-ET6 (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[A2J1N5_HUMAN]
B7Z962 190 19.9 10.84 2.430 cDNA FLJ52231 OS=Homo sapiens PE=2 SV=1 - [B7Z962_HUMAN]
Q05D28 370 41.8 5.44 2.342
CCDC91 protein (Fragment) OS=Homo sapiens GN=CCDC91 PE=2 SV=1 - 
[Q05D28_HUMAN]
B3KS56 594 68.5 5.45 2.327 cDNA FLJ35559 fis, clone SPLEN2005009, highly similar to GRIP and coiled-
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coil domain-containing protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B3KS56_HUMAN]
Q92531 187 19.7 6.32 2.313
P35-related protein (Fragment) OS=Homo sapiens GN=FCN1 PE=4 SV=1 - 
[Q92531_HUMAN]
H0Y892 688 79.3 9.14 2.291
Zinc finger protein 782 (Fragment) OS=Homo sapiens GN=ZNF782 PE=4 
SV=1 - [H0Y892_HUMAN]
Q3MI39 167 16.7 9.70 2.287
HNRPA1 protein (Fragment) OS=Homo sapiens GN=HNRPA1 PE=2 SV=1 - 
[Q3MI39_HUMAN]
B2R8C8 140 15.1 5.26 2.263
Ubiquitin-like protein ATG12 OS=Homo sapiens PE=2 SV=1 - 
[B2R8C8_HUMAN]
Q7L7X3 1001 116.0 7.65 2.241
Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 
SV=1 - [TAOK1_HUMAN]
B3KMU4 481 54.5 5.08 2.107
cDNA FLJ12640 fis, clone NT2RM4001940, highly similar to Timeless 
homolog OS=Homo sapiens PE=2 SV=1 - [B3KMU4_HUMAN]
P14555 144 16.1 9.23 2.101
Phospholipase A2, membrane associated OS=Homo sapiens GN=PLA2G2A 
PE=1 SV=2 - [PA2GA_HUMAN]
B0QYR0 100 11.1 5.36 2.088
BTB/POZ domain-containing protein 3 (Fragment) OS=Homo sapiens 
GN=BTBD3 PE=4 SV=3 - [B0QYR0_HUMAN]
P11678 715 81.0 10.29 2.012
Eosinophil peroxidase OS=Homo sapiens GN=EPX PE=1 SV=2 - 
[PERE_HUMAN]
P46109 303 33.8 6.74 2.003 Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 - [CRKL_HUMAN]
Q8NEY1 1877 202.3 8.07 1.998
Neuron navigator 1 OS=Homo sapiens GN=NAV1 PE=1 SV=2 - 
[NAV1_HUMAN]
Q0PNF2 2570 275.3 6.49 1.979 FEX1 OS=Homo sapiens PE=2 SV=1 - [Q0PNF2_HUMAN]
H0YF46 255 28.3 5.82 1.977
SPOC domain-containing protein 1 (Fragment) OS=Homo sapiens 
GN=SPOCD1 PE=4 SV=1 - [H0YF46_HUMAN]
Q8TBP3 101 11.8 9.92 1.941
TOP1MT protein (Fragment) OS=Homo sapiens GN=TOP1MT PE=2 SV=1 - 
[Q8TBP3_HUMAN]
Q05707 1796 193.4 5.30 1.917
Collagen alpha-1(XIV) chain OS=Homo sapiens GN=COL14A1 PE=1 SV=3 - 
[COEA1_HUMAN]
M0QZ50 93 9.8 4.48 1.907
Microtubule-associated protein 1S OS=Homo sapiens GN=MAP1S PE=1 
SV=1 - [M0QZ50_HUMAN]
H7BZ55 2252 248.2 5.83 1.883
Putative ciliary rootlet coiled-coil protein-like 3 protein OS=Homo sapiens 
PE=5 SV=2 - [CROL3_HUMAN]
Q8N1W1 1705 191.8 6.04 1.874 Rho guanine nucleotide exchange factor 28 OS=Homo sapiens 
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GN=ARHGEF28 PE=1 SV=3 - [ARG28_HUMAN]
P20851 252 28.3 5.14 1.835
C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB PE=1 SV=1 - 
[C4BPB_HUMAN]
Q8N1G4 583 63.4 8.28 1.830
Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 
PE=1 SV=1 - [LRC47_HUMAN]
D6RC64 136 15.6 10.14 1.819
SH3 domain-binding protein 2 (Fragment) OS=Homo sapiens GN=SH3BP2 
PE=4 SV=1 - [D6RC64_HUMAN]
Q7L0Q8 258 28.2 8.06 1.811
Rho-related GTP-binding protein RhoU OS=Homo sapiens GN=RHOU PE=1 
SV=1 - [RHOU_HUMAN]
H0YCG2 258 28.2 6.52 1.809
Lysosome-associated membrane glycoprotein 2 (Fragment) OS=Homo 
sapiens GN=LAMP2 PE=1 SV=1 - [H0YCG2_HUMAN]
Q05315 142 16.4 7.37 1.809 Galectin-10 OS=Homo sapiens GN=CLC PE=1 SV=3 - [LEG10_HUMAN]
Q6P3R8 708 81.4 8.87 1.805
Serine/threonine-protein kinase Nek5 OS=Homo sapiens GN=NEK5 PE=1 
SV=1 - [NEK5_HUMAN]
Q5T4S7 5183 573.5 6.04 1.799
E3 ubiquitin-protein ligase UBR4 OS=Homo sapiens GN=UBR4 PE=1 SV=1 - 
[UBR4_HUMAN]
Q7Z3E2 898 103.6 6.27 1.778
Coiled-coil domain-containing protein 186 OS=Homo sapiens GN=CCDC186 
PE=1 SV=2 - [CC186_HUMAN]
B4DLF9 342 39.4 8.68 1.768
cDNA FLJ56988, highly similar to cGMP-dependent protein kinase 2 (EC 
2.7.11.12) OS=Homo sapiens PE=2 SV=1 - [B4DLF9_HUMAN]
P62854 115 13.0 11.00 1.742
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 - 
[RS26_HUMAN]
A0A024R637 1298 146.5 7.01 1.737
TBC1 domain family, member 4, isoform CRA_b OS=Homo sapiens 
GN=TBC1D4 PE=4 SV=1 - [A0A024R637_HUMAN]
Q9H029 130 14.8 5.30 1.735
GTP-binding protein SAR1b OS=Homo sapiens GN=DKFZp434B2017 PE=1 
SV=1 - [Q9H029_HUMAN]
S6BGD6 235 24.8 7.24 1.733 IgG L chain OS=Homo sapiens PE=1 SV=1 - [S6BGD6_HUMAN]
Q30058 257 29.1 6.54 1.728
HLA-DP protein OS=Homo sapiens GN=HLA-DP PE=2 SV=1 - 
[Q30058_HUMAN]
H3BMN5 158 18.5 4.82 1.727
Calretinin (Fragment) OS=Homo sapiens GN=CALB2 PE=4 SV=2 - 
[H3BMN5_HUMAN]
P02452 1464 138.9 5.80 1.710
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 - 
[CO1A1_HUMAN]
B2R9B9 120 13.0 6.37 1.705
cDNA, FLJ94321, highly similar to Homo sapiens eukaryotic translation 
initiation factor 4E binding protein 2 (EIF4EBP2), mRNA OS=Homo sapiens 
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PE=2 SV=1 - [B2R9B9_HUMAN]
B4DVF1 785 87.3 6.96 1.702
cDNA FLJ51111, highly similar to Aldehyde oxidase (EC 1.2.3.1) (Fragment) 
OS=Homo sapiens PE=2 SV=1 - [B4DVF1_HUMAN]
P12724 160 18.4 10.02 1.692
Eosinophil cationic protein OS=Homo sapiens GN=RNASE3 PE=1 SV=2 - 
[ECP_HUMAN]
Q9BXN1 380 43.4 7.08 1.691 Asporin OS=Homo sapiens GN=ASPN PE=1 SV=2 - [ASPN_HUMAN]
Q9HCM7 1045 110.8 9.67 1.667
Fibrosin-1-like protein OS=Homo sapiens GN=FBRSL1 PE=1 SV=4 - 
[FBSL_HUMAN]
Q86UX7 667 75.9 6.98 1.660
Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 - 
[URP2_HUMAN]
Q4QZC0 273 31.8 6.09 1.654
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 - 
[Q4QZC0_HUMAN]
B2R6V9 732 83.2 6.00 1.638
cDNA, FLJ93141, highly similar to Homo sapiens coagulation factor XIII, A1 
polypeptide (F13A1), mRNA OS=Homo sapiens PE=2 SV=1 - 
[B2R6V9_HUMAN]
P15529 392 43.7 6.74 1.634
Membrane cofactor protein OS=Homo sapiens GN=CD46 PE=1 SV=3 - 
[MCP_HUMAN]
H0YH87 916 98.1 9.41 1.633
Ataxin-2 (Fragment) OS=Homo sapiens GN=ATXN2 PE=1 SV=1 - 
[H0YH87_HUMAN]
P27487 766 88.2 6.04 1.628
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 - 
[DPP4_HUMAN]
P08311 255 28.8 11.19 1.624 Cathepsin G OS=Homo sapiens GN=CTSG PE=1 SV=2 - [CATG_HUMAN]
O76013 467 52.2 4.94 1.624
Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 SV=1 - 
[KRT36_HUMAN]
A0A075B785 1018 112.7 5.49 1.610
LisH domain and HEAT repeat-containing protein KIAA1468 OS=Homo 
sapiens GN=KIAA1468 PE=1 SV=2 - [A0A075B785_HUMAN]
P31146 461 51.0 6.68 1.607 Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 - [COR1A_HUMAN]
P10109 184 19.4 5.83 1.604
Adrenodoxin, mitochondrial OS=Homo sapiens GN=FDX1 PE=1 SV=1 - 
[ADX_HUMAN]
O15078 2479 290.2 5.95 1.604
Centrosomal protein of 290 kDa OS=Homo sapiens GN=CEP290 PE=1 SV=2 
- [CE290_HUMAN]
B2R4M6 114 13.2 6.13 1.604 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN]
A0A024RDI4 1851 203.3 6.23 1.600
Ankyrin 2, neuronal, isoform CRA_a OS=Homo sapiens GN=ANK2 PE=4 
SV=1 - [A0A024RDI4_HUMAN]
Q6EVJ6 105 10.9 8.81 1.597 Peptidyl arginine deiminase type IV (Fragment) OS=Homo sapiens 
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GN=PADI4 PE=4 SV=1 - [Q6EVJ6_HUMAN]
P46108 304 33.8 5.55 1.592
Adapter molecule crk OS=Homo sapiens GN=CRK PE=1 SV=2 - 
[CRK_HUMAN]
C9JW69 372 39.6 8.37 1.588
Regulator of chromosome condensation (Fragment) OS=Homo sapiens 
GN=RCC1 PE=1 SV=1 - [C9JW69_HUMAN]
P98095 1184 126.5 4.82 1.586 Fibulin-2 OS=Homo sapiens GN=FBLN2 PE=1 SV=2 - [FBLN2_HUMAN]
Q19UK3 33 3.7 8.09 1.582
Truncated coagulation factor IX (Fragment) OS=Homo sapiens GN=F9 
PE=4 SV=1 - [Q19UK3_HUMAN]
F5H4Z6 171 20.0 7.84 1.581
Folate receptor beta (Fragment) OS=Homo sapiens GN=FOLR2 PE=4 SV=1 
- [F5H4Z6_HUMAN]
P49913 170 19.3 9.41 1.578
Cathelicidin antimicrobial peptide OS=Homo sapiens GN=CAMP PE=1 SV=1 
- [CAMP_HUMAN]
B4DSW4 157 16.4 12.25 1.578
cDNA FLJ51541, moderately similar to Transcription factor Sp8 OS=Homo 
sapiens PE=2 SV=1 - [B4DSW4_HUMAN]
E9PQ22 191 22.9 9.45 1.578
Uncharacterized protein C11orf65 (Fragment) OS=Homo sapiens 
GN=C11orf65 PE=4 SV=3 - [E9PQ22_HUMAN]
E9PC44 393 43.9 6.15 1.577
Protein transport protein Sec24D OS=Homo sapiens GN=SEC24D PE=1 
SV=2 - [E9PC44_HUMAN]
B4DLX8 617 69.4 6.61 1.575
cDNA FLJ57031, highly similar to Midline-1 (EC 6.3.2.-) OS=Homo sapiens 
PE=2 SV=1 - [B4DLX8_HUMAN]
E9PQI8 164 17.5 11.17 1.575
U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 
PE=1 SV=1 - [E9PQI8_HUMAN]
B4DI03 156 17.4 8.91 1.573
SEC11-like 3 (S. cerevisiae), isoform CRA_a OS=Homo sapiens 
GN=SEC11L3 PE=2 SV=1 - [B4DI03_HUMAN]
Q9Y281 166 18.7 7.88 1.571 Cofilin-2 OS=Homo sapiens GN=CFL2 PE=1 SV=1 - [COF2_HUMAN]
A0A087WX11 918 103.3 5.12 1.570
Folliculin-interacting protein 1 OS=Homo sapiens GN=FNIP1 PE=4 SV=1 - 
[A0A087WX11_HUMAN]
G3V2R9 217 23.4 6.19 1.560
Prostaglandin reductase 2 OS=Homo sapiens GN=PTGR2 PE=1 SV=1 - 
[G3V2R9_HUMAN]
Q9UK54 128 14.0 6.95 1.560
Hemoglobin beta subunit variant (Fragment) OS=Homo sapiens GN=HBB 
PE=2 SV=1 - [Q9UK54_HUMAN]
P59665 94 10.2 6.99 1.557
Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 - 
[DEF1_HUMAN]
Q4ZGM8 100 10.8 9.04 1.549
Hemoglobin alpha-2 globin mutant (Fragment) OS=Homo sapiens PE=3 
SV=1 - [Q4ZGM8_HUMAN]
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B4DJ12 1253 139.2 6.57 1.546
cDNA FLJ58355, highly similar to Tyrosine-protein phosphatase non-
receptor type 23 (EC 3.1.3.48) OS=Homo sapiens PE=2 SV=1 - 
[B4DJ12_HUMAN]
A0A087WUP0 265 30.0 5.34 1.541
Annexin A8-like protein 1 OS=Homo sapiens GN=ANXA8L1 PE=4 SV=1 - 
[A0A087WUP0_HUMAN]
E9PAR0 99 11.2 10.36 1.540
Peptidyl-prolyl cis-trans isomerase OS=Homo sapiens GN=FKBP11 PE=1 
SV=1 - [E9PAR0_HUMAN]
B2R4C9 102 11.2 9.52 1.537
cDNA, FLJ92044, highly similar to Homo sapiens death-associated protein 
(DAP), mRNA OS=Homo sapiens PE=2 SV=1 - [B2R4C9_HUMAN]
Q9NWH4 148 16.9 11.09 1.534
cDNA FLJ10024 fis, clone HEMBA1000636 OS=Homo sapiens PE=2 SV=1 - 
[Q9NWH4_HUMAN]
E3Q1J2 273 31.6 5.97 1.531
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-B PE=3 SV=1 - 
[E3Q1J2_HUMAN]
Q67AK3 233 26.9 7.42 1.531
MHC class II antigen (Fragment) OS=Homo sapiens GN=HLA-DQB1 PE=4 
SV=1 - [Q67AK3_HUMAN]
B4DLR0 579 61.1 5.26 1.529
cDNA FLJ55719, highly similar to Mus musculus armadillo repeat containing 
5 (Armc5), mRNA OS=Homo sapiens PE=2 SV=1 - [B4DLR0_HUMAN]
Q86UY0 360 40.3 5.83 1.526
Protein BLOC1S5-TXNDC5 OS=Homo sapiens GN=TXNDC5 PE=2 SV=1 - 
[Q86UY0_HUMAN]
E7EQB2 696 76.6 8.02 1.526
Lactotransferrin (Fragment) OS=Homo sapiens GN=LTF PE=1 SV=1 - 
[E7EQB2_HUMAN]
Q9P2B2 879 98.5 6.61 1.520
Prostaglandin F2 receptor negative regulator OS=Homo sapiens 
GN=PTGFRN PE=1 SV=2 - [FPRP_HUMAN]
Q96P70 1041 115.9 4.81 1.517 Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 - [IPO9_HUMAN]
Q5CZ93 159 19.2 9.88 1.517
Putative uncharacterized protein DKFZp686A0568 OS=Homo sapiens 
GN=DKFZp686A0568 PE=2 SV=1 - [Q5CZ93_HUMAN]
Q5VX52 437 50.3 8.43 1.514
Spermatogenesis-associated protein 1 OS=Homo sapiens GN=SPATA1 PE=2 
SV=3 - [SPAT1_HUMAN]
P80511 92 10.6 6.25 1.513
Protein S100-A12 OS=Homo sapiens GN=S100A12 PE=1 SV=2 - 
[S10AC_HUMAN]
A8MVU1 366 41.8 8.84 1.512
Putative neutrophil cytosol factor 1C OS=Homo sapiens GN=NCF1C PE=5 
SV=1 - [NCF1C_HUMAN]
B5BTZ6 769 87.9 6.20 1.502
Signal transducer and activator of transcription OS=Homo sapiens 
GN=STAT3 PE=2 SV=1 - [B5BTZ6_HUMAN]
Q15323 416 47.2 4.88 1.502 Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 - 
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[K1H1_HUMAN]
P07585 359 39.7 8.54 1.501 Decorin OS=Homo sapiens GN=DCN PE=1 SV=1 - [PGS2_HUMAN]
C9JKG1 238 26.7 6.79 1.501
Biglycan (Fragment) OS=Homo sapiens GN=BGN PE=4 SV=1 - 
[C9JKG1_HUMAN]
H0YA93 1400 158.1 5.82 1.501
NEDD4-binding protein 2 (Fragment) OS=Homo sapiens GN=N4BP2 PE=1 
SV=1 - [H0YA93_HUMAN]
G3V295 203 22.8 8.32 0.660
Proteasome subunit alpha type OS=Homo sapiens GN=PSMA6 PE=1 SV=1 - 
[G3V295_HUMAN]
O96009 420 45.4 6.61 0.658 Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 - [NAPSA_HUMAN]
E9PN95 56 6.3 4.96 0.626
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=4 SV=1 - 
[E9PN95_HUMAN]
P07339 412 44.5 6.54 0.615 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 - [CATD_HUMAN]
A8K987 222 25.7 9.00 0.603
Glutathione S-transferase OS=Homo sapiens PE=2 SV=1 - 
[A8K987_HUMAN]
B2R7Z6 484 52.5 7.55 0.591 cDNA, FLJ93674 OS=Homo sapiens PE=2 SV=1 - [B2R7Z6_HUMAN]
B4E1L4 668 71.6 5.63 0.531
cDNA FLJ59081, highly similar to Mucin-5B OS=Homo sapiens PE=2 SV=1 - 
[B4E1L4_HUMAN]
B7Z269 351 40.3 7.24 0.181
cDNA FLJ50754, highly similar to Voltage-dependent L-type calcium channel 
subunit alpha-1D OS=Homo sapiens PE=2 SV=1 - [B7Z269_HUMAN]
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Table 9:
Changes in proteins (with 1.5x cutoff) following surgery with LFV. Proteins with 









Q701L7 513 56.6 6.74 14.876
Type II hair keratin 2 OS=Homo sapiens GN=KRTHB2 PE=2 SV=1 - 
[Q701L7_HUMAN]
Q9BYT5 123 12.9 7.81 14.741
Keratin-associated protein 2-2 OS=Homo sapiens GN=KRTAP2-2 
PE=2 SV=3 - [KRA22_HUMAN]
O76013 467 52.2 4.94 7.140
Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 
SV=1 - [KRT36_HUMAN]
A0A087X2I6 404 46.1 4.84 4.627
Keratin, type I cuticular Ha3-II OS=Homo sapiens GN=KRT33B PE=4 
SV=1 - [A0A087X2I6_HUMAN]
A0JNT2 447 49.6 5.39 3.857
KRT83 protein OS=Homo sapiens GN=KRT83 PE=2 SV=1 - 
[A0JNT2_HUMAN]
B7Z269 351 40.3 7.24 2.379
cDNA FLJ50754, highly similar to Voltage-dependent L-type calcium 
channel subunit alpha-1D OS=Homo sapiens PE=2 SV=1 - 
[B7Z269_HUMAN]
Q15323 416 47.2 4.88 2.158
Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 
SV=3 - [K1H1_HUMAN]
Q96Q06 1357 134.3 8.73 1.840
Perilipin-4 OS=Homo sapiens GN=PLIN4 PE=2 SV=2 - 
[PLIN4_HUMAN]
Q05315 142 16.4 7.37 1.823
Galectin-10 OS=Homo sapiens GN=CLC PE=1 SV=3 - 
[LEG10_HUMAN]
H0YF46 255 28.3 5.82 1.698
SPOC domain-containing protein 1 (Fragment) OS=Homo sapiens 
GN=SPOCD1 PE=4 SV=1 - [H0YF46_HUMAN]
Q7Z6I6 1101 118.5 4.81 1.687
Rho GTPase-activating protein 30 OS=Homo sapiens GN=ARHGAP30 
PE=1 SV=3 - [RHG30_HUMAN]
P11678 715 81.0 10.29 1.663
Eosinophil peroxidase OS=Homo sapiens GN=EPX PE=1 SV=2 - 
[PERE_HUMAN]
A4FU00 317 35.6 5.81 1.651
SYT2 protein (Fragment) OS=Homo sapiens GN=SYT2 PE=2 SV=1 - 
[A4FU00_HUMAN]
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P27701 267 29.6 5.24 1.574
CD82 antigen OS=Homo sapiens GN=CD82 PE=1 SV=1 - 
[CD82_HUMAN]
B4DMJ5 242 27.3 4.50 1.547
cDNA FLJ53012, highly similar to Tubulin beta-7 chain OS=Homo 
sapiens PE=2 SV=1 - [B4DMJ5_HUMAN]
Q6P4A8 553 63.2 9.06 1.524
Phospholipase B-like 1 OS=Homo sapiens GN=PLBD1 PE=1 SV=2 - 
[PLBL1_HUMAN]
A0A024R637 1298 146.5 7.01 1.514
TBC1 domain family, member 4, isoform CRA_b OS=Homo sapiens 
GN=TBC1D4 PE=4 SV=1 - [A0A024R637_HUMAN]
M0QZ50 93 9.8 4.48 1.512
Microtubule-associated protein 1S OS=Homo sapiens GN=MAP1S 
PE=1 SV=1 - [M0QZ50_HUMAN]
B3KQ72 130 14.3 5.52 1.500
cDNA FLJ32987 fis, clone THYMU1000032 OS=Homo sapiens PE=2 
SV=1 - [B3KQ72_HUMAN]
H6VRF8 644 66.0 8.12 0.665
Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - 
[H6VRF8_HUMAN]
P35237 376 42.6 5.27 0.658
Serpin B6 OS=Homo sapiens GN=SERPINB6 PE=1 SV=3 - 
[SPB6_HUMAN]
D6RF35 476 53.0 5.52 0.658
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 - 
[D6RF35_HUMAN]
B7Z445 386 43.3 6.83 0.656
cDNA FLJ51492, highly similar to Arachidonate 15-lipoxygenase (EC 
1.13.11.33) OS=Homo sapiens PE=2 SV=1 - [B7Z445_HUMAN]
P62851 125 13.7 10.11 0.650
40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 
- [RS25_HUMAN]
Q99549 860 97.1 6.06 0.644
M-phase phosphoprotein 8 OS=Homo sapiens GN=MPHOSPH8 PE=1 
SV=2 - [MPP8_HUMAN]
Q7Z6G4 31 3.2 5.78 0.634
HBA2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 SV=1 - 
[Q7Z6G4_HUMAN]
K7EPK9 51 5.5 5.11 0.626
Mucin-like protein 1 (Fragment) OS=Homo sapiens GN=MUCL1 PE=4 
SV=3 - [K7EPK9_HUMAN]
Q86TT1 375 41.2 6.79 0.616
Full-length cDNA clone CS0DD006YL02 of Neuroblastoma of Homo 
sapiens (human) OS=Homo sapiens PE=2 SV=1 - [Q86TT1_HUMAN]
B2R6F5 350 39.6 5.12 0.607
cDNA, FLJ92928, highly similar to Homo sapiens retinitis pigmentosa 2 
(X-linked recessive) (RP2), mRNA OS=Homo sapiens PE=2 SV=1 - 
[B2R6F5_HUMAN]
P23527 126 13.9 10.32 0.605
Histone H2B type 1-O OS=Homo sapiens GN=HIST1H2BO PE=1 SV=3 
- [H2B1O_HUMAN]
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B3KUR3 242 28.0 5.85 0.604
cDNA FLJ40459 fis, clone TESTI2041800, highly similar to 
BISPHOSPHOGLYCERATE MUTASE (EC 5.4.2.4) OS=Homo sapiens 
PE=2 SV=1 - [B3KUR3_HUMAN]
P11277 2137 246.3 5.27 0.591
Spectrin beta chain, erythrocytic OS=Homo sapiens GN=SPTB PE=1 
SV=5 - [SPTB1_HUMAN]
P02656 99 10.8 5.41 0.591
Apolipoprotein C-III OS=Homo sapiens GN=APOC3 PE=1 SV=1 - 
[APOC3_HUMAN]
Q9NZD4 102 11.8 5.00 0.584
Alpha-hemoglobin-stabilizing protein OS=Homo sapiens GN=AHSP 
PE=1 SV=1 - [AHSP_HUMAN]
G4V2I8 911 101.7 5.21 0.574
Anion exchanger-1 variant OS=Homo sapiens PE=2 SV=1 - 
[G4V2I8_HUMAN]
B7Z4Q8 613 68.2 7.85 0.574
cDNA FLJ52333, highly similar to Erythrocyte membrane protein band 
4.2 OS=Homo sapiens PE=2 SV=1 - [B7Z4Q8_HUMAN]
P03973 132 14.3 8.75 0.570
Antileukoproteinase OS=Homo sapiens GN=SLPI PE=1 SV=2 - 
[SLPI_HUMAN]
P02549 2419 279.8 5.05 0.569
Spectrin alpha chain, erythrocytic 1 OS=Homo sapiens GN=SPTA1 
PE=1 SV=5 - [SPTA1_HUMAN]
Q14587 947 108.3 8.87 0.566
Zinc finger protein 268 OS=Homo sapiens GN=ZNF268 PE=1 SV=2 - 
[ZN268_HUMAN]
P69892 147 16.1 7.20 0.553
Hemoglobin subunit gamma-2 OS=Homo sapiens GN=HBG2 PE=1 
SV=2 - [HBG2_HUMAN]
P01833 764 83.2 5.74 0.549
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR 
PE=1 SV=4 - [PIGR_HUMAN]
P16157 1881 206.1 6.01 0.548 Ankyrin-1 OS=Homo sapiens GN=ANK1 PE=1 SV=3 - [ANK1_HUMAN]
Q4ZGM8 100 10.8 9.04 0.543
Hemoglobin alpha-2 globin mutant (Fragment) OS=Homo sapiens 
PE=3 SV=1 - [Q4ZGM8_HUMAN]
B3KVN0 416 45.8 8.60 0.534
cDNA FLJ16785 fis, clone NT2RI2015342, highly similar to Solute 
carrier family 2, facilitated glucose transporter member 1 OS=Homo 
sapiens PE=2 SV=1 - [B3KVN0_HUMAN]
Q4VB87 615 68.4 5.91 0.532
EPB41 protein (Fragment) OS=Homo sapiens GN=EPB41 PE=2 SV=1 
- [Q4VB87_HUMAN]
B4DF70 183 20.1 8.78 0.527
cDNA FLJ60461, highly similar to Peroxiredoxin-2 (EC 1.11.1.15) 
OS=Homo sapiens PE=2 SV=1 - [B4DF70_HUMAN]
Q4TZM4 101 11.0 6.52 0.518
Hemoglobin beta chain (Fragment) OS=Homo sapiens GN=HBB PE=3 
SV=1 - [Q4TZM4_HUMAN]
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P00918 260 29.2 7.40 0.507
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 - 
[CAH2_HUMAN]
O75602 509 55.4 6.83 0.504
Sperm-associated antigen 6 OS=Homo sapiens GN=SPAG6 PE=2 
SV=1 - [SPAG6_HUMAN]
Q6J1Z9 90 9.6 9.50 0.501
Hemoglobin alpha 1 (Fragment) OS=Homo sapiens GN=HBA1 PE=3 
SV=1 - [Q6J1Z9_HUMAN]
Q86YQ1 91 9.7 9.25 0.497
Hemoglobin alpha-2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 
SV=1 - [Q86YQ1_HUMAN]
Q13938 189 21.0 4.89 0.495
Calcyphosin OS=Homo sapiens GN=CAPS PE=1 SV=1 - 
[CAYP1_HUMAN]
E9PN95 56 6.3 4.96 0.450
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=4 SV=1 - 
[E9PN95_HUMAN]
A8K987 222 25.7 9.00 0.448
Glutathione S-transferase OS=Homo sapiens PE=2 SV=1 - 
[A8K987_HUMAN]
P00915 261 28.9 7.12 0.442
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 - 
[CAH1_HUMAN]
Q6J1Z8 42 4.5 9.38 0.429
Hemoglobin beta (Fragment) OS=Homo sapiens GN=HBB PE=3 SV=1 
- [Q6J1Z8_HUMAN]
H3BML9 118 13.1 5.68 0.397
Myosin regulatory light chain 2, skeletal muscle isoform (Fragment) 
OS=Homo sapiens GN=MYLPF PE=4 SV=1 - [H3BML9_HUMAN]
E5RGQ7 148 16.8 8.88 0.388
Dematin (Fragment) OS=Homo sapiens GN=DMTN PE=1 SV=1 - 
[E5RGQ7_HUMAN]
Q6VFQ6 42 4.5 8.24 0.384
Hemoglobin beta chain (Fragment) OS=Homo sapiens GN=HBB PE=3 
SV=1 - [Q6VFQ6_HUMAN]
P02042 147 16.0 8.05 0.383
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 - 
[HBD_HUMAN]
Q5T619 568 62.3 8.62 0.380
Zinc finger protein 648 OS=Homo sapiens GN=ZNF648 PE=2 SV=1 - 
[ZN648_HUMAN]
Q5RHS7 95 11.0 9.28 0.346
Protein S100-A2 OS=Homo sapiens GN=S100A2 PE=1 SV=2 - 
[Q5RHS7_HUMAN]
Q8IUL9 105 11.5 6.05 0.270
Hemoglobin beta chain variant Hb.Sinai-Bel Air (Fragment) OS=Homo 
sapiens GN=HBB PE=3 SV=1 - [Q8IUL9_HUMAN]
B4E1L4 668 71.6 5.63 0.257
cDNA FLJ59081, highly similar to Mucin-5B OS=Homo sapiens PE=2 
SV=1 - [B4E1L4_HUMAN]




Principle component analysis (by Partek) of gene expression data, showing no 
significant outliers within the data. 
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Supplemental Figure 2:
There were no significant changes in (A) lipid species or (B) lipid class (as a percentage of the total) following surgery either with 






































































































































































































































































































 Cardiopulmonary bypass surgery causes systemic and pulmonary inflammation 
 Surgery increases oxidative stress and hypoxia in the lungs and free iron in the blood
 Omics suggest ischemia is the principle driver of inflammation
 Unlike animal models lung ventilation during surgery increases inflammation
 Ventilation increased ischemia, potentially through increased surgical time
Abstract
Background
Heart surgery with cardio-pulmonary bypass (CPB) is associated with lung ischemia leading 
to injury and inflammation. It has been suggested this is a result of the lungs being kept deflated 
throughout the duration of CPB.  Low frequency ventilation (LFV) during CPB has been 
proposed to reduce lung dysfunction. 
Methods
We used a semi-biased multi-omic approach to analyse lung biopsies taken before and after 
CPB from 37 patients undergoing coronary artery bypass surgery randomised to both lungs left 
collapsed or using LFV for the duration of CPB. We also examined inflammatory and oxidative 
stress markers from blood samples from the same patients.
Results
30 genes were induced when the lungs were left collapsed and 80 by LFV. Post-surgery 26 
genes were significantly higher in the LFV vs. lungs left collapsed, including genes associated 
with inflammation (e.g. IL6 and IL8) and hypoxia/ischemia (e.g. HIF1A, IER3 and FOS). 
Relatively few changes in protein levels were detected, perhaps reflecting the early time point 
or the importance of post-translational modifications. However, pathway analysis of proteomic 
data indicated that LFV was associated with increased “cellular component morphogenesis” 
and a decrease in “blood circulation”. Lipidomic analysis did not identify any lipids 
significantly altered by either intervention. 
Discussion
Taken together these data indicate the keeping both lungs collapsed during CPB significantly 
induces lung damage, oxidative stress and inflammation. LFV during CPB increases these 
deleterious effects, potentially through prolonged surgery time, further decreasing blood flow 
to the lungs and enhancing hypoxia/ischemia.
Multi-omic analysis of the effects of low frequency ventilation 
during cardiopulmonary bypass surgery.
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3 Heart surgery with cardio-pulmonary bypass (CPB) is associated with lung ischemia 
4 leading to injury and inflammation. It has been suggested this is a result of the lungs 
5 being kept deflated throughout the duration of CPB.  Low frequency ventilation 
6 (LFV) during CPB has been proposed to reduce lung dysfunction. 
7
8 Methods
9 We used a semi-biased multi-omic approach to analyse lung biopsies taken before and 
10 after CPB from 37 patients undergoing coronary artery bypass surgery randomised to 
11 both lungs left collapsed or using LFV for the duration of CPB. We also examined 




16 30 genes were induced when the lungs were left collapsed and 80 by LFV. Post-
17 surgery 26 genes were significantly higher in the LFV vs. lungs left collapsed, 
18 including genes associated with inflammation (e.g. IL6 and IL8) and 
19 hypoxia/ischemia (e.g. HIF1A, IER3 and FOS). Relatively few changes in protein 
20 levels were detected, perhaps reflecting the early time point or the importance of post-
21 translational modifications. However, pathway analysis of proteomic data indicated 
22 that LFV was associated with increased “cellular component morphogenesis” and a 
23 decrease in “blood circulation”. Lipidomic analysis did not identify any lipids 
































































2 Taken together these data indicate the keeping both lungs collapsed during CPB 
3 significantly induces lung damage, oxidative stress and inflammation. LFV during 
4 CPB increases these deleterious effects, potentially through prolonged surgery time, 








































































2 Cardiopulmonary bypass (CPB), which allows operation on a motionless and 
3 bloodless heart, is used in most heart surgery procedures. Recovery from cardiac 
4 surgery utilising CPB is generally good with a 30 day survival rate of 98.4% [1]. 
5 However, CPB is still associated with severe systemic inflammation and tissue 
6 damage with an accompanying mortality of 1.5% along with post-operative lung 
7 dysfunction of various degrees in  up to 30% of patients [2]. The underlying 
8 mechanisms driving inflammation following CPB are yet to be fully elucidated and 
9 there are currently no strategies to effectively prevent it. 
10
11 Institution of CPB is associated with significant physiological changes and insults to 
12 the lung. Ventilation is generally stopped, and lungs deflated to reduce mediastinal 
13 motions. Venous return is directed away from the right heart thereby pulmonary 
14 artery flow is dramatically reduced. Furthermore, bronchial blood flow is reduced due 
15 to haemodynamic and pulsatility changes during bypass and changes in vascular 
16 resistances. These atelectatic and ischemic changes may promote tissue hypoxia, 
17 oxidative stress and lung cellular damage [3–6]. Towards the end of CPB, full 
18 ventilation is recommenced and pulmonary blood flow is restored with potential 
19 injury by reperfusion including oxidative stress [7,8], and inflammatory cell 
20 infiltration [9]. Further oxidative stress could be triggered by free iron catalysed 
21 reactions [10,11] from iron released by haemolysis as the blood passes through the 
22 bypass circuit. 
23
24 There have been various attempts made to protect the lung during CPB. Among these, 






























































1 hypoxia and ischemia of the lungs and thereby help to reduce inflammation.  In 
2 contrast to previous animal trials [12], we have recently provided evidence that in 
3 patients undergoing elective coronary artery bypass grafting (CABG), the use of LFV 
4 during CPB when compared to both lungs left collapsed does not seem to reduce 
5 inflammation in lung biopsies and blood [13,14]. 
6  
7 The low frequency ventilation technique reported in our study has been investigated 
8 previously by different groups with contrasting results.  This study, for the first time, 
9 uses the simultaneous of human lung biopsy and blood samples to assess the effect of 
10 the technique. In order to establish a mechanistic link between the effects of both 
11 interventions on the lung we used a semi-biased multi-omics approach 
12 (transcriptomics, proteomics and lipidomics) to analyse lung biopsies taken at the start 
13 of surgery before CPB and at the end of surgery after lung reperfusion but before 
14 weaning from CPB from the above mentioned randomised study recently published 
































































2 2.1 Study design
3 37 patients undergoing elective or urgent CABG with CPB and cold blood 
4 cardioplegic arrest at the Hammersmith Hospital, were recruited as part of a  single-
5 centre, parallel group, randomised, controlled trial investigating low frequency 
6 ventilation study recently published [14]. 
7  
8 Venous blood samples were taken from the patients at induction, 10mins, 2, 6 and 24 
9 hours post CPB. 
10 Lung biopsies were taken both prior to and immediately after surgery. The pre-
11 surgery biopsies were taken from the left upper lobe immediately after sternotomy 
12 with lungs ventilated for both groups. The post-surgery biopsy was taken from the left 
13 lower lobe at the end of the operation just before weaning from CPB.  
14 This study was approved by the NRES committee London- Camden and Islington 
15 (Research Ethics Committee reference number 12/LO/0458) on 25/04/2012. Further 
16 approval was obtained from the research and development department of the Imperial 
17 College Healthcare NHS Trust. This research complied with the Helsinki Declaration. 
18 The trial is registered as ISRCTN No: 34428459. All patients involved in the study 
19 gave written and informed consent
20
21 2.2 Luminex:
22 Cytokines in human plasma samples, taken 24 hours post-surgery, were quantified 
































































1 RNA was extracted and analysed by Affymetrix GeneChip Human Gene 1.0 ST 
2 Array (ThermoFisher) following the manufacturer’s instructions.  




7 Protein was extracted as described previously [14]. More details are available in the 
8 supplemental materials.
9
10 2.5 Heme assay:
11 Heme levels in the whole cell protein extracts were measured using the Heme 
12 colorimetric assay kit (BioVision, Milpitas, CA, USA) following manufacturer’s 
13 instruction.  
14
15 2.6 Lipidomics:
16 Lung tissue was processed as described previously [15,16].  
17 More details are available in the supplemental materials.
18
19 2.7 Oxidative stress/ Anti-oxidant capacity:
20 We used the RedoxSys® to electrochemically measure the oxidant redox potential 
21 (ORP) and antioxidant capacity (AOC), following manufacturer’s instructions (Aytu 
22 Biosciences, Englewood, CO, USA). 
23






























































1 Gene arrays were analysed by Partek genomics Suite (Partek Inc). Gene and protein 
2 classification were tested using PANTHER Overrepresentation Test analysed against 
3 the Homo Sapiens reference list, using the PANTHER Go-SLIM Biological process 
4 annotation dataset [17]. Analysis included Bonferroni correction for multiple data.
5
6 The remaining data were analysed using Graphpad Prism 6 (Graphpad Software Inc, 
7 La Jolla, CA, USA) utilising Friedman and using Dunn’s multiple comparison test 
































































2 Patient demographics and clinical characterisation are provided in detail in Fiorentino 
3 et al, 2019 [14].
4
5 3.1 Patient serum samples:
6 3.1.1 Luminex of serum cytokines:
7 Plasma IL-6, IL-8 and IL-10 levels increased significantly 24 hours post-surgery in 
8 both groups compared to the pre-surgery control samples. IL-6 levels increased 17-
9 fold in lungs collapsed group and 25-fold in the LFV group (Figure 1A). IL-8 levels 
10 (Figure 1B) increased approximately 1.5-fold in both study groups, whilst IL-10 
11 (Figure 1C) increased approximately 1.3x. In contrast, there was no significant 
12 change in inflammatory cytokines IL-1β and MCP-1 in the plasma of patients before 
13 CPB and 24hrs after CPB in both groups (Figure 1D & E). 
14
15 3.1.2 Cell-Free heme:
16 The levels of cell free heme were measured in the blood plasma following surgery. 
17 Cell free heme was significantly higher in both groups at 10 minutes and 2 hours after 
18 surgery before returning to baseline. Cell-free heme levels in plasma were increased 
19 but not significantly in the LFV group (51.5μM vs 38.1μM, 2-way ANOVA p=0.17) 
20 (Figure 2).
21
22 3.1.3 Oxidative stress in blood:
23 Plasma ORP and AOC from all patients were measured following bypass. By 2-way 
24 ANOVA time after surgery was linked to significantly increased ORP (p<0.0001) and 






























































1 did not identify any statistical significance related to intervention, indicating that CPB 
2 induced changes in ORP and AOC were not altered by LFV (p=0.44, p=0.16 
3 respectively) (Figure 2). 
4
5 Since LFV intervention did not effect plasma ORP or AOC we examined the 
6 combined data to increase statistical power and determine the effects of surgery. The 
7 combined data showed a significant increase in ORP within 10 minutes following 
8 surgery, which increased at all timepoints measured but appeared to plateau at 6 
9 hours. Similarly, the decrease in AOC following surgery reached a nadir at 6 hours 
10 which was maintained (Figure 2).
11
12 3.2 Biopsy RNA gene expression data:
13 Full data set is available at https://figshare.com/articles/_/4772167. Principle 
14 component analysis (PCA) did not identify any significant outliers; therefore, no 
15 patient samples were excluded from the analysis (Supplemental Figure 1).  There 
16 were no significant differences in gene expression between the two groups at baseline. 
17
18 3.2.1 Transcriptional response to CPB with lungs collapsed:
19 Lungs left collapsed significantly increased the expression of 30 genes in the biopsy 
20 immediately after surgery (Supplemental data: Table 1). These genes include the 
21 inflammatory genes CCL2 (encoding MCP-1) and IL6, which had the highest increase 
22 following surgery (6.7x and 6.6x higher than baseline respectively). Panther pathway 
23 analysis identified the “cholecystokinin receptor (CCKR) signalling map” (p=2.26E-






























































1 02) as significantly over-represented within the genes induced in the lung collapsed 
2 group (Supplemental data: Table 2). 
3
4 3.2.2 Transcription response to CPB with LFV:
5 LFV significantly induced 80 genes in lung tissue after surgery (Supplemental data: 
6 Table 3). No genes were significantly suppressed.  All CPB-induced genes were 
7 enhanced in the LFV group and up-regulated genes shared the same pathways as 
8 those induced by lungs collapsed CPB namely the “CCKR signalling map” (p= 
9 2.14E-10), the “interleukin signaling pathway” (p=4.34E-03) and the “p53 pathway” 
10 (p=4.46E-02)(Supplemental data: Table 4).  In addition, the “Inflammation 
11 mediated by chemokine and cytokine signaling pathway” and the “Gonadotropin-
12 releasing hormone receptor pathway” were also enriched.  Biological process analysis 
13 identified “endoderm development”, “MAPK cascade”, “cell death” and “response to 
14 stress” as significantly over-represented.
15
16 The 50 genes that were upregulated in the LFV group alone (i.e. not in CPB lungs 
17 collapsed group) included inflammatory genes such as IL1B and CYR61.  Pathway 
18 and biological process analysis did not identify any specific pathways or processes as 
19 overrepresented in these 50 genes although raw, uncorrected p values indicated over-
20 representation of the ‘CCKR signalling map’ and “Inflammation mediated by 
21 chemokine and cytokine signaling” pathways (p=2.01E-03).  
22
23 3.2.3 Effect of low frequency ventilation: 
24 Comparing gene expression biopsies from the LFV and lungs left collapsed groups 






























































1 who underwent LFV compared to patients undergoing lungs collapsed CPB 
2 (Supplemental data: Table 5).  HLA-DRB5, encoding the HLA class II 
3 histocompatibility antigen DRB5 was reduced in the LFV group whilst the remaining 
4 25 genes were increased with LFV.  The expression of HLA-DRB5 was not 
5 significantly altered following surgery in either groups compared to their respective 
6 pre-surgical controls.
7
8 The genes significantly increased by LFV intervention compared to lungs left 
9 collapsed included the inflammatory IL6, CCL2 and CCL8 (encoding IL-6, MCP1 and 
10 MCP2 respectively). Pathway analysis showed that LFV significantly activated the 
11 “Plasminogen activating cascade” (p=3.17E-02), “CCKR signaling map” (p=6.81E-
12 03), and “Inflammation mediated by chemokine and cytokine signaling pathway” 
13 (p=3.30E-02)(Supplemental data: Table 2).
14
15 Combining both intervention groups to increase the analytical power of the effects of 
16 surgery identified 51 genes with significantly altered expression following surgery 
17 (Supplemental data: Table 6). Pathway analysis of this data identified the 
18 “Oxidative stress response” (p= 4.76E-02), “Interleukin signaling” (p= 5.10E-04), 
19 “CCKR signaling map” (p=9.53E-07) and “p53” (p= 8.22E-03) pathways as over-
20 represented.
21
22 3.2.4 Validation of transcriptomic response:
23 We have previously examined the induction of IL6, IL8 and IL1B gene expression in 
24 the lung biopsies by Taqman qPCR. The gene expression data following CPB showed 






























































1 lungs collapsed group [14].   In addition, we demonstrated significant up-regulation of 
2 hypoxia inducible factor 1A (HIF1A) gene expression in the biopsies after lungs 
3 collapsed CBP, which was further enhanced in the biopsies from patients who 
4 underwent LFV (Figure 3A), compared to the pre-surgery control biopsies.
5
6 3.3 Biopsy Proteomic analysis:
7 Full data set is available at https://figshare.com/articles/_/4772167. Whole cell protein 
8 extracts from each biopsy were pooled into 4 groups: lungs left collapsed or LFV both 
9 pre and post-surgery. Tandem mass tagging (TMT) identified over 3000 distinct 
10 proteins in the pooled biopsy samples. There was minimal variation in the pre-surgery 
11 baseline levels of proteins detected.  Two proteins were significantly elevated >2-fold 
12 in the lungs left collapsed group and 34 were elevated >2x in the LFV group 
13 (Supplemental data: Table 7) before surgery.  Panther pathways analysis of these 
14 proteins did not identify any biological pathways or processes as overrepresented.  
15 Using a 1.5-fold cut-off, there were 4 significantly different proteins in the lungs 
16 collapsed group and 155 proteins more highly expressed in the LFV group.  
17 PANTHER analysis of these proteins identified “immune system process” as over-
18 represented in the LFV group at baseline before surgery.
19
20 3.3.1 Proteomic response to CPB with lungs collapsed:
21 Lungs collapsed CBP resulted in 25 proteins having a >2-fold increase in expression 
22 post-surgery and 1 protein decreased >2-fold (Supplemental data: Table 8) relative 
23 to the same donors before surgery. The up-regulated proteins included the detoxifying 
24 enzyme glutathione S-transferase P (GSTP1), and eosinophil peroxidase.  The 






























































1 dependent L-type calcium channel subunit alpha-1D”.  Reducing the cut-off ratio to 
2 1.5-fold change increased the number of differentially expressed proteins to 109 with 
3 enhanced expression and 8 proteins that were decreased.  These did not reflect any 
4 pathways or processes although at the unadjusted p value level the “CCKR signalling 
5 map” and “intergrin signalling pathways” were identified as over-represented 
6 (p=4.91E-2 and p=1.33E-02 respectively). 
7
8 3.3.2 Proteomic response to CPB with LFV:
9 CBP in the presence of LFV resulted in >2-fold upregulation of 7 proteins with 
10 keratin, both type I and II, making up 6 out of 7 of these proteins (Supplemental 
11 data: Table 8).  Keratin is a common contaminant of proteomic experiments, so these 
12 changes may simply be an artefact, however keratin expression in the lungs has 
13 previously been reported, including its upregulation during lung repair [18] and by 
14 shear forces.[19,20] The remaining protein was “cDNA FLJ50754, highly similar to 
15 Voltage-dependent L-type calcium channel subunit alpha-1D”.  Whilst no pathways 
16 were identified as changed the keratin proteins were all linked to the process of 
17 “cellular component organisation or biogenesis” (p=2.8x10-6).  15 proteins were 
18 decreased >2-fold following surgery with LFV, including 5 haemoglobin subunits 
19 (HBA2, HBB, HBD). Analysis of biological processes identified “blood circulation” 
20 as overrepresented (p>0.001).  
21
22 19 proteins were increased following LFV using a 1.5-fold cut off, 7 of which were 
23 linked to the “cellular component morphogenesis” process (p>0.001).  47 proteins 






























































1 significantly altered by LFV at the protein level, however, cellular process analysis 
2 again identified “blood circulation” as overrepresented (p=0.001).   
3
4 3.3.3 Comparison of LFV with lungs left collapsed:
5 Direct comparison of the post-bypass samples identified 4 proteins that were 
6 increased in the lungs collapsed group with >2-fold change and 9 proteins that were 
7 increased in the LFV group (Supplemental data: Table 5). Biological pathway and 
8 process analysis did not identify any significantly over-represented 
9 pathways/processes between these groups.  16 proteins were identified as >1.5-fold 
10 higher in lungs collapsed compared to LFV, of which 3 were also higher at baseline 
11 and therefore excluded from the analysis.  Proteins increased in the lungs collapsed 
12 group included haemoglobin alpha, beta and delta. These proteins were not associated 
13 with any significant changes in biological pathways but were identified with the 
14 processes of blood circulation (p=2.27E-04) and transport (p=3.14E-05).   
15 11 proteins were higher in the LFV group compared to lungs collapsed post-surgery 
16 but not pre-surgery. No processes or pathways were identified as significant. 
17
18 3.4 Confirmation of reduced haemoglobin in biopsies following LFV:
19 Due to the proteomics identification of haemoglobin as downregulated in the LFV 
20 group the level of heme was measured in the protein isolated from each lung biopsy 
21 (Figure 3B). The amount of heme in the biopsies did not significantly change 
22 following CPB with lungs collapsed, however, it was significantly reduced following 
































































1 Full data set is available at https://figshare.com/articles/_/4772167. There were no 
2 significant differences in lipid class or species between groups either before or after 
































































2 Surgery with CPB is associated with acute systemic and pulmonary inflammation and 
3 can lead to pulmonary dysfunction in a significant number of patients.  We confirmed 
4 previous data showing enhanced levels of inflammatory cytokines, oxidative stress, 
5 cell free heme and decreased plasma anti-oxidant capacity with CPB. We also 
6 provided evidence for the first time in transcriptomic analysis of lung biopsy in 
7 patients undergoing CABG, that CPB triggers a significant increase in hypoxic and 
8 inflammatory responses and a decrease in genes associated with blood flow. These 
9 effects were amplified in patients undergoing CPB with LFV when compared with 
10 CPB with lungs collapsed.  These data provide a mechanistic link to the adverse 
11 clinical effects seen with the addition of LFV to CPB in patients undergoing CABG 
12 (14).  
13
14 Analysis of the patients’ plasma showed that following CPB with lungs collapsed 
15 there was a significant increase in the levels of inflammatory cytokines, oxidative 
16 stress, cell free heme and a decrease in plasma anti-oxidant capacity corresponding to 
17 the effects of CPB surgery previously reported [21]. These systemic effects were not 
18 significantly altered by CPB with LFV intervention. 
19
20 LFV may increase the deleterious effects of CPB by three main mechanisms: 
21 increased surgical time, direct oxygenation of the lungs or ventilator-associated 
22 injury.  The movement of the lungs during CPB with LFV may increase surgery time.  
23 The LFV group had a  higher levels of cell free heme in the blood following CPB, a  






























































1 (87.5 minutes median (range 68-97) vs 69 minutes median (range 54-79)) (p=0.03) 
2 [14]. 
3
4 The increased oxygenation of the lungs during LFV may also enhance lung injury. 
5 Without the hypoxic response to reduce metabolic rates, LFV may cause a more rapid 
6 use of metabolic substrates and the build-up of by-products causing increased lung 
7 damage. Hyperoxia during surgery showed similar inflammation and stress following 
8 CPB as normoxia, although hyperoxia led to oxygen-mediated myocardial, hepatic 
9 and cerebral injury [22]. This hypothesis is unlikely as the LFV group showed 
10 increased HIF1A gene expression in blood indicating that the lungs were less, not 
11 more, oxygenated during LFV. However, intermittent hypoxia has been shown to be 
12 more potent at activating HIF-1α and FOS/AP-1  than continuous hypoxia [23].
13
14 Finally, LFV may cause biotrauma to the lung by repetitive alveolar collapse and 
15 hyperinflation [24]. 
16
17 Our data are unique because of the use of lung biopsies taken during the surgery in the 
18 on-going debate regarding relative contributions of ischaemia and reperfusion to 
19 tissue injury. The data indicate that the practice of lungs left collapsed during CPB 
20 prior to reperfusion, can trigger gene expression, inflammation and stress in the lungs. 
21 These could be the consequence of atelectasis, direct effect of lung hypoperfusion and 
22 ischemia superimposed by perfusion with activated inflammatory cells due to their 
23 activation by the CPB machine and circuit.  There has been considerable debate as to 
24 the relative importance of these mechanisms in driving lung inflammation [3,4,25] but 






























































1 support the hypothesis that ischemia alone is enough to drive inflammation.   
2 Ischemia during surgery is associated with significant changes in inflammation 
3 (interleukin signalling pathway) and stress (CCKR and p53 pathways) in the lung. 
4
5 In addition, the principle driver of increased inflammation in the LFV group appears 
6 to be increased surgery time, and hence ischemic, time, whilst reperfusion remained 
7 unchanged. As our lung biopsies were collected immediately after reperfusion it is 
8 unlikely that systemic inflammation or reperfusion injury would have been able to 
9 influence gene expression, but rather that ischemia alone is capable of significantly 
10 damaging the lungs.
11
12 Whilst the proteomic analysis of CPB identified several proteins that changed 
13 expression in the pooled samples, this did not identify any specific pathways as 
14 activated by routine CPB with lungs left collapsed. Proteomic analysis is hampered by 
15 the short timeframes in which the surgery occurs and (to overcome resource 
16 constraints) the pooling of samples from all patients in each treatment group. Whilst 
17 pooling the samples loses the ability to discern individual patient variation, this 
18 approach reduces biological variation and thereby increases the power to detect 
19 treatment differences [26]. Nevertheless, CCKR signalling and integrin signalling 
20 pathways were significantly over-represented by proteins up-regulated by CPB when 
21 assessed using a raw p value <0.05.  As stated above, the CCKR signalling may be 
22 induced by hypoxic conditions and up-regulated protein levels correlated well with 
23 gene expression. The integrin signalling proteins consisted of collagen alpha-1 (I) 
24 chain, the collagen alpha-1 (XIV) chain, the adapter molecule Crk and Crk-like 






























































1 and transformation of fibroblasts, which are the principle produces of extracellular 
2 matrix, including collagen in response to injury. These data indicate that fibroblast 
3 activation, in response to lung injury, occurs at an early stage in CPB. This study 
4 provides valuable insight into the underlying mechanisms that drive lung 
5 inflammation during CPB. This increased understanding may lead to more effective 
6 interventions in the future.
7
8
9 Proteomic analysis of the LFV group showed a significant decrease in proteins 
10 representing blood circulation, such as haemoglobin, which was confirmed in the 
11 biopsy samples. These data indicate that LFV may have increased vascular resistance 
12 and further reduced pulmonary blood flow during surgery, which may increase the 
13 level of ischemia and the level of pulmonary inflammation [27]. Patients undergoing 
14 LFV did show an increase in requiring haemodynamic support following surgery 
15 compared to those undergoing CPB with lungs left collapsed, so alternatively this 
16 may reflect a reduction in blood pressure [14].
17
18 Whilst changes in lipids have been reported in response to oxidative stress, such as 
19 the accumulation of pro-inflammatory isoprostanes and oxylipins in smokers and in 
20 patients with cardiovascular disease, no significant changes in lipidomics were 
21 detected following CPB, indicating that either the timeframe of the study was too 
22 short for these changes to occur or CPB has little effect on the lipid composition of 
23 the lung. The lack of change in the proteomics and lipidomic profiles detected may 






























































1 protein and lipid function. Unfortunately, examination of post-translational 
2 modifications was beyond the scope of this study. 
3
4 A major limitation of the study is the timing of the sample collection. The initial pilot 
5 study was not designed to identify differences between ischemia and reperfusion and 
6 ideally lung biopsies should have been taken immediately before and after reperfusion 
7 occurred. Additionally the timing may be suboptimal for detecting changes which  
8 drive lung injury following CPB. A study by Hepponstall examining the plasma 
9 proteome following CPB found changes in C-reactive protein and hepatoglobin 
10 peaked at 12-24 hours following surgery [28]. This is reflected in the differences in 
11 results between the Luminex measure of cytokines in the plasma and the lung biopsy 
12 proteomics. In the biopsies collected immediately post-surgery there was no 
13 significant increases in the levels of inflammatory cytokines detected, which 
14 contrasted with the significant increases in the plasma samples collected 24 hours 
15 later, reflecting the several hours of transcription, translation and post-translational 
16 modification required for fully mature cytokines to be produced. However, as shown 
17 by our previous publication on LFV and CPB inflammatory signals, such as NF-κB 
18 were significantly higher immediately after surgery in the lung biopsies [14]. 




23 LFV increased pulmonary, but not systemic inflammation, following CPB. Semi-
24 biased transcriptomic and proteomic analysis of lung biopsies suggest that ischemia is 






























































1 possibly through reduced blood flow through the bronchial artery and increased 
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Figure 1. Cytokine levels following surgery. 
Plasma was extracted from the blood of patients collected after anaesthetic induction 
but before the cardio-pulmonary bypass (CPB) procedure (pre-CPB), and at 24hrs 
post-operation (post-CPB). Patients who underwent CPB with lungs left collapsed 
shown in black (n=18). Patients shown in grey (n=18) received CPB with low 
frequency ventilation (LFV). Concentrations of (A) IL-6, (B) IL-8, (C) IL-10, (D) IL-
1β and (E) MCP-1 in the plasma were quantified with a multiplex assay. Data was 
analysed Freidman Test statistical analysis with Dunn’s multiple comparison post-
test; **p<0.01, ***p<0.001, ****p<0.0001. 
Figure 2. Measurements in blood plasma following surgery. 
Plasma samples were measured at various timepoints following surgery, (A) cell free 
heme in the patients undergoing CPB with lungs left collapsed (n=18), (B) heme in 
patients undergoing CPB with LFV (n=18) (C) oxidation reduction potential (ORP) 
(D) anti-oxidant capacity (AOC). The control group is shown in black and the LFV 
group in grey. Data from both patient groups were combined to examine the effects of 
the CPB circuit on (E) ORP and (F) AOC. Data were analysed using Freidman Test 
statistical analysis with Dunn’s multiple comparison post-test *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 






























































(A) Hypoxia inducible factor 1 alpha (HIF1A) gene expression in lung biopsies pre- 
and post-surgery using either CPB with lungs left collapsed or with LFV. HIF1A gene 
expression (normalised to 18S) was significantly increased (the median gene 
expression doubled) in lung tissue following CPB, with (n=18) or without LFV 
(n=18). LFV biopsies had significantly higher levels of HIF1A gene expression 
compared to biopsies from patients who underwent CPB with lungs left collapsed. 
Lung biopsies were taken prior to bypass (Pre) and after surgery, immediately before 
reperfusion (Post). n=18 in each group of patients *p<0.05, **p<0.01 comparing 
groups post-surgery, Wilcoxon matched-pairs signed rank test.
(B) Total Heme in lung biopsy samples from both groups, both pre- and post-surgery. 
Whilst heme levels were not significantly altered in the biopsies from patients 
undergoing CPB with lungs left collapsed they were significantly reduced in the 
biopsies from patients undergoing CPB with LFV following surgery. n=18 in each 
group of patients *p<0.05, **p<0.01 comparing groups post-surgery, Wilcoxon 
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13 For RNA extraction biopsies were placed in in RLT buffer (Qiagen) and 
14 homogenized using Precellys® ceramic beads (Cayman Chemicals, Cambridge, 
15 UK). Subsequently RNA was extracted using RNeasy extraction kit following 
16 manufacturer’s instructions (Qiagen, Manchester, UK).
17
18 RNA was quantified by NanoDrop spectrophotometer (ThermoFisher, Waltham, 
19 MA, USA) and quality was checked by LabChip® spectrophotometer (Perkin 
20 Elmer). Subsequently RNA was amplified, converted to cDNA using the cDNA 
21 Ovation Pico WTA System (NuGen, San Carlos, CA, USA) and biotin labelled, using 
22 the Encore BiotinIL Module (Nugen), following the manufacturer’s instructions.  
23 The cDNA was quantified and qualified, as above, and gene expression was 
24 measured using the Affymetrix GeneChip Human Gene 1.0 ST Array 
25 (ThermoFisher) following the manufacturer’s instructions. Microarray data was 
2
1 analysed using Partek Genomics Suite 6.6 (Partek GS, St. Louis, MI, USA ) 
2 software and PANTHER gene ontology.[1]
3
4 RNA samples were also quantified using RT-qPCR. In brief the RNA 
5 concentration was determined using a NanoDrop 2000c spectrophotometer and 
6 standardised to 50ng/L.  Reverse transcription to create single stranded cDNA 
7 was performed using a high-capacity cDNA kit (Applied Biosystems, Foster City, 
8 CA, USA), following the manufacturer's instructions. qPCR was performed using a 
9 Rotor-Gene 3000 PCR machine (Corbett Research, Cambridge, UK) using a 
10 QuantiTect SYBR Green PCR kit and normalised to 18S rRNA. 
11
12 Proteomics:
13 Protein was extracted as described previously. In brief samples were 
14 homogenized in RIPA buffer (Sigma Aldrich, Poole, UK) containing HALT 
15 protease and phosphatase inhibitors (ThermoFisher, Paisley, UK) using 
16 Precellys® ceramic beads (Cayman Chemicals). After 30 minutes incubation at 
17 4°C the samples were centrifuged (13,000g, 5 minutes, 4°C). 
18
19 Supernatants from each group were quantified against a standard curve using 
20 the bininchoninic acid (BCA) assay (Sigma Aldrich) and equal amounts from each 
21 sample were pooled and changes in protein expression analysed using tandem 
22 mass tagging (TMT), as described previously.[2] 
23
24 TMT Labelling and cation exchange chromatography
3
1 Aliquots of 100µg of each sample were digested with trypsin (2.5µg trypsin per 
2 100µg protein; 37°C, overnight) and labelled with Tandem Mass Tag (TMT) 
3 sixplex reagents according to the manufacturer’s protocol (Thermo Fisher 
4 Scientific, Loughborough, LE11 5RG, UK).  After labelling, samples were pooled 
5 and a 50µg aliquot evaporated to dryness and resuspended in Buffer A (10mM 
6 KH2PO4, 25%MeCN pH3) prior to fractionation by strong cation exchange using 
7 an Ettan LC system (GE Healthcare).  In brief, the sample was loaded onto a 
8 PolysulphoethylA column (100 x 2.1mm, 5µm, 200A; PolyLC Inc.) in buffer A and 
9 peptides eluted with an increasing gradient of buffer B (10mM KH2PO4, 
10 25%MeCN 1M KCl pH3) from 0-100% over 30 minutes.  The resulting fractions 
11 were evaporated to dryness, resuspended in 5% formic acid and then desalted 
12 using SepPak cartridges according to the manufacturer’s instructions (Waters, 
13 Milford, Massachusetts, USA)).  Eluate from the SepPak cartridge was again 
14 evaporated to dryness and resuspended in 1% formic acid prior to analysis by 
15 nano-LC MSMS using an LTQ-Orbitrap Velos Mass Spectrometer.  
16
17 Nano-LC Mass Spectromerty
18 Cation exchange fractions were further fractionated using an Ultimate 3000 
19 nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrometer 
20 (Thermo Scientific).  In brief, peptides in 1% (vol/vol) formic acid were injected 
21 onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 
22 washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides 
23 were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse phase 
24 analytical column (Thermo Scientific) over a 150 min. organic gradient, using 7 
25 gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 15-32%B 
4
1 over 58min., 32-40%B over 5min., 40-90%B over 1min., held at 90%B for 6min 
2 and then reduced to 1%B over 1min.) with a flow rate of 300 nl min−1.  Solvent A 
3 was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% 
4 formic acid.  Peptides were ionized by nano-electrospray ionization at 2.0kV 
5 using a stainless-steel emitter with an internal diameter of 30 μm (Thermo 
6 Scientific) and a capillary temperature of 250°C. Tandem mass spectra were 
7 acquired using an LTQ- Orbitrap Velos mass spectrometer controlled by Xcalibur 
8 2.1 software (Thermo Scientific) and operated in data-dependent acquisition 
9 mode.  The Orbitrap was set to analyze the survey scans at 60,000 resolution (at 
10 m/z 400) in the mass range m/z 300 to 1800 and the top ten multiply charged 
11 ions in each duty cycle selected for MS/MS fragmentation using higher-energy 
12 collisional dissociation (HCD) with normalized collision energy of 45%, 
13 activation time of 0.1 ms and at a resolution of 7500 within the Orbitrap.  Charge 
14 state filtering, where unassigned precursor ions were not selected for 
15 fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30s; 
16 exclusion list size, 500) were used. 
17
18 Data Analysis
19 The raw data files were processed and quantified using Proteome Discoverer 
20 software v1.2 (Thermo Scientific) and searched against the UniProt Human 
21 database using the SEQUEST algorithm.  Peptide precursor mass tolerance was 
22 set at 10ppm, and MS/MS tolerance was set at 20mmu.  Search criteria included 
23 oxidation of methionine (+15.9949) as a variable modification and 
24 carbamidomethylation of cysteine (+57.0214) and the addition of the TMT 6Plex 
25 mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. 
5
1 Searches were performed with full tryptic digestion and a maximum of 1 missed 
2 cleavage was allowed.  The reverse database search option was enabled and all 
3 peptide data was filtered to satisfy false discovery rate (FDR) of 5%.  
4
5 Lipidomics:
6 Lung tissue was weighed and homogenised on ice in 1.6ml of 0.9% saline 
7 together with 20μl of the anti-oxidant butylated hydroxyl toluene (BHT) (20 
8 mg/ml in methanol), using a Heidolph Silent Crusher S. The homogenised lung 
9 samples were stored at -80oC for subsequent lipid extraction. An aliquot of lung 
10 homogenate (800 μl) was lipid extracted with dichloromethane and methanol[3] 
11 after addition of internal quantification standards (PC14:0/14:0 10nmol, 
12 PE14:0/14:0 4nmol, TAG14:0/14:0/14:0 10nmol, PG14:0/14:0 2nmol, 
13 PS14:0/14:0 2nmol, PS14:0/14:0 2nmole, CE17:0 1nmol, 
14 CL14:0/14:0/14:0/14:0/14:0 1nmol) in 100μl methanol.  The dichloromethane 
15 fraction was dried under nitrogen gas and the resultant extract was analysed 
16 using a Waters Xevo TQ mass spectrometer (Waters, Wythenshaw, UK). Samples 
17 were introduced to the mass spectrometer by syringe-driven direct infusion and 
18 the various lipid classes analysed by a comprehensive platform of diagnostic 
19 precursor and neutral loss scans as described previously.[4]  Mass spectrometry 
20 results were initially processed by MassLynx software and subsequently 
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2 Table 1. Differentially expressed genes in lung following CBP with lungs left 
3 collapsed.
4 Gene expression was measured in lung biopsies taken immediately following 
5 induction of bypass and immediately prior to the commencement of reperfusion. 
6 Data are organised by ratio of gene expression of the post: pre-surgery samples 
7 from patients undergoing CPB with lungs left collapsed.
8




































1 Table 2. Altered transcriptomic pathways and processes altered by lungs left collapsed and LFV. 
2 Table showing the pathways and biological processes activated during cardio-pulmonary bypass with lungs left collapsed (collapsed) or 
3 with low-frequency ventilation (LFV) during surgery. Data shows the fold enrichment compared to the expected gene number in the 
4 sample size. P values include Bonferroni correction for multiple comparisons.
5
Collapsed LFV LFV vs. Collapsed
Combined Collapsed and 
LFV groups post vs. pre 
surgery
Pathway Fold-change Adj P value Fold-change Adj P value Fold-change Adj P value Fold-change Adj P value
CCKR signalling map + 31.28 2.26E-08 + 19.66 2.14E-10 + 20.20 6.81E-03 + 20.20 9.53E-07
Interleukin signaling pathway + 34.52 5.41E-05 + 14.46 4.34E-03 + 22.29 5.10E-04
p53 pathway + 23.06 4.81E-02 + 12.88 4.46E-02 + 19.86 8.22E-03
Inflammation mediated by 
chemokine and cytokine 
signaling pathway





Plasminogen activating cascade + 97.09 3.17E-02
Oxidative Stress Response + 23.41 4.76E-02
Process
Endoderm development + >100 3.66E-02 + >100 1.53E-02
MAPK cascade + 7.75 3.16E-02 + 11.95 4.62E-04
Cell death + 65.40 3.30E-02 + >100 2.53E-02
Response to stress + 4.28 2.23E-03 5.08 5.05E-03





1 Table 3. Differentially expressed genes in lung samples in the LFV group. The 
2 expression of the same genes in the lungs left collapsed (Collapsed) group is 
3 shown for comparison (where also significantly changed).
4 The data shows the genes that were significantly changed post-surgery 
5 comparing the pre- and post-surgery samples from the LFV group. Data are 
6 organised by ratio of gene expression of the post: pre-surgery samples. Also 
7 shown are the p-values and ratios for the same genes in the CPB group pre- and 





post vs. pre 
LFV)
Ratio (Post LFV 
post vs. pre 
LFV)
p-value (Collapsed 
post vs. Collapsed 
pre)
Ratio (Collapsed 
post vs. Collapsed 
pre)
EGR1 1.52E-10 4.31211 1.19E-11 4.85421
CCL2 3.14E-11 3.7367 1.56E-17 6.7442
ZFP36 2.33E-10 3.39726 8.06E-13 4.24673
IER3 5.24E-10 3.36618 3.45E-14 4.95907
FOSB 1.97E-06 3.23688 1.59E-05 2.85606
IL6 4.20E-07 3.20897 2.66E-13 6.59224
AXUD1 7.36E-09 2.97975 6.87E-12 3.93191
GADD45B 8.53E-09 2.84233 7.16E-11 3.41388
RGS2 9.57E-09 2.82692 1.27E-09 3.05557
PTGS2 2.02E-07 2.71364 1.89E-10 3.63922
NAMPT 2.76E-08 2.69011 7.02E-14 4.38552
12
ADAMTS1 3.20E-07 2.65546 9.20E-13 4.52339
THBS1 4.31E-05 2.58619 2.69E-10 4.99284
CDKN1A 2.66E-09 2.58471 7.22E-13 3.39603
NR4A2 4.81E-08 2.54051 4.01E-10 3.03127
MT2A 1.58E-05 2.3859 9.45E-11 4.18274
MYC 3.80E-08 2.34622 6.46E-13 3.37585
SIK1 2.79E-08 2.33506 4.11E-11 2.88863
DUSP5 1.37E-08 2.3046 2.27E-10 2.61988
CYR61 0.000139197 2.28028
BHLHB2 1.21E-07 2.26944 7.16E-10 2.69932
MT1A 0.00023541 2.21719
FOS 9.31E-06 2.21653 1.52E-05 2.16802
SLC2A3 1.90E-07 2.20188 8.13E-09 2.44753
NFIL3 5.29E-08 2.19547 4.68E-14 3.38138
IL8 1.23E-05 2.17884 2.29E-09 3.11566
PIM1 4.81E-07 2.172 1.77E-11 3.07144
CXCL2 7.34E-07 2.13394 1.13E-10 2.87649
DUSP1 0.000566532 2.12812
CRISPLD2 0.000119155 2.12754
MIDN 1.03E-05 2.087 7.50E-07 2.31974
NR4A3 1.67E-07 2.02404 4.53E-11 2.57595
EGR3 2.96E-07 2.00958 6.07E-11 2.59004
SGK 0.000488729 2.00601



















































1 Table 4.  Differentially expressed proteins identified by TMT, comparing CPB 
2 with lungs left collapsed and LFV. 











Q15423 64 7.1 8.18 3.700 Serum amyloid A protein (Fragment) 
B4DIF5 345 39.2 8.92 2.478 cDNA FLJ55687, highly similar to Cell 
cycle control protein 50A 
P20851 252 28.3 5.14 2.283 C4b-binding protein beta chain
Q8IUL9 105 11.5 6.05 2.251 Hemoglobin beta chain variant 
Hb.Sinai-Bel Air (Fragment) 
Q6VFQ6 42 4.5 8.24 1.766 Hemoglobin beta chain (Fragment) 
Q92531 187 19.7 6.32 1.712 P35-related protein (Fragment) 
Q3MIB5 262 28.7 5.27 1.617 INMT protein (Fragment) 
P02774 474 52.9 5.54 1.608 Vitamin D-binding protein 
B4DWJ7 155 17.5 8.37 1.597 cDNA FLJ54968 
P11686 197 21.0 6.65 1.583 Pulmonary surfactant-associated 
protein C 
Q5T619 568 62.3 8.62 1.573 Zinc finger protein 648 
E5RGQ7 148 16.8 8.88 1.563 Dematin (Fragment) 
S6BGD6 235 24.8 7.24 1.557 IgG L chain 
Q6J1Z9 90 9.6 9.50 1.540 Hemoglobin alpha 1 (Fragment)
16
P02042 147 16.0 8.05 1.522 Hemoglobin subunit delta 
Q6J1Z8 42 4.5 9.38 1.507 Hemoglobin beta (Fragment) 
D3DTX7 885 84.7 6.24 0.664 Collagen, type I, alpha 1, isoform 
CRA_a 
M0QZ50 93 9.8 4.48 0.663 Microtubule-associated protein 1S 
P01861 327 35.9 7.36 0.662 Ig gamma-4 chain C region 
A0A087WTA8 1364 129.1 9.01 0.658 Collagen alpha-2(I) chain 
O76041 1014 116.4 7.99 0.654 Nebulette 
P08519 4548 501.0 5.88 0.652 Apolipoprotein(a) 
C9JNE5 191 21.7 9.61 0.648 Myeloid leukemia factor 1 (Fragment) 
H3BRW3 109 11.7 9.96 0.636 FAD-linked sulfhydryl oxidase ALR 
P27701 267 29.6 5.24 0.636 CD82 antigen 
Q9NZ09 502 55.0 5.11 0.635 Ubiquitin-associated protein 1 
A4FU00 317 35.6 5.81 0.634 SYT2 protein (Fragment) 
B4DMJ5 242 27.3 4.50 0.634 cDNA FLJ53012, highly similar to 
Tubulin beta-7 chain 
P07451 260 29.5 7.34 0.633 Carbonic anhydrase 3 
Q6PII6 533 58.3 4.77 0.610 TMF1 protein (Fragment) 
P35908 639 65.4 8.00 0.603 Keratin, type II cytoskeletal 2 
epidermal 
P01880 384 42.2 7.93 0.591 Ig delta chain C region 
A2J1N5 94 10.4 9.13 0.590 Rheumatoid factor RF-ET6 (Fragment) 
P81605 110 11.3 6.54 0.586 Dermcidin 
Q7Z6I6 1101 118.5 4.81 0.567 Rho GTPase-activating protein 30 
SV=3 
17
P13761 266 29.8 7.44 0.562 HLA class II histocompatibility antigen, 
DRB1-7 beta chain 
A8K9A9 638 71.3 8.22 0.521 cDNA FLJ77744, highly similar to 
Homo sapiens kallikrein B, plasma 
(Fletcher factor) 1 (KLKB1), mRNA 
Q96Q06 1357 134.3 8.73 0.519 Perilipin-4 
B3KMX3 270 28.5 4.73 0.497 cDNA FLJ12857 fis, clone 
NT2RP2003513, highly similar to 
Homo sapiens paralemmin (PALM), 
Q15323 416 47.2 4.88 0.436 Keratin, type I cuticular Ha1 
Q30167 266 30.0 7.75 0.373 HLA class II histocompatibility antigen, 
DRB1-10 beta chain 
B7Z269 351 40.3 7.24 0.299 cDNA FLJ50754, highly similar to 
Voltage-dependent L-type calcium 
channel subunit alpha-1D 
A0JNT2 447 49.6 5.39 0.240 KRT83 protein 
A0A087X2I6 404 46.1 4.84 0.206 Keratin, type I cuticular Ha3-II 
O76013 467 52.2 4.94 0.144 Keratin, type I cuticular Ha6 
Q701L7 513 56.6 6.74 0.073 Type II hair keratin 2 







1 Table 5. Differentially expressed genes in lung biopsies post CBP with collapsed 
2 lungs (Collapsed) versus post CBP+LFV (LFV).
3 The data shows the genes that were significantly changed post-surgery 
4 comparing the LFV and CPB with lungs collapsed groups. Data are organised by 
5 ratio of gene expression in the CPB:LFV groups. Also shown are the p-values and 























post vs. LFV 
pre)
HLA-DRB5 0.0311729 1.69779
MIR21 0.00716334 0.664162 0.00026313 1.76523 3.13E-08 2.5143
PLAU 0.00027089 0.663153 9.09E-05 1.56036 3.92E-10 2.18467
NAMPT 0.00887185 0.653954 2.76E-08 2.69011 7.02E-14 4.38552
CRISPLD2 0.0245826 0.65374 0.00011915 2.12754 2.77E-08 3.19182
SPSB1 0.00543046 0.652837 0.0011272 1.65691 3.46E-08 2.51871
PIM1 0.00237397 0.643988 4.81E-07 2.172 1.77E-11 3.07144
MT2A 0.0212365 0.64331 1.58E-05 2.3859 9.45E-11 4.18274
CYR61 0.0334855 0.642119 0.00013919 2.28028 1.35E-05 2.60616
PTX3 3.35E-05 0.633302 0.0140338 1.29593 3.50E-09 2.00809
NFIL3 0.00061884 0.630321 5.29E-08 2.19547 4.68E-14 3.38138
C13ORF33 4.01E-06 0.629229 0.00088378 1.3788 9.54E-13 2.24342
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PTGS2 0.00877579 0.627638 2.02E-07 2.71364 1.89E-10 3.63922
OBFC2A 0.00039958 0.619068 0.00020414 1.65775 1.34E-09 2.46718
SERPINB2 6.89E-05 0.604865 0.00229441 1.45598 4.19E-10 2.37424
FST 3.24E-07 0.604399 0.0263664 1.22358 1.07E-09 1.87432
TRK1 9.80E-05 0.598732 0.0259384 1.32595 3.25E-08 2.16599
NNMT 0.00050317 0.598371 0.00555558 1.49559 2.12E-10 2.85178
IER3 0.00213579 0.585514 5.24E-10 3.36618 3.45E-14 4.95907
TRQ1 1.05E-06 0.575413 0.00924457 1.3179 3.91E-10 2.12356
ADAMTS1 0.00128987 0.560691 3.20E-07 2.65546 9.20E-13 4.52339
CCL2 0.00088664 0.560328 3.14E-11 3.7367 1.56E-17 6.7442
CCL8 8.14E-06 0.537271 0.00033771 1.62543 2.39E-12 2.99664
ALDH1A3 0.00014072 0.498751 0.00342271 1.68698 3.40E-09 3.22296
IL6 0.00081229 0.481974 4.20E-07 3.20897 2.66E-13 6.59224






Genes significantly altered in the combined CPB with collapsed lungs and LFV 
dataset (all patients) comparing biopsies taken before and immediately post-
surgery (prior to reperfusion).
Probeset ID p-value Fold-Change (Post vs. Pre) Fold-Change (Post vs. Pre)
ADAMTS1 2.29E-14 3.46579 Post up vs Pre
ALDH1A3 2.06E-08 2.33175 Post up vs Pre
AXUD1 7.62E-16 3.42288 Post up vs Pre
BHLHB2 1.27E-13 2.47507 Post up vs Pre
CCL2 5.10E-20 5.02006 Post up vs Pre
CCL8 9.21E-11 2.20699 Post up vs Pre
CDKN1A 2.13E-16 2.96273 Post up vs Pre
CEBPD 1.48E-12 2.29829 Post up vs Pre
CHSY1 2.26E-09 2.15588 Post up vs Pre
CRISPLD2 6.38E-10 2.6059 Post up vs Pre
CXCL2 3.47E-13 2.47755 Post up vs Pre
CYR61 9.06E-08 2.43778 Post up vs Pre
DUSP1 7.63E-07 2.21634 Post up vs Pre
DUSP5 1.01E-14 2.45719 Post up vs Pre
EGR1 6.78E-17 4.57514 Post up vs Pre
EGR3 1.29E-13 2.28143 Post up vs Pre
ELL2 9.39E-10 2.13515 Post up vs Pre
ERRFI1 7.92E-10 2.21222 Post up vs Pre
FOS 3.79E-09 2.19214 Post up vs Pre
FOSB 9.80E-10 3.04051 Post up vs Pre
FOSL2 1.28E-13 2.11261 Post up vs Pre
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GADD45A 1.46E-14 2.10184 Post up vs Pre
GADD45B 4.21E-15 3.11502 Post up vs Pre
IER3 3.18E-17 4.08572 Post up vs Pre
IL6 1.54E-14 4.59938 Post up vs Pre
IL8 1.49E-11 2.60548 Post up vs Pre
LOC441019 4.99E-12 2.27893 Post up vs Pre
MIDN 5.01E-10 2.20029 Post up vs Pre
MIR21 2.24E-09 2.10673 Post up vs Pre
MT1A 4.47E-10 2.90963 Post up vs Pre
MT2A 2.60E-12 3.15905 Post up vs Pre
MTE 1.97E-09 2.35834 Post up vs Pre
MYC 1.82E-15 2.81434 Post up vs Pre
NAMPT 2.56E-16 3.43475 Post up vs Pre
NFIL3 1.39E-15 2.72465 Post up vs Pre
NNMT 3.81E-09 2.06521 Post up vs Pre
NR4A2 3.74E-14 2.77506 Post up vs Pre
NR4A3 5.09E-14 2.28338 Post up vs Pre
OBFC2A 7.07E-10 2.02236 Post up vs Pre
PIM1 1.76E-13 2.58286 Post up vs Pre
PTGS2 2.79E-13 3.14254 Post up vs Pre
RASD1 5.52E-07 2.12328 Post up vs Pre
RGS2 2.93E-14 2.93902 Post up vs Pre
RNF122 3.02E-12 2.34752 Post up vs Pre
SGK 9.65E-07 2.07768 Post up vs Pre
SIK1 4.42E-15 2.59714 Post up vs Pre
SLC2A3 8.98E-13 2.32146 Post up vs Pre
SPSB1 9.27E-09 2.04286 Post up vs Pre
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THBS1 4.71E-11 3.59339 Post up vs Pre
TRIB1 3.44E-08 2.15623 Post up vs Pre
ZFP36 1.56E-17 3.79832 Post up vs Pre
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Table 7:
Data showing the proteins changed between the pooled control CPB with 
collapsed lung and LFV groups immediately prior to surgery, with a 1.5x change 
cutoff. Only 2 proteins had a greater than 2x increase in the CPB group and 34 









Q15423 64 7.1 8.18 4.664
Serum amyloid A protein (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q15423_HUMAN]
B7Z269 351 40.3 7.24 3.939
cDNA FLJ50754, highly similar to Voltage-dependent L-type calcium channel 
subunit alpha-1D OS=Homo sapiens PE=2 SV=1 - [B7Z269_HUMAN]
Q6P4A8 553 63.2 9.06 1.677
Phospholipase B-like 1 OS=Homo sapiens GN=PLBD1 PE=1 SV=2 - 
[PLBL1_HUMAN]
O96009 420 45.4 6.61 1.507 Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 - [NAPSA_HUMAN]
F2X0V0 23 2.8 7.78 0.666
Truncated CD61 (Fragment) OS=Homo sapiens GN=ITGB3 PE=4 SV=1 - 
[F2X0V0_HUMAN]
Q96T46 76 8.4 7.14 0.666
Hemoglobin alpha 2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 SV=1 - 
[Q96T46_HUMAN]
Q96P70 1041 115.9 4.81 0.665 Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 - [IPO9_HUMAN]
Q86Z07 374 41.7 9.14 0.664
Guanine nucleotide binding protein-like 1 OS=Homo sapiens GN=HSR1 PE=4 
SV=1 - [Q86Z07_HUMAN]
Q9NWH4 148 16.9 11.09 0.664
cDNA FLJ10024 fis, clone HEMBA1000636 OS=Homo sapiens PE=2 SV=1 - 
[Q9NWH4_HUMAN]
Q7Z379 478 51.6 6.52 0.664
Putative uncharacterized protein DKFZp686K04218 (Fragment) OS=Homo 
sapiens GN=DKFZp686K04218 PE=1 SV=1 - [Q7Z379_HUMAN]
B4E0V3 947 107.2 6.11 0.663
cDNA FLJ61519, highly similar to Leukocyte common antigen (EC 3.1.3.48) 
OS=Homo sapiens PE=2 SV=1 - [B4E0V3_HUMAN]
P32456 591 67.2 5.71 0.661
Interferon-induced guanylate-binding protein 2 OS=Homo sapiens GN=GBP2 
PE=1 SV=3 - [GBP2_HUMAN]
Q0PNF2 2570 275.3 6.49 0.661 FEX1 OS=Homo sapiens PE=2 SV=1 - [Q0PNF2_HUMAN]
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Q5VW33 215 24.2 7.09 0.660
BRO1 domain-containing protein BROX (Fragment) OS=Homo sapiens 
GN=BROX PE=1 SV=1 - [Q5VW33_HUMAN]
A2MYC8 104 11.0 7.28 0.659
V5-2 protein (Fragment) OS=Homo sapiens GN=V5-2 PE=1 SV=1 - 
[A2MYC8_HUMAN]
F8WD82 762 88.1 6.95 0.659
Sodium channel protein type 7 subunit alpha OS=Homo sapiens GN=SCN7A 
PE=4 SV=1 - [F8WD82_HUMAN]
B2R4C9 102 11.2 9.52 0.659
cDNA, FLJ92044, highly similar to Homo sapiens death-associated protein 
(DAP), mRNA OS=Homo sapiens PE=2 SV=1 - [B2R4C9_HUMAN]
A8K6V3 1217 135.5 5.21 0.659
cDNA FLJ78677, highly similar to Homo sapiens splicing factor 3b, subunit 3, 
130kDa (SF3B3), mRNA OS=Homo sapiens PE=2 SV=1 - [A8K6V3_HUMAN]
S6B2A1 184 20.4 5.52 0.658 IgG L chain OS=Homo sapiens PE=2 SV=1 - [S6B2A1_HUMAN]
Q9H3P7 528 60.6 5.06 0.658
Golgi resident protein GCP60 OS=Homo sapiens GN=ACBD3 PE=1 SV=4 - 
[GCP60_HUMAN]
C9JIN6 264 29.8 7.84 0.657
Transporter (Fragment) OS=Homo sapiens GN=SLC6A20 PE=3 SV=1 - 
[C9JIN6_HUMAN]
E5RHW5 125 13.1 5.39 0.657
Pulmonary surfactant-associated protein C (Fragment) OS=Homo sapiens 
GN=SFTPC PE=4 SV=3 - [E5RHW5_HUMAN]
F8WAW4 140 15.6 9.13 0.656
Enoyl-CoA delta isomerase 2, mitochondrial OS=Homo sapiens GN=ECI2 PE=1 
SV=1 - [F8WAW4_HUMAN]
B8ZZ75 194 21.5 6.93 0.655
Aldose 1-epimerase OS=Homo sapiens GN=GALM PE=1 SV=1 - 
[B8ZZ75_HUMAN]
H3BML9 118 13.1 5.68 0.655
Myosin regulatory light chain 2, skeletal muscle isoform (Fragment) OS=Homo 
sapiens GN=MYLPF PE=4 SV=1 - [H3BML9_HUMAN]
P16157 1881 206.1 6.01 0.655 Ankyrin-1 OS=Homo sapiens GN=ANK1 PE=1 SV=3 - [ANK1_HUMAN]
A0A087WXZ6 250 28.9 9.00 0.655
High affinity immunoglobulin gamma Fc receptor IB (Fragment) OS=Homo 
sapiens GN=FCGR1B PE=4 SV=1 - [A0A087WXZ6_HUMAN]
P31942 346 36.9 6.87 0.654
Heterogeneous nuclear ribonucleoprotein H3 OS=Homo sapiens GN=HNRNPH3 
PE=1 SV=2 - [HNRH3_HUMAN]
P40261 264 29.6 5.74 0.654
Nicotinamide N-methyltransferase OS=Homo sapiens GN=NNMT PE=1 SV=1 - 
[NNMT_HUMAN]
P15529 392 43.7 6.74 0.654
Membrane cofactor protein OS=Homo sapiens GN=CD46 PE=1 SV=3 - 
[MCP_HUMAN]
G3XAJ6 542 58.7 5.34 0.653
Raft-linking protein, isoform CRA_c OS=Homo sapiens GN=RFTN1 PE=1 SV=1 
- [G3XAJ6_HUMAN]
H7BZW6 143 16.0 9.13 0.652 Histone deacetylase complex subunit SAP18 (Fragment) OS=Homo sapiens 
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GN=SAP18 PE=1 SV=2 - [H7BZW6_HUMAN]
P19397 219 24.3 7.52 0.652
Leukocyte surface antigen CD53 OS=Homo sapiens GN=CD53 PE=1 SV=1 - 
[CD53_HUMAN]
Q9C055 306 35.6 7.50 0.652
Inositol polyphosphate-5-phosphatase (Fragment) OS=Homo sapiens 
GN=INPP5A PE=4 SV=1 - [Q9C055_HUMAN]
P16402 221 22.3 11.02 0.651 Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=2 - [H13_HUMAN]
P01023 1474 163.2 6.46 0.650
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 - 
[A2MG_HUMAN]
Q19UK3 33 3.7 8.09 0.648
Truncated coagulation factor IX (Fragment) OS=Homo sapiens GN=F9 PE=4 
SV=1 - [Q19UK3_HUMAN]
Q59FC4 687 75.9 6.51 0.648
Presynaptic protein SAP97 variant (Fragment) OS=Homo sapiens PE=4 SV=1 - 
[Q59FC4_HUMAN]
Q15661 275 30.5 7.11 0.647
Tryptase alpha/beta-1 OS=Homo sapiens GN=TPSAB1 PE=1 SV=1 - 
[TRYB1_HUMAN]
D3JV43 68 7.4 8.78 0.646
C-X-C motif chemokine (Fragment) OS=Homo sapiens PE=3 SV=1 - 
[D3JV43_HUMAN]
H0YH87 916 98.1 9.41 0.639
Ataxin-2 (Fragment) OS=Homo sapiens GN=ATXN2 PE=1 SV=1 - 
[H0YH87_HUMAN]
B7Z7P4 547 59.9 5.59 0.639
cDNA FLJ53627, highly similar to Antigen peptide transporter 1 OS=Homo 
sapiens PE=2 SV=1 - [B7Z7P4_HUMAN]
P13761 266 29.8 7.44 0.638
HLA class II histocompatibility antigen, DRB1-7 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=1 - [2B17_HUMAN]
B7Z539 645 72.1 7.68 0.637
cDNA FLJ56954, highly similar to Inter-alpha-trypsin inhibitor heavy chain H1 
OS=Homo sapiens PE=2 SV=1 - [B7Z539_HUMAN]
H7C034 173 19.3 4.88 0.636
AP-1 complex subunit beta-1 (Fragment) OS=Homo sapiens GN=AP1B1 PE=1 
SV=1 - [H7C034_HUMAN]
A8K2T4 843 93.3 6.51 0.636
cDNA FLJ78207, highly similar to Human complement protein component C7 
mRNA OS=Homo sapiens PE=2 SV=1 - [A8K2T4_HUMAN]
Q9UL88 131 14.1 9.63 0.636
Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 - [Q9UL88_HUMAN]
P23381 471 53.1 6.23 0.636
Tryptophan--tRNA ligase, cytoplasmic OS=Homo sapiens GN=WARS PE=1 
SV=2 - [SYWC_HUMAN]
E9PC44 393 43.9 6.15 0.635
Protein transport protein Sec24D OS=Homo sapiens GN=SEC24D PE=1 SV=2 - 
[E9PC44_HUMAN]
O76013 467 52.2 4.94 0.634 Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 SV=1 - 
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[KRT36_HUMAN]
B4DM28 634 72.1 9.67 0.633
cDNA FLJ50575, highly similar to U4/U6 small nuclear ribonucleoprotein Prp3 
OS=Homo sapiens PE=2 SV=1 - [B4DM28_HUMAN]
M0R088 681 78.1 12.06 0.633
Serine/arginine repetitive matrix protein 1 (Fragment) OS=Homo sapiens 
GN=SRRM1 PE=1 SV=1 - [M0R088_HUMAN]
E3Q1J2 273 31.6 5.97 0.633
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-B PE=3 SV=1 - 
[E3Q1J2_HUMAN]
Q5JTB5 87 9.3 7.09 0.631
Placenta-specific protein 9 OS=Homo sapiens GN=PLAC9 PE=4 SV=1 - 
[Q5JTB5_HUMAN]
Q5CZ93 159 19.2 9.88 0.630
Putative uncharacterized protein DKFZp686A0568 OS=Homo sapiens 
GN=DKFZp686A0568 PE=2 SV=1 - [Q5CZ93_HUMAN]
P33764 101 11.7 4.78 0.628
Protein S100-A3 OS=Homo sapiens GN=S100A3 PE=1 SV=1 - 
[S10A3_HUMAN]
Q6GMX6 465 51.1 8.69 0.628 IGH@ protein OS=Homo sapiens GN=IGH@ PE=1 SV=1 - [Q6GMX6_HUMAN]
Q9P2B2 879 98.5 6.61 0.628
Prostaglandin F2 receptor negative regulator OS=Homo sapiens GN=PTGFRN 
PE=1 SV=2 - [FPRP_HUMAN]
Q15323 416 47.2 4.88 0.627
Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 - 
[K1H1_HUMAN]
H0YA93 1400 158.1 5.82 0.625
NEDD4-binding protein 2 (Fragment) OS=Homo sapiens GN=N4BP2 PE=1 
SV=1 - [H0YA93_HUMAN]
A5Z217 470 53.6 5.27 0.623 Mutant desmin OS=Homo sapiens PE=2 SV=1 - [A5Z217_HUMAN]
K7EMQ9 140 16.3 6.89 0.622
Eukaryotic translation initiation factor 3 subunit K (Fragment) OS=Homo 
sapiens GN=EIF3K PE=1 SV=1 - [K7EMQ9_HUMAN]
A0A024RAL1 2409 264.9 4.54 0.620
Chondroitin sulfate proteoglycan 2 (Versican), isoform CRA_c OS=Homo 
sapiens GN=CSPG2 PE=4 SV=1 - [A0A024RAL1_HUMAN]
H3BPF7 236 25.5 8.46 0.618
Lon protease homolog 2, peroxisomal (Fragment) OS=Homo sapiens 
GN=LONP2 PE=4 SV=3 - [H3BPF7_HUMAN]
A0A087WUP0 265 30.0 5.34 0.617
Annexin A8-like protein 1 OS=Homo sapiens GN=ANXA8L1 PE=4 SV=1 - 
[A0A087WUP0_HUMAN]
A0A068LKQ0 120 13.3 5.99 0.617
Ig heavy chain variable region (Fragment) OS=Homo sapiens PE=4 SV=1 - 
[A0A068LKQ0_HUMAN]
Q86YQ1 91 9.7 9.25 0.614
Hemoglobin alpha-2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 SV=1 - 
[Q86YQ1_HUMAN]
B5MBZ8 274 31.3 4.63 0.610
Protein phosphatase 1 regulatory subunit 7 OS=Homo sapiens GN=PPP1R7 
PE=1 SV=1 - [B5MBZ8_HUMAN]
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Q8N1G4 583 63.4 8.28 0.609
Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 
PE=1 SV=1 - [LRC47_HUMAN]
O15078 2479 290.2 5.95 0.609
Centrosomal protein of 290 kDa OS=Homo sapiens GN=CEP290 PE=1 SV=2 - 
[CE290_HUMAN]
Q9BXN1 380 43.4 7.08 0.608 Asporin OS=Homo sapiens GN=ASPN PE=1 SV=2 - [ASPN_HUMAN]
C0IMJ3 781 87.2 7.94 0.604 Periostin isoform thy6 OS=Homo sapiens PE=2 SV=1 - [C0IMJ3_HUMAN]
B7ZMG8 83 9.1 4.59 0.602 Uncharacterized protein OS=Homo sapiens PE=2 SV=1 - [B7ZMG8_HUMAN]
E9PQ22 191 22.9 9.45 0.602
Uncharacterized protein C11orf65 (Fragment) OS=Homo sapiens GN=C11orf65 
PE=4 SV=3 - [E9PQ22_HUMAN]
Q5CZB5 1157 125.0 4.49 0.601
Putative uncharacterized protein DKFZp686M0430 OS=Homo sapiens 
GN=DKFZp686M0430 PE=2 SV=1 - [Q5CZB5_HUMAN]
E9PQI8 164 17.5 11.17 0.600
U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 PE=1 
SV=1 - [E9PQI8_HUMAN]
P19075 237 26.0 5.60 0.600 Tetraspanin-8 OS=Homo sapiens GN=TSPAN8 PE=1 SV=1 - [TSN8_HUMAN]
B4DSW4 157 16.4 12.25 0.598
cDNA FLJ51541, moderately similar to Transcription factor Sp8 OS=Homo 
sapiens PE=2 SV=1 - [B4DSW4_HUMAN]
P31146 461 51.0 6.68 0.597 Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 - [COR1A_HUMAN]
Q0KKI6 219 24.0 8.06 0.593
Immunoblobulin light chain (Fragment) OS=Homo sapiens PE=1 SV=1 - 
[Q0KKI6_HUMAN]
P01623 109 11.7 8.91 0.593
Ig kappa chain V-III region WOL OS=Homo sapiens PE=1 SV=1 - 
[KV305_HUMAN]
P08311 255 28.8 11.19 0.593 Cathepsin G OS=Homo sapiens GN=CTSG PE=1 SV=2 - [CATG_HUMAN]
P01598 108 11.8 8.44 0.592
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 - 
[KV106_HUMAN]
Q6P3R8 708 81.4 8.87 0.592
Serine/threonine-protein kinase Nek5 OS=Homo sapiens GN=NEK5 PE=1 SV=1 
- [NEK5_HUMAN]
Q4QZC0 273 31.8 6.09 0.592
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 - 
[Q4QZC0_HUMAN]
C9JW69 372 39.6 8.37 0.591
Regulator of chromosome condensation (Fragment) OS=Homo sapiens 
GN=RCC1 PE=1 SV=1 - [C9JW69_HUMAN]
P10109 184 19.4 5.83 0.591
Adrenodoxin, mitochondrial OS=Homo sapiens GN=FDX1 PE=1 SV=1 - 
[ADX_HUMAN]
A0A075B785 1018 112.7 5.49 0.591
LisH domain and HEAT repeat-containing protein KIAA1468 OS=Homo sapiens 
GN=KIAA1468 PE=1 SV=2 - [A0A075B785_HUMAN]
K7ERI9 77 8.6 6.71 0.590 Truncated apolipoprotein C-I (Fragment) OS=Homo sapiens GN=APOC1 PE=4 
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SV=1 - [K7ERI9_HUMAN]
P01833 764 83.2 5.74 0.589
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 - 
[PIGR_HUMAN]
P62854 115 13.0 11.00 0.587
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 - 
[RS26_HUMAN]
B4E1L5 555 63.8 6.37 0.585
cDNA FLJ51601, highly similar to Interferon-induced guanylate-binding protein 
1 OS=Homo sapiens PE=2 SV=1 - [B4E1L5_HUMAN]
Q9HCM7 1045 110.8 9.67 0.585
Fibrosin-1-like protein OS=Homo sapiens GN=FBRSL1 PE=1 SV=4 - 
[FBSL_HUMAN]
P01611 108 11.6 7.28 0.581
Ig kappa chain V-I region Wes OS=Homo sapiens PE=1 SV=1 - 
[KV119_HUMAN]
B4DRW1 474 51.7 6.81 0.576
cDNA FLJ55805, highly similar to Keratin, type II cytoskeletal 4 OS=Homo 
sapiens PE=2 SV=1 - [B4DRW1_HUMAN]
J3KPM9 714 83.3 6.42 0.574
Signal transducer and activator of transcription OS=Homo sapiens GN=STAT1 
PE=1 SV=1 - [J3KPM9_HUMAN]
Q8N1W1 1705 191.8 6.04 0.573
Rho guanine nucleotide exchange factor 28 OS=Homo sapiens GN=ARHGEF28 
PE=1 SV=3 - [ARG28_HUMAN]
P23946 247 27.3 9.29 0.573 Chymase OS=Homo sapiens GN=CMA1 PE=1 SV=1 - [CMA1_HUMAN]
Q7L0Q8 258 28.2 8.06 0.572
Rho-related GTP-binding protein RhoU OS=Homo sapiens GN=RHOU PE=1 
SV=1 - [RHOU_HUMAN]
O75443 2155 239.4 5.40 0.569 Alpha-tectorin OS=Homo sapiens GN=TECTA PE=1 SV=3 - [TECTA_HUMAN]
A0A087WZW8 233 25.6 6.01 0.569
Protein IGKV3-11 OS=Homo sapiens GN=IGKV3-11 PE=4 SV=1 - 
[A0A087WZW8_HUMAN]
A0A087WX11 918 103.3 5.12 0.565
Folliculin-interacting protein 1 OS=Homo sapiens GN=FNIP1 PE=4 SV=1 - 
[A0A087WX11_HUMAN]
Q9H029 130 14.8 5.30 0.564
GTP-binding protein SAR1b OS=Homo sapiens GN=DKFZp434B2017 PE=1 
SV=1 - [Q9H029_HUMAN]
H0YD72 237 26.1 9.39 0.563
Liprin-alpha-1 (Fragment) OS=Homo sapiens GN=PPFIA1 PE=1 SV=1 - 
[H0YD72_HUMAN]
Q5NV82 104 11.1 7.97 0.562
V4-2 protein (Fragment) OS=Homo sapiens GN=V4-2 PE=1 SV=1 - 
[Q5NV82_HUMAN]
H3BRW3 109 11.7 9.96 0.562
FAD-linked sulfhydryl oxidase ALR OS=Homo sapiens GN=GFER PE=1 SV=1 - 
[H3BRW3_HUMAN]
P02452 1464 138.9 5.80 0.555
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 - 
[CO1A1_HUMAN]
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B2R9B9 120 13.0 6.37 0.551
cDNA, FLJ94321, highly similar to Homo sapiens eukaryotic translation 
initiation factor 4E binding protein 2 (EIF4EBP2), mRNA OS=Homo sapiens 
PE=2 SV=1 - [B2R9B9_HUMAN]
Q9UK54 128 14.0 6.95 0.547
Hemoglobin beta subunit variant (Fragment) OS=Homo sapiens GN=HBB PE=2 
SV=1 - [Q9UK54_HUMAN]
P81605 110 11.3 6.54 0.547 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN]
Q05707 1796 193.4 5.30 0.547
Collagen alpha-1(XIV) chain OS=Homo sapiens GN=COL14A1 PE=1 SV=3 - 
[COEA1_HUMAN]
C9JA05 70 8.2 8.56 0.547
Immunoglobulin J chain (Fragment) OS=Homo sapiens GN=IGJ PE=1 SV=1 - 
[C9JA05_HUMAN]
S6C4R7 212 22.5 8.24 0.546 IgG L chain OS=Homo sapiens PE=2 SV=1 - [S6C4R7_HUMAN]
P01861 327 35.9 7.36 0.541
Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 - 
[IGHG4_HUMAN]
B2R7Z6 484 52.5 7.55 0.539 cDNA, FLJ93674 OS=Homo sapiens PE=2 SV=1 - [B2R7Z6_HUMAN]
Q9NZ09 502 55.0 5.11 0.532
Ubiquitin-associated protein 1 OS=Homo sapiens GN=UBAP1 PE=1 SV=1 - 
[UBAP1_HUMAN]
Q64FY1 1364 146.2 6.60 0.530
AKNA transcript B1 (Fragment) OS=Homo sapiens GN=AKNA PE=2 SV=1 - 
[Q64FY1_HUMAN]
M0QZ50 93 9.8 4.48 0.526
Microtubule-associated protein 1S OS=Homo sapiens GN=MAP1S PE=1 SV=1 - 
[M0QZ50_HUMAN]
B4DQY2 711 78.9 7.06 0.525
cDNA FLJ59388, highly similar to Mitochondrial inner membrane protein 
OS=Homo sapiens PE=2 SV=1 - [B4DQY2_HUMAN]
B4DEH8 168 19.0 9.23 0.516
Polyadenylate-binding protein 2 OS=Homo sapiens GN=PABPN1 PE=1 SV=1 - 
[B4DEH8_HUMAN]
D6RC64 136 15.6 10.14 0.513
SH3 domain-binding protein 2 (Fragment) OS=Homo sapiens GN=SH3BP2 
PE=4 SV=1 - [D6RC64_HUMAN]
Q6N095 475 52.3 8.57 0.511
Putative uncharacterized protein DKFZp686K03196 OS=Homo sapiens 
GN=DKFZp686K03196 PE=1 SV=1 - [Q6N095_HUMAN]
B4DLF9 342 39.4 8.68 0.510
cDNA FLJ56988, highly similar to cGMP-dependent protein kinase 2 (EC 
2.7.11.12) OS=Homo sapiens PE=2 SV=1 - [B4DLF9_HUMAN]
H0Y892 688 79.3 9.14 0.508
Zinc finger protein 782 (Fragment) OS=Homo sapiens GN=ZNF782 PE=4 SV=1 
- [H0Y892_HUMAN]
Q4ZGM8 100 10.8 9.04 0.502
Hemoglobin alpha-2 globin mutant (Fragment) OS=Homo sapiens PE=3 SV=1 
- [Q4ZGM8_HUMAN]
Q6N093 417 46.0 7.59 0.497 Putative uncharacterized protein DKFZp686I04196 (Fragment) OS=Homo 
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sapiens GN=DKFZp686I04196 PE=1 SV=1 - [Q6N093_HUMAN]
A0A075B6L1 106 11.3 8.29 0.496
Ig lambda-7 chain C region (Fragment) OS=Homo sapiens GN=IGLC7 PE=4 
SV=2 - [A0A075B6L1_HUMAN]
B2R941 417 48.7 9.00 0.495
cDNA, FLJ94198, highly similar to Homo sapiens carboxypeptidase A3 (mast 
cell) (CPA3), mRNA OS=Homo sapiens PE=2 SV=1 - [B2R941_HUMAN]
P14555 144 16.1 9.23 0.492
Phospholipase A2, membrane associated OS=Homo sapiens GN=PLA2G2A 
PE=1 SV=2 - [PA2GA_HUMAN]
C9JNE5 191 21.7 9.61 0.481
Myeloid leukemia factor 1 (Fragment) OS=Homo sapiens GN=MLF1 PE=4 
SV=1 - [C9JNE5_HUMAN]
Q7Z3E2 898 103.6 6.27 0.478
Coiled-coil domain-containing protein 186 OS=Homo sapiens GN=CCDC186 
PE=1 SV=2 - [CC186_HUMAN]
P08519 4548 501.0 5.88 0.474 Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 - [APOA_HUMAN]
Q7L7X3 1001 116.0 7.65 0.468
Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 
SV=1 - [TAOK1_HUMAN]
B2R8C8 140 15.1 5.26 0.461
Ubiquitin-like protein ATG12 OS=Homo sapiens PE=2 SV=1 - 
[B2R8C8_HUMAN]
B7Z962 190 19.9 10.84 0.461 cDNA FLJ52231 OS=Homo sapiens PE=2 SV=1 - [B7Z962_HUMAN]
F8W9J4 7461 847.4 5.25 0.457 Dystonin OS=Homo sapiens GN=DST PE=1 SV=1 - [F8W9J4_HUMAN]
Q5T4S7 5183 573.5 6.04 0.450
E3 ubiquitin-protein ligase UBR4 OS=Homo sapiens GN=UBR4 PE=1 SV=1 - 
[UBR4_HUMAN]
B0QYR0 100 11.1 5.36 0.447
BTB/POZ domain-containing protein 3 (Fragment) OS=Homo sapiens 
GN=BTBD3 PE=4 SV=3 - [B0QYR0_HUMAN]
Q3MI39 167 16.7 9.70 0.447
HNRPA1 protein (Fragment) OS=Homo sapiens GN=HNRPA1 PE=2 SV=1 - 
[Q3MI39_HUMAN]
Q701L7 513 56.6 6.74 0.430
Type II hair keratin 2 OS=Homo sapiens GN=KRTHB2 PE=2 SV=1 - 
[Q701L7_HUMAN]
P01880 384 42.2 7.93 0.404
Ig delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 - 
[IGHD_HUMAN]
B3KMX3 270 28.5 4.73 0.398
cDNA FLJ12857 fis, clone NT2RP2003513, highly similar to Homo sapiens 
paralemmin (PALM), transcript variant 2, mRNA OS=Homo sapiens PE=2 SV=1 
- [B3KMX3_HUMAN]
Q9BYT5 123 12.9 7.81 0.397
Keratin-associated protein 2-2 OS=Homo sapiens GN=KRTAP2-2 PE=2 SV=3 - 
[KRA22_HUMAN]
P46109 303 33.8 6.74 0.388 Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 - [CRKL_HUMAN]
H7BZ55 2252 248.2 5.83 0.386 Putative ciliary rootlet coiled-coil protein-like 3 protein OS=Homo sapiens PE=5 
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SV=2 - [CROL3_HUMAN]
Q5RHS7 95 11.0 9.28 0.379
Protein S100-A2 OS=Homo sapiens GN=S100A2 PE=1 SV=2 - 
[Q5RHS7_HUMAN]
Q05D28 370 41.8 5.44 0.377
CCDC91 protein (Fragment) OS=Homo sapiens GN=CCDC91 PE=2 SV=1 - 
[Q05D28_HUMAN]
B3KS56 594 68.5 5.45 0.376
cDNA FLJ35559 fis, clone SPLEN2005009, highly similar to GRIP and coiled-coil 
domain-containing protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B3KS56_HUMAN]
H0UI60 536 60.7 5.17 0.369
Taxilin beta, isoform CRA_a OS=Homo sapiens GN=TXLNB PE=4 SV=1 - 
[H0UI60_HUMAN]
Q30167 266 30.0 7.75 0.357
HLA class II histocompatibility antigen, DRB1-10 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=2 - [2B1A_HUMAN]
A4FU00 317 35.6 5.81 0.351
SYT2 protein (Fragment) OS=Homo sapiens GN=SYT2 PE=2 SV=1 - 
[A4FU00_HUMAN]
B4E1L4 668 71.6 5.63 0.347
cDNA FLJ59081, highly similar to Mucin-5B OS=Homo sapiens PE=2 SV=1 - 
[B4E1L4_HUMAN]
Q69YL0 99 10.9 12.00 0.337
Uncharacterized protein NCBP2-AS2 OS=Homo sapiens GN=NCBP2-AS2 PE=4 
SV=1 - [NCAS2_HUMAN]
A8K9A9 638 71.3 8.22 0.334
cDNA FLJ77744, highly similar to Homo sapiens kallikrein B, plasma (Fletcher 
factor) 1 (KLKB1), mRNA OS=Homo sapiens PE=2 SV=1 - [A8K9A9_HUMAN]
A2J1N5 94 10.4 9.13 0.306
Rheumatoid factor RF-ET6 (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[A2J1N5_HUMAN]
Q6PII6 533 58.3 4.77 0.288
TMF1 protein (Fragment) OS=Homo sapiens GN=TMF1 PE=2 SV=1 - 
[Q6PII6_HUMAN]
A0A087X243 69 7.4 7.08 0.286
Glutathione S-transferase P (Fragment) OS=Homo sapiens GN=GSTP1 PE=4 
SV=1 - [A0A087X243_HUMAN]
O76041 1014 116.4 7.99 0.275 Nebulette OS=Homo sapiens GN=NEBL PE=1 SV=1 - [NEBL_HUMAN]
B4DMJ5 242 27.3 4.50 0.118
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B4DMJ5 242 27.3 4.50 8.276
cDNA FLJ53012, highly similar to Tubulin beta-7 chain OS=Homo sapiens 
PE=2 SV=1 - [B4DMJ5_HUMAN]
A0A087X243 69 7.4 7.08 3.627
Glutathione S-transferase P (Fragment) OS=Homo sapiens GN=GSTP1 
PE=4 SV=1 - [A0A087X243_HUMAN]
Q69YL0 99 10.9 12.00 3.266
Uncharacterized protein NCBP2-AS2 OS=Homo sapiens GN=NCBP2-AS2 
PE=4 SV=1 - [NCAS2_HUMAN]
A4FU00 317 35.6 5.81 2.985
SYT2 protein (Fragment) OS=Homo sapiens GN=SYT2 PE=2 SV=1 - 
[A4FU00_HUMAN]
B4DIF5 345 39.2 8.92 2.960
cDNA FLJ55687, highly similar to Cell cycle control protein 50A OS=Homo 
sapiens PE=2 SV=1 - [B4DIF5_HUMAN]
H0UI60 536 60.7 5.17 2.740
Taxilin beta, isoform CRA_a OS=Homo sapiens GN=TXLNB PE=4 SV=1 - 
[H0UI60_HUMAN]
Q9BYT5 123 12.9 7.81 2.683
Keratin-associated protein 2-2 OS=Homo sapiens GN=KRTAP2-2 PE=2 
SV=3 - [KRA22_HUMAN]
O76041 1014 116.4 7.99 2.555 Nebulette OS=Homo sapiens GN=NEBL PE=1 SV=1 - [NEBL_HUMAN]
F8W9J4 7461 847.4 5.25 2.521 Dystonin OS=Homo sapiens GN=DST PE=1 SV=1 - [F8W9J4_HUMAN]
Q701L7 513 56.6 6.74 2.519
Type II hair keratin 2 OS=Homo sapiens GN=KRTHB2 PE=2 SV=1 - 
[Q701L7_HUMAN]
Q6PII6 533 58.3 4.77 2.512
TMF1 protein (Fragment) OS=Homo sapiens GN=TMF1 PE=2 SV=1 - 
[Q6PII6_HUMAN]
A2J1N5 94 10.4 9.13 2.497
Rheumatoid factor RF-ET6 (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[A2J1N5_HUMAN]
B7Z962 190 19.9 10.84 2.430 cDNA FLJ52231 OS=Homo sapiens PE=2 SV=1 - [B7Z962_HUMAN]
Q05D28 370 41.8 5.44 2.342
CCDC91 protein (Fragment) OS=Homo sapiens GN=CCDC91 PE=2 SV=1 - 
[Q05D28_HUMAN]
B3KS56 594 68.5 5.45 2.327 cDNA FLJ35559 fis, clone SPLEN2005009, highly similar to GRIP and coiled-
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coil domain-containing protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B3KS56_HUMAN]
Q92531 187 19.7 6.32 2.313
P35-related protein (Fragment) OS=Homo sapiens GN=FCN1 PE=4 SV=1 - 
[Q92531_HUMAN]
H0Y892 688 79.3 9.14 2.291
Zinc finger protein 782 (Fragment) OS=Homo sapiens GN=ZNF782 PE=4 
SV=1 - [H0Y892_HUMAN]
Q3MI39 167 16.7 9.70 2.287
HNRPA1 protein (Fragment) OS=Homo sapiens GN=HNRPA1 PE=2 SV=1 - 
[Q3MI39_HUMAN]
B2R8C8 140 15.1 5.26 2.263
Ubiquitin-like protein ATG12 OS=Homo sapiens PE=2 SV=1 - 
[B2R8C8_HUMAN]
Q7L7X3 1001 116.0 7.65 2.241
Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 
SV=1 - [TAOK1_HUMAN]
B3KMU4 481 54.5 5.08 2.107
cDNA FLJ12640 fis, clone NT2RM4001940, highly similar to Timeless 
homolog OS=Homo sapiens PE=2 SV=1 - [B3KMU4_HUMAN]
P14555 144 16.1 9.23 2.101
Phospholipase A2, membrane associated OS=Homo sapiens GN=PLA2G2A 
PE=1 SV=2 - [PA2GA_HUMAN]
B0QYR0 100 11.1 5.36 2.088
BTB/POZ domain-containing protein 3 (Fragment) OS=Homo sapiens 
GN=BTBD3 PE=4 SV=3 - [B0QYR0_HUMAN]
P11678 715 81.0 10.29 2.012
Eosinophil peroxidase OS=Homo sapiens GN=EPX PE=1 SV=2 - 
[PERE_HUMAN]
P46109 303 33.8 6.74 2.003 Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 - [CRKL_HUMAN]
Q8NEY1 1877 202.3 8.07 1.998
Neuron navigator 1 OS=Homo sapiens GN=NAV1 PE=1 SV=2 - 
[NAV1_HUMAN]
Q0PNF2 2570 275.3 6.49 1.979 FEX1 OS=Homo sapiens PE=2 SV=1 - [Q0PNF2_HUMAN]
H0YF46 255 28.3 5.82 1.977
SPOC domain-containing protein 1 (Fragment) OS=Homo sapiens 
GN=SPOCD1 PE=4 SV=1 - [H0YF46_HUMAN]
Q8TBP3 101 11.8 9.92 1.941
TOP1MT protein (Fragment) OS=Homo sapiens GN=TOP1MT PE=2 SV=1 - 
[Q8TBP3_HUMAN]
Q05707 1796 193.4 5.30 1.917
Collagen alpha-1(XIV) chain OS=Homo sapiens GN=COL14A1 PE=1 SV=3 - 
[COEA1_HUMAN]
M0QZ50 93 9.8 4.48 1.907
Microtubule-associated protein 1S OS=Homo sapiens GN=MAP1S PE=1 
SV=1 - [M0QZ50_HUMAN]
H7BZ55 2252 248.2 5.83 1.883
Putative ciliary rootlet coiled-coil protein-like 3 protein OS=Homo sapiens 
PE=5 SV=2 - [CROL3_HUMAN]
Q8N1W1 1705 191.8 6.04 1.874 Rho guanine nucleotide exchange factor 28 OS=Homo sapiens 
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GN=ARHGEF28 PE=1 SV=3 - [ARG28_HUMAN]
P20851 252 28.3 5.14 1.835
C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB PE=1 SV=1 - 
[C4BPB_HUMAN]
Q8N1G4 583 63.4 8.28 1.830
Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 
PE=1 SV=1 - [LRC47_HUMAN]
D6RC64 136 15.6 10.14 1.819
SH3 domain-binding protein 2 (Fragment) OS=Homo sapiens GN=SH3BP2 
PE=4 SV=1 - [D6RC64_HUMAN]
Q7L0Q8 258 28.2 8.06 1.811
Rho-related GTP-binding protein RhoU OS=Homo sapiens GN=RHOU PE=1 
SV=1 - [RHOU_HUMAN]
H0YCG2 258 28.2 6.52 1.809
Lysosome-associated membrane glycoprotein 2 (Fragment) OS=Homo 
sapiens GN=LAMP2 PE=1 SV=1 - [H0YCG2_HUMAN]
Q05315 142 16.4 7.37 1.809 Galectin-10 OS=Homo sapiens GN=CLC PE=1 SV=3 - [LEG10_HUMAN]
Q6P3R8 708 81.4 8.87 1.805
Serine/threonine-protein kinase Nek5 OS=Homo sapiens GN=NEK5 PE=1 
SV=1 - [NEK5_HUMAN]
Q5T4S7 5183 573.5 6.04 1.799
E3 ubiquitin-protein ligase UBR4 OS=Homo sapiens GN=UBR4 PE=1 SV=1 - 
[UBR4_HUMAN]
Q7Z3E2 898 103.6 6.27 1.778
Coiled-coil domain-containing protein 186 OS=Homo sapiens GN=CCDC186 
PE=1 SV=2 - [CC186_HUMAN]
B4DLF9 342 39.4 8.68 1.768
cDNA FLJ56988, highly similar to cGMP-dependent protein kinase 2 (EC 
2.7.11.12) OS=Homo sapiens PE=2 SV=1 - [B4DLF9_HUMAN]
P62854 115 13.0 11.00 1.742
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 - 
[RS26_HUMAN]
A0A024R637 1298 146.5 7.01 1.737
TBC1 domain family, member 4, isoform CRA_b OS=Homo sapiens 
GN=TBC1D4 PE=4 SV=1 - [A0A024R637_HUMAN]
Q9H029 130 14.8 5.30 1.735
GTP-binding protein SAR1b OS=Homo sapiens GN=DKFZp434B2017 PE=1 
SV=1 - [Q9H029_HUMAN]
S6BGD6 235 24.8 7.24 1.733 IgG L chain OS=Homo sapiens PE=1 SV=1 - [S6BGD6_HUMAN]
Q30058 257 29.1 6.54 1.728
HLA-DP protein OS=Homo sapiens GN=HLA-DP PE=2 SV=1 - 
[Q30058_HUMAN]
H3BMN5 158 18.5 4.82 1.727
Calretinin (Fragment) OS=Homo sapiens GN=CALB2 PE=4 SV=2 - 
[H3BMN5_HUMAN]
P02452 1464 138.9 5.80 1.710
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 - 
[CO1A1_HUMAN]
B2R9B9 120 13.0 6.37 1.705
cDNA, FLJ94321, highly similar to Homo sapiens eukaryotic translation 
initiation factor 4E binding protein 2 (EIF4EBP2), mRNA OS=Homo sapiens 
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PE=2 SV=1 - [B2R9B9_HUMAN]
B4DVF1 785 87.3 6.96 1.702
cDNA FLJ51111, highly similar to Aldehyde oxidase (EC 1.2.3.1) (Fragment) 
OS=Homo sapiens PE=2 SV=1 - [B4DVF1_HUMAN]
P12724 160 18.4 10.02 1.692
Eosinophil cationic protein OS=Homo sapiens GN=RNASE3 PE=1 SV=2 - 
[ECP_HUMAN]
Q9BXN1 380 43.4 7.08 1.691 Asporin OS=Homo sapiens GN=ASPN PE=1 SV=2 - [ASPN_HUMAN]
Q9HCM7 1045 110.8 9.67 1.667
Fibrosin-1-like protein OS=Homo sapiens GN=FBRSL1 PE=1 SV=4 - 
[FBSL_HUMAN]
Q86UX7 667 75.9 6.98 1.660
Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 - 
[URP2_HUMAN]
Q4QZC0 273 31.8 6.09 1.654
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 - 
[Q4QZC0_HUMAN]
B2R6V9 732 83.2 6.00 1.638
cDNA, FLJ93141, highly similar to Homo sapiens coagulation factor XIII, A1 
polypeptide (F13A1), mRNA OS=Homo sapiens PE=2 SV=1 - 
[B2R6V9_HUMAN]
P15529 392 43.7 6.74 1.634
Membrane cofactor protein OS=Homo sapiens GN=CD46 PE=1 SV=3 - 
[MCP_HUMAN]
H0YH87 916 98.1 9.41 1.633
Ataxin-2 (Fragment) OS=Homo sapiens GN=ATXN2 PE=1 SV=1 - 
[H0YH87_HUMAN]
P27487 766 88.2 6.04 1.628
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 - 
[DPP4_HUMAN]
P08311 255 28.8 11.19 1.624 Cathepsin G OS=Homo sapiens GN=CTSG PE=1 SV=2 - [CATG_HUMAN]
O76013 467 52.2 4.94 1.624
Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 SV=1 - 
[KRT36_HUMAN]
A0A075B785 1018 112.7 5.49 1.610
LisH domain and HEAT repeat-containing protein KIAA1468 OS=Homo 
sapiens GN=KIAA1468 PE=1 SV=2 - [A0A075B785_HUMAN]
P31146 461 51.0 6.68 1.607 Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 - [COR1A_HUMAN]
P10109 184 19.4 5.83 1.604
Adrenodoxin, mitochondrial OS=Homo sapiens GN=FDX1 PE=1 SV=1 - 
[ADX_HUMAN]
O15078 2479 290.2 5.95 1.604
Centrosomal protein of 290 kDa OS=Homo sapiens GN=CEP290 PE=1 SV=2 
- [CE290_HUMAN]
B2R4M6 114 13.2 6.13 1.604 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN]
A0A024RDI4 1851 203.3 6.23 1.600
Ankyrin 2, neuronal, isoform CRA_a OS=Homo sapiens GN=ANK2 PE=4 
SV=1 - [A0A024RDI4_HUMAN]
Q6EVJ6 105 10.9 8.81 1.597 Peptidyl arginine deiminase type IV (Fragment) OS=Homo sapiens 
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GN=PADI4 PE=4 SV=1 - [Q6EVJ6_HUMAN]
P46108 304 33.8 5.55 1.592
Adapter molecule crk OS=Homo sapiens GN=CRK PE=1 SV=2 - 
[CRK_HUMAN]
C9JW69 372 39.6 8.37 1.588
Regulator of chromosome condensation (Fragment) OS=Homo sapiens 
GN=RCC1 PE=1 SV=1 - [C9JW69_HUMAN]
P98095 1184 126.5 4.82 1.586 Fibulin-2 OS=Homo sapiens GN=FBLN2 PE=1 SV=2 - [FBLN2_HUMAN]
Q19UK3 33 3.7 8.09 1.582
Truncated coagulation factor IX (Fragment) OS=Homo sapiens GN=F9 
PE=4 SV=1 - [Q19UK3_HUMAN]
F5H4Z6 171 20.0 7.84 1.581
Folate receptor beta (Fragment) OS=Homo sapiens GN=FOLR2 PE=4 SV=1 
- [F5H4Z6_HUMAN]
P49913 170 19.3 9.41 1.578
Cathelicidin antimicrobial peptide OS=Homo sapiens GN=CAMP PE=1 SV=1 
- [CAMP_HUMAN]
B4DSW4 157 16.4 12.25 1.578
cDNA FLJ51541, moderately similar to Transcription factor Sp8 OS=Homo 
sapiens PE=2 SV=1 - [B4DSW4_HUMAN]
E9PQ22 191 22.9 9.45 1.578
Uncharacterized protein C11orf65 (Fragment) OS=Homo sapiens 
GN=C11orf65 PE=4 SV=3 - [E9PQ22_HUMAN]
E9PC44 393 43.9 6.15 1.577
Protein transport protein Sec24D OS=Homo sapiens GN=SEC24D PE=1 
SV=2 - [E9PC44_HUMAN]
B4DLX8 617 69.4 6.61 1.575
cDNA FLJ57031, highly similar to Midline-1 (EC 6.3.2.-) OS=Homo sapiens 
PE=2 SV=1 - [B4DLX8_HUMAN]
E9PQI8 164 17.5 11.17 1.575
U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 
PE=1 SV=1 - [E9PQI8_HUMAN]
B4DI03 156 17.4 8.91 1.573
SEC11-like 3 (S. cerevisiae), isoform CRA_a OS=Homo sapiens 
GN=SEC11L3 PE=2 SV=1 - [B4DI03_HUMAN]
Q9Y281 166 18.7 7.88 1.571 Cofilin-2 OS=Homo sapiens GN=CFL2 PE=1 SV=1 - [COF2_HUMAN]
A0A087WX11 918 103.3 5.12 1.570
Folliculin-interacting protein 1 OS=Homo sapiens GN=FNIP1 PE=4 SV=1 - 
[A0A087WX11_HUMAN]
G3V2R9 217 23.4 6.19 1.560
Prostaglandin reductase 2 OS=Homo sapiens GN=PTGR2 PE=1 SV=1 - 
[G3V2R9_HUMAN]
Q9UK54 128 14.0 6.95 1.560
Hemoglobin beta subunit variant (Fragment) OS=Homo sapiens GN=HBB 
PE=2 SV=1 - [Q9UK54_HUMAN]
P59665 94 10.2 6.99 1.557
Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 - 
[DEF1_HUMAN]
Q4ZGM8 100 10.8 9.04 1.549
Hemoglobin alpha-2 globin mutant (Fragment) OS=Homo sapiens PE=3 
SV=1 - [Q4ZGM8_HUMAN]
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B4DJ12 1253 139.2 6.57 1.546
cDNA FLJ58355, highly similar to Tyrosine-protein phosphatase non-
receptor type 23 (EC 3.1.3.48) OS=Homo sapiens PE=2 SV=1 - 
[B4DJ12_HUMAN]
A0A087WUP0 265 30.0 5.34 1.541
Annexin A8-like protein 1 OS=Homo sapiens GN=ANXA8L1 PE=4 SV=1 - 
[A0A087WUP0_HUMAN]
E9PAR0 99 11.2 10.36 1.540
Peptidyl-prolyl cis-trans isomerase OS=Homo sapiens GN=FKBP11 PE=1 
SV=1 - [E9PAR0_HUMAN]
B2R4C9 102 11.2 9.52 1.537
cDNA, FLJ92044, highly similar to Homo sapiens death-associated protein 
(DAP), mRNA OS=Homo sapiens PE=2 SV=1 - [B2R4C9_HUMAN]
Q9NWH4 148 16.9 11.09 1.534
cDNA FLJ10024 fis, clone HEMBA1000636 OS=Homo sapiens PE=2 SV=1 - 
[Q9NWH4_HUMAN]
E3Q1J2 273 31.6 5.97 1.531
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-B PE=3 SV=1 - 
[E3Q1J2_HUMAN]
Q67AK3 233 26.9 7.42 1.531
MHC class II antigen (Fragment) OS=Homo sapiens GN=HLA-DQB1 PE=4 
SV=1 - [Q67AK3_HUMAN]
B4DLR0 579 61.1 5.26 1.529
cDNA FLJ55719, highly similar to Mus musculus armadillo repeat containing 
5 (Armc5), mRNA OS=Homo sapiens PE=2 SV=1 - [B4DLR0_HUMAN]
Q86UY0 360 40.3 5.83 1.526
Protein BLOC1S5-TXNDC5 OS=Homo sapiens GN=TXNDC5 PE=2 SV=1 - 
[Q86UY0_HUMAN]
E7EQB2 696 76.6 8.02 1.526
Lactotransferrin (Fragment) OS=Homo sapiens GN=LTF PE=1 SV=1 - 
[E7EQB2_HUMAN]
Q9P2B2 879 98.5 6.61 1.520
Prostaglandin F2 receptor negative regulator OS=Homo sapiens 
GN=PTGFRN PE=1 SV=2 - [FPRP_HUMAN]
Q96P70 1041 115.9 4.81 1.517 Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 - [IPO9_HUMAN]
Q5CZ93 159 19.2 9.88 1.517
Putative uncharacterized protein DKFZp686A0568 OS=Homo sapiens 
GN=DKFZp686A0568 PE=2 SV=1 - [Q5CZ93_HUMAN]
Q5VX52 437 50.3 8.43 1.514
Spermatogenesis-associated protein 1 OS=Homo sapiens GN=SPATA1 PE=2 
SV=3 - [SPAT1_HUMAN]
P80511 92 10.6 6.25 1.513
Protein S100-A12 OS=Homo sapiens GN=S100A12 PE=1 SV=2 - 
[S10AC_HUMAN]
A8MVU1 366 41.8 8.84 1.512
Putative neutrophil cytosol factor 1C OS=Homo sapiens GN=NCF1C PE=5 
SV=1 - [NCF1C_HUMAN]
B5BTZ6 769 87.9 6.20 1.502
Signal transducer and activator of transcription OS=Homo sapiens 
GN=STAT3 PE=2 SV=1 - [B5BTZ6_HUMAN]
Q15323 416 47.2 4.88 1.502 Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 - 
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[K1H1_HUMAN]
P07585 359 39.7 8.54 1.501 Decorin OS=Homo sapiens GN=DCN PE=1 SV=1 - [PGS2_HUMAN]
C9JKG1 238 26.7 6.79 1.501
Biglycan (Fragment) OS=Homo sapiens GN=BGN PE=4 SV=1 - 
[C9JKG1_HUMAN]
H0YA93 1400 158.1 5.82 1.501
NEDD4-binding protein 2 (Fragment) OS=Homo sapiens GN=N4BP2 PE=1 
SV=1 - [H0YA93_HUMAN]
G3V295 203 22.8 8.32 0.660
Proteasome subunit alpha type OS=Homo sapiens GN=PSMA6 PE=1 SV=1 - 
[G3V295_HUMAN]
O96009 420 45.4 6.61 0.658 Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 - [NAPSA_HUMAN]
E9PN95 56 6.3 4.96 0.626
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=4 SV=1 - 
[E9PN95_HUMAN]
P07339 412 44.5 6.54 0.615 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 - [CATD_HUMAN]
A8K987 222 25.7 9.00 0.603
Glutathione S-transferase OS=Homo sapiens PE=2 SV=1 - 
[A8K987_HUMAN]
B2R7Z6 484 52.5 7.55 0.591 cDNA, FLJ93674 OS=Homo sapiens PE=2 SV=1 - [B2R7Z6_HUMAN]
B4E1L4 668 71.6 5.63 0.531
cDNA FLJ59081, highly similar to Mucin-5B OS=Homo sapiens PE=2 SV=1 - 
[B4E1L4_HUMAN]
B7Z269 351 40.3 7.24 0.181
cDNA FLJ50754, highly similar to Voltage-dependent L-type calcium channel 
subunit alpha-1D OS=Homo sapiens PE=2 SV=1 - [B7Z269_HUMAN]
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Table 9:
Changes in proteins (with 1.5x cutoff) following surgery with LFV. Proteins with 









Q701L7 513 56.6 6.74 14.876
Type II hair keratin 2 OS=Homo sapiens GN=KRTHB2 PE=2 SV=1 - 
[Q701L7_HUMAN]
Q9BYT5 123 12.9 7.81 14.741
Keratin-associated protein 2-2 OS=Homo sapiens GN=KRTAP2-2 
PE=2 SV=3 - [KRA22_HUMAN]
O76013 467 52.2 4.94 7.140
Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 
SV=1 - [KRT36_HUMAN]
A0A087X2I6 404 46.1 4.84 4.627
Keratin, type I cuticular Ha3-II OS=Homo sapiens GN=KRT33B PE=4 
SV=1 - [A0A087X2I6_HUMAN]
A0JNT2 447 49.6 5.39 3.857
KRT83 protein OS=Homo sapiens GN=KRT83 PE=2 SV=1 - 
[A0JNT2_HUMAN]
B7Z269 351 40.3 7.24 2.379
cDNA FLJ50754, highly similar to Voltage-dependent L-type calcium 
channel subunit alpha-1D OS=Homo sapiens PE=2 SV=1 - 
[B7Z269_HUMAN]
Q15323 416 47.2 4.88 2.158
Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 
SV=3 - [K1H1_HUMAN]
Q96Q06 1357 134.3 8.73 1.840
Perilipin-4 OS=Homo sapiens GN=PLIN4 PE=2 SV=2 - 
[PLIN4_HUMAN]
Q05315 142 16.4 7.37 1.823
Galectin-10 OS=Homo sapiens GN=CLC PE=1 SV=3 - 
[LEG10_HUMAN]
H0YF46 255 28.3 5.82 1.698
SPOC domain-containing protein 1 (Fragment) OS=Homo sapiens 
GN=SPOCD1 PE=4 SV=1 - [H0YF46_HUMAN]
Q7Z6I6 1101 118.5 4.81 1.687
Rho GTPase-activating protein 30 OS=Homo sapiens GN=ARHGAP30 
PE=1 SV=3 - [RHG30_HUMAN]
P11678 715 81.0 10.29 1.663
Eosinophil peroxidase OS=Homo sapiens GN=EPX PE=1 SV=2 - 
[PERE_HUMAN]
A4FU00 317 35.6 5.81 1.651
SYT2 protein (Fragment) OS=Homo sapiens GN=SYT2 PE=2 SV=1 - 
[A4FU00_HUMAN]
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P27701 267 29.6 5.24 1.574
CD82 antigen OS=Homo sapiens GN=CD82 PE=1 SV=1 - 
[CD82_HUMAN]
B4DMJ5 242 27.3 4.50 1.547
cDNA FLJ53012, highly similar to Tubulin beta-7 chain OS=Homo 
sapiens PE=2 SV=1 - [B4DMJ5_HUMAN]
Q6P4A8 553 63.2 9.06 1.524
Phospholipase B-like 1 OS=Homo sapiens GN=PLBD1 PE=1 SV=2 - 
[PLBL1_HUMAN]
A0A024R637 1298 146.5 7.01 1.514
TBC1 domain family, member 4, isoform CRA_b OS=Homo sapiens 
GN=TBC1D4 PE=4 SV=1 - [A0A024R637_HUMAN]
M0QZ50 93 9.8 4.48 1.512
Microtubule-associated protein 1S OS=Homo sapiens GN=MAP1S 
PE=1 SV=1 - [M0QZ50_HUMAN]
B3KQ72 130 14.3 5.52 1.500
cDNA FLJ32987 fis, clone THYMU1000032 OS=Homo sapiens PE=2 
SV=1 - [B3KQ72_HUMAN]
H6VRF8 644 66.0 8.12 0.665
Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - 
[H6VRF8_HUMAN]
P35237 376 42.6 5.27 0.658
Serpin B6 OS=Homo sapiens GN=SERPINB6 PE=1 SV=3 - 
[SPB6_HUMAN]
D6RF35 476 53.0 5.52 0.658
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 - 
[D6RF35_HUMAN]
B7Z445 386 43.3 6.83 0.656
cDNA FLJ51492, highly similar to Arachidonate 15-lipoxygenase (EC 
1.13.11.33) OS=Homo sapiens PE=2 SV=1 - [B7Z445_HUMAN]
P62851 125 13.7 10.11 0.650
40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 
- [RS25_HUMAN]
Q99549 860 97.1 6.06 0.644
M-phase phosphoprotein 8 OS=Homo sapiens GN=MPHOSPH8 PE=1 
SV=2 - [MPP8_HUMAN]
Q7Z6G4 31 3.2 5.78 0.634
HBA2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 SV=1 - 
[Q7Z6G4_HUMAN]
K7EPK9 51 5.5 5.11 0.626
Mucin-like protein 1 (Fragment) OS=Homo sapiens GN=MUCL1 PE=4 
SV=3 - [K7EPK9_HUMAN]
Q86TT1 375 41.2 6.79 0.616
Full-length cDNA clone CS0DD006YL02 of Neuroblastoma of Homo 
sapiens (human) OS=Homo sapiens PE=2 SV=1 - [Q86TT1_HUMAN]
B2R6F5 350 39.6 5.12 0.607
cDNA, FLJ92928, highly similar to Homo sapiens retinitis pigmentosa 2 
(X-linked recessive) (RP2), mRNA OS=Homo sapiens PE=2 SV=1 - 
[B2R6F5_HUMAN]
P23527 126 13.9 10.32 0.605
Histone H2B type 1-O OS=Homo sapiens GN=HIST1H2BO PE=1 SV=3 
- [H2B1O_HUMAN]
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B3KUR3 242 28.0 5.85 0.604
cDNA FLJ40459 fis, clone TESTI2041800, highly similar to 
BISPHOSPHOGLYCERATE MUTASE (EC 5.4.2.4) OS=Homo sapiens 
PE=2 SV=1 - [B3KUR3_HUMAN]
P11277 2137 246.3 5.27 0.591
Spectrin beta chain, erythrocytic OS=Homo sapiens GN=SPTB PE=1 
SV=5 - [SPTB1_HUMAN]
P02656 99 10.8 5.41 0.591
Apolipoprotein C-III OS=Homo sapiens GN=APOC3 PE=1 SV=1 - 
[APOC3_HUMAN]
Q9NZD4 102 11.8 5.00 0.584
Alpha-hemoglobin-stabilizing protein OS=Homo sapiens GN=AHSP 
PE=1 SV=1 - [AHSP_HUMAN]
G4V2I8 911 101.7 5.21 0.574
Anion exchanger-1 variant OS=Homo sapiens PE=2 SV=1 - 
[G4V2I8_HUMAN]
B7Z4Q8 613 68.2 7.85 0.574
cDNA FLJ52333, highly similar to Erythrocyte membrane protein band 
4.2 OS=Homo sapiens PE=2 SV=1 - [B7Z4Q8_HUMAN]
P03973 132 14.3 8.75 0.570
Antileukoproteinase OS=Homo sapiens GN=SLPI PE=1 SV=2 - 
[SLPI_HUMAN]
P02549 2419 279.8 5.05 0.569
Spectrin alpha chain, erythrocytic 1 OS=Homo sapiens GN=SPTA1 
PE=1 SV=5 - [SPTA1_HUMAN]
Q14587 947 108.3 8.87 0.566
Zinc finger protein 268 OS=Homo sapiens GN=ZNF268 PE=1 SV=2 - 
[ZN268_HUMAN]
P69892 147 16.1 7.20 0.553
Hemoglobin subunit gamma-2 OS=Homo sapiens GN=HBG2 PE=1 
SV=2 - [HBG2_HUMAN]
P01833 764 83.2 5.74 0.549
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR 
PE=1 SV=4 - [PIGR_HUMAN]
P16157 1881 206.1 6.01 0.548 Ankyrin-1 OS=Homo sapiens GN=ANK1 PE=1 SV=3 - [ANK1_HUMAN]
Q4ZGM8 100 10.8 9.04 0.543
Hemoglobin alpha-2 globin mutant (Fragment) OS=Homo sapiens 
PE=3 SV=1 - [Q4ZGM8_HUMAN]
B3KVN0 416 45.8 8.60 0.534
cDNA FLJ16785 fis, clone NT2RI2015342, highly similar to Solute 
carrier family 2, facilitated glucose transporter member 1 OS=Homo 
sapiens PE=2 SV=1 - [B3KVN0_HUMAN]
Q4VB87 615 68.4 5.91 0.532
EPB41 protein (Fragment) OS=Homo sapiens GN=EPB41 PE=2 SV=1 
- [Q4VB87_HUMAN]
B4DF70 183 20.1 8.78 0.527
cDNA FLJ60461, highly similar to Peroxiredoxin-2 (EC 1.11.1.15) 
OS=Homo sapiens PE=2 SV=1 - [B4DF70_HUMAN]
Q4TZM4 101 11.0 6.52 0.518
Hemoglobin beta chain (Fragment) OS=Homo sapiens GN=HBB PE=3 
SV=1 - [Q4TZM4_HUMAN]
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P00918 260 29.2 7.40 0.507
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 - 
[CAH2_HUMAN]
O75602 509 55.4 6.83 0.504
Sperm-associated antigen 6 OS=Homo sapiens GN=SPAG6 PE=2 
SV=1 - [SPAG6_HUMAN]
Q6J1Z9 90 9.6 9.50 0.501
Hemoglobin alpha 1 (Fragment) OS=Homo sapiens GN=HBA1 PE=3 
SV=1 - [Q6J1Z9_HUMAN]
Q86YQ1 91 9.7 9.25 0.497
Hemoglobin alpha-2 (Fragment) OS=Homo sapiens GN=HBA2 PE=3 
SV=1 - [Q86YQ1_HUMAN]
Q13938 189 21.0 4.89 0.495
Calcyphosin OS=Homo sapiens GN=CAPS PE=1 SV=1 - 
[CAYP1_HUMAN]
E9PN95 56 6.3 4.96 0.450
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=4 SV=1 - 
[E9PN95_HUMAN]
A8K987 222 25.7 9.00 0.448
Glutathione S-transferase OS=Homo sapiens PE=2 SV=1 - 
[A8K987_HUMAN]
P00915 261 28.9 7.12 0.442
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 - 
[CAH1_HUMAN]
Q6J1Z8 42 4.5 9.38 0.429
Hemoglobin beta (Fragment) OS=Homo sapiens GN=HBB PE=3 SV=1 
- [Q6J1Z8_HUMAN]
H3BML9 118 13.1 5.68 0.397
Myosin regulatory light chain 2, skeletal muscle isoform (Fragment) 
OS=Homo sapiens GN=MYLPF PE=4 SV=1 - [H3BML9_HUMAN]
E5RGQ7 148 16.8 8.88 0.388
Dematin (Fragment) OS=Homo sapiens GN=DMTN PE=1 SV=1 - 
[E5RGQ7_HUMAN]
Q6VFQ6 42 4.5 8.24 0.384
Hemoglobin beta chain (Fragment) OS=Homo sapiens GN=HBB PE=3 
SV=1 - [Q6VFQ6_HUMAN]
P02042 147 16.0 8.05 0.383
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 - 
[HBD_HUMAN]
Q5T619 568 62.3 8.62 0.380
Zinc finger protein 648 OS=Homo sapiens GN=ZNF648 PE=2 SV=1 - 
[ZN648_HUMAN]
Q5RHS7 95 11.0 9.28 0.346
Protein S100-A2 OS=Homo sapiens GN=S100A2 PE=1 SV=2 - 
[Q5RHS7_HUMAN]
Q8IUL9 105 11.5 6.05 0.270
Hemoglobin beta chain variant Hb.Sinai-Bel Air (Fragment) OS=Homo 
sapiens GN=HBB PE=3 SV=1 - [Q8IUL9_HUMAN]
B4E1L4 668 71.6 5.63 0.257
cDNA FLJ59081, highly similar to Mucin-5B OS=Homo sapiens PE=2 
SV=1 - [B4E1L4_HUMAN]




Principle component analysis (by Partek) of gene expression data, showing no 
significant outliers within the data. 
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Supplemental Figure 2:
There were no significant changes in (A) lipid species or (B) lipid class (as a percentage of the total) following surgery either with 
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